

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/47, 16/18, G01N 33/68, C12N 15/11, 9/00		A1	(11) International Publication Number: WO 95/08629 (43) International Publication Date: 30 March 1995 (30.03.95)
(21) International Application Number: PCT/US94/10849 (22) International Filing Date: 26 September 1994 (26.09.94) (30) Priority Data: 08/126,588 24 September 1993 (24.09.93) US 08/126,595 24 September 1993 (24.09.93) US 08/212,185 11 March 1994 (11.03.94) US 08/212,184 11 March 1994 (11.03.94) US (71) Applicant: THE ROCKEFELLER UNIVERSITY [US/US]; 1230 York Avenue, New York, NY 10021 (US). (72) Inventors: DARNELL, James, E., Jr.; 22 Chestnut Street, Larchmont, NY 10538 (US). SCHINDLER, Christian, W.; 18 Terrell Avenue, Rockville Center, New York, NY 11327 (US). SHUAL, Ke; 500 East 63rd Street, Apt. 22D, New York, NY 10021 (US). WEN, Zilong; 1230 York Avenue, New York, NY 10021-6399 (US). ZHONG, Zhong; 1230 York Avenue, New York, NY 10021-6399 (US). (74) Agents: JACKSON, David, A. et al.; Klauber & Jackson, 411 Hackensack Avenue, Hackensack, NJ 07601 (US).			(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: RECEPTOR RECOGNITION FACTORS, PROTEIN SEQUENCES AND METHODS OF USE THEREOF			
(57) Abstract <p>Receptor recognition factors exist that recognize the specific cell receptor to which a specific ligand has been bound, and that may thereby signal and/or initiate the binding of the transcription factor to the DNA site. The receptor recognition factor is in one instance, a part of a transcription factor, and also may interact with other transcription factors to cause them to activate and travel to the nucleus for DNA binding. The receptor recognition factor appears to be second-messenger-independent in its activity, as overt perturbations in second messenger concentrations are of no effect. The concept of the invention is illustrated by the results of studies conducted with interferon (IFN)-stimulated gene transcription, and particularly, the activation caused by both IFNα and IFNγ. Specific DNA and amino acid sequences for various human and murine receptor recognition factors are provided, as are polypeptide fragments of two of the ISGF-3 genes, and antibodies have also been prepared and tested. The polypeptides confirm direct involvement of tyrosine kinase in intracellular message transmission. Numerous diagnostic and therapeutic materials and utilities are also disclosed.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

RECEPTOR RECOGNITION FACTORS, PROTEIN SEQUENCES AND METHODS OF USE THEREOF

RELATED PUBLICATIONS

5

- The Applicants are authors or co-authors of several articles directed to the subject matter of the present invention. (1) Darnell et al., "Interferon-Dependent Transcriptional Activation: Signal Transduction Without Second Messenger Involvement?" *THE NEW BIOLOGIST*, 2(10):1-4, (1990); (2) X. Fu et al.,
- 10 "ISGF3, The Transcriptional Activator Induced by Interferon α , Consists of Multiple Interacting Polypeptide Chains" *PROC. NATL. ACAD. SCI. USA*, 87:8555-8559 (1990); (3) D.S. Kessler et al., "IFN α Regulates Nuclear Translocation and DNA-Binding Affinity of ISGF3, A Multimeric Transcriptional Activator" *GENES AND DEVELOPMENT*, 4:1753 (1990); (4) C. Schindler et al.,
- 15 "Interferon-Dependent Tyrosine Phosphorylation of a Latent Cytoplasmic Transcription Factor" *Science*, 257:809-812 (1992); (5) Ke Shuai et al., "Interferon- γ triggers transcription through cytoplasmic tyrosine phosphorylation of a 91 kD DNA binding protein" *Science*, 258:1808 (1992); and (6) International Patent Publication No. WO 93/19179, "IFN RECEPTORS RECOGNITION
- 20 FACTORS, PROTEIN SEQUENCES AND METHODS OF USE THEREOF," published 30 September 1993.

TECHNICAL FIELD OF THE INVENTION

- 25 The present invention relates generally to intracellular receptor recognition proteins or factors (i.e. groups of proteins), and to methods and compositions including such factors or the antibodies reactive toward them, or analogs thereof in assays and for diagnosing, preventing and/or treating cellular debilitation, derangement or dysfunction. More particularly, the present invention relates to
- 30 particular molecules that exhibit both receptor recognition and message delivery via DNA binding in an interferon-dependent manner, and specifically that directly participate both in the interaction with the liganded receptor at the cell surface and in the activity of transcription in the nucleus as a DNA binding protein. The

invention likewise relates to the antibodies and other entities that are specific to this factor and that would thereby selectively modulate its activity.

BACKGROUND OF THE INVENTION

5

There are several possible pathways of signal transduction that might be followed after a polypeptide ligand binds to its cognate cell surface receptor. Within minutes of such ligand-receptor interaction, genes that were previously quiescent are rapidly transcribed (Murdoch et al., 1982; Larner et al., 1984; Friedman et al., 1984; Greenberg and Ziff, 1984; Greenberg et al., 1985). One of the most physiologically important, yet poorly understood, aspects of these immediate transcriptional responses is their specificity: the set of genes activated, for example, by platelet-derived growth factor (PDGF), does not completely overlap with the one activated by nerve growth factor (NGF) or tumor necrosis factor (TNF) (Cochran et al., 1983; Greenberg et al., 1985; Almendral et al., 1988; Lee et al., 1990). The interferons (IFN) activate sets of other genes entirely. Even IFN α and IFN γ , whose presence results in the slowing of cell growth and in an increased resistance to viruses (Tamm et al., 1987) do not activate exactly the same set of genes (Larner et al., 1984; Friedman et al., 1984; Celis et al., 1987, 1985; Larner et al., 1986).

The current hypotheses related to signal transduction pathways in the cytoplasm do not adequately explain the high degree of specificity observed in polypeptide-dependent transcriptional responses. The most commonly discussed pathways of signal transduction that might ultimately lead to the nucleus depend on properties of cell surface receptors containing tyrosine kinase domains [for example, PDGF, epidermal growth factor (EGF), colony-stimulating factor (CSF), insulin-like growth factor-1 (IGF-1); see Gill, 1990; Hunter, 1990) or of receptors that interact with G-proteins (Gilman, 1987). These two groups of receptors mediate changes in the intracellular concentrations of second messengers that, in turn, activate one

of a series of protein phosphokinases, resulting in a cascade of phosphorylations (or dephosphorylations) of cytoplasmic proteins.

It has been widely conjectured that the cascade of phosphorylations secondary to changes in intracellular second messenger levels is responsible for variations in the rates of transcription of particular genes (Bourne, 1988, 1990; Berridge, 1987; Gill, 1990; Hunter, 1990). However, there are at least two reasons to question the suggestion that global changes in second messengers participate in the chain of events leading to specific transcriptional responses dependent on specific receptor occupation by polypeptide ligands.

First, there is a limited number of second messengers (cAMP, diacyl glycerol, phosphoinositides, and Ca^{2+} are the most prominently discussed), whereas the number of known cell surface receptor-ligand pairs of only the tyrosine kinase and G-protein varieties, for example, already greatly outnumbers the list of second messengers, and could easily stretch into the hundreds (Gill, 1990; Hunter, 1990). In addition, since many different receptors can coexist on one cell type at any instant, a cell can be called upon to respond simultaneously to two or more different ligands with an individually specific transcriptional response each involving a different set of target genes. Second, a number of receptors for polypeptide ligands are now known that have neither tyrosine kinase domains nor any structure suggesting interaction with G-proteins. These include the receptors for interleukin-2 (IL-2) (Leonard et al., 1985), $\text{IFN}\alpha$ (Uze et al., 1990), $\text{IFN}\gamma$ (Aguet et al., 1988), NGF (Johnson et al., 1986), and growth hormone (Leung et al., 1987). The binding of each of these receptors to its specific ligand has been demonstrated to stimulate transcription of a specific set of genes. For these reasons it seems unlikely that global intracellular fluctuations in a limited set of second messengers are integral to the pathway of specific, polypeptide ligand-dependent, immediate transcriptional responses.

International Patent Publication No. WO 93/19179 (30 September 1993, by James E. Darnell, Jr. et al.) disclosed the existence of receptor recognition factors, now termed signal transducers and activators of transcription (STAT). The nucleotide sequences of cDNA encoding receptor recognition factors having molecular weights of 113 kD (*i.e.*, 113 kD protein, Stat113, or Stat2), 91 kD (*i.e.*, 91 kD protein, Stat91, or Stat1 α) and 84 kD (*i.e.*, 84 kD protein, Stat84, or Stat1 β) are reiterated herein in SEQ ID NOS:1, 3, and 5, respectively; the corresponding deduced amino acid sequences of the STAT proteins are shown in SEQ ID NOS:2, 4, and 6, respectively. Stat84 was found to be a truncated form of Stat91. There is 42% amino acid sequence similarity between Stat113 and Stat91/84 in an overlapping 715 amino acid sequence, including four leucine and one valine heptad repeats in the middle helix region, and several tyrosine residues were conserved near the ends of both proteins. The receptor recognition proteins thus possess multiple properties, among them: 1) recognizing and being activated during such recognition by receptors; 2) being translocated to the nucleus by an inhibitable process (*e.g.*, NaF inhibits translocation); and 3) combining with transcription activating proteins or acting themselves as transcription activation proteins, and that all of these properties are possessed by the proteins described herein. In particular, the proteins are activated by binding of interferons to receptors on cells, in particular interferon- α (all three Stat proteins) and interferon- γ (Stat91).

SUMMARY OF THE INVENTION

In accordance with the present invention, additional members of the family of receptor recognition factors (also termed herein signal transducers and activators of transcription -- STAT) have been further characterized that appear to interact directly with receptors that have been occupied by their ligand on cellular surfaces, and which in turn either become active transcription factors, or activate or directly associate with transcription factors that enter the cells' nucleus and specifically binds on predetermined sites and thereby activates the genes. It should be noted that the receptor recognition proteins thus possess multiple properties,

among them: 1) recognizing and being activated during such recognition by receptors; 2) being translocated to the nucleus by an inhibitable process (eg. NaF inhibits translocation); and 3) combining with transcription activating proteins or acting themselves as transcription activation proteins, and that all of these
5 properties are possessed by the proteins described herein.

A further property of the receptor recognition factors is dimerization to form homodimers or heterodimers upon activation by phosphorylation of tyrosine. In a specific embodiment, *infra*, Stat91 and Stat84 form homodimers and a Stat91-
10 Stat84 heterodimer. Accordingly, the present invention is directed to such dimers, which can form spontaneously by phosphorylation of the STAT protein, or which can be prepared synthetically by chemically cross-linking two like or unlike STAT proteins.

15 The present invention further relates to receptor recognition factors that are functionally active fragments of the 91 kD receptor recognition factor, particularly such fragments that contain an amino acid residue corresponding to the tyrosine 701 residue, and preferably that contain a corresponding phosphotyrosine residue. In a different embodiment, the functionally active fragments further comprises the
20 SH2 domain, particularly the SH2 domain that has a residue corresponding to an arginine-602 residue. It is envisioned that such functionally active receptor recognition factors comprise at least about 8 amino acid residues.

The invention contemplates inhibitory fragments of the 91 kD protein. In one
25 embodiment, the SH2 domain of the 91 kD protein can competitively inhibit phosphorylation of the whole protein or fragment thereof containing tyrosine 701. In another embodiment, an inhibitory fragment can compete with the 91 kD protein for binding to a tyrosine kinase. Such an inhibitory fragment may contain a residue corresponding to tyrosine 701.

The receptor recognition factor is proteinaceous in composition and is believed to be present in the cytoplasm. The recognition factor is not demonstrably affected by concentrations of second messengers, however does exhibit direct interaction with tyrosine kinase domains, although it exhibits no apparent interaction with G-proteins. More particularly, the 91 kD human interferon (IFN)- γ factor (hence, formerly also termed "GAF"), represented by SEQ ID NO:4 directly interacts with DNA after acquiring phosphate on tyrosine located at position 701 of the amino acid sequence.

10 The recognition factor is now known to comprise several proteinaceous substituents, in the instance of IFN α and IFN γ . Three proteins derived from the factor ISGF-3 have been successfully sequenced and their sequences are set forth in SEQ ID NOS:1, 2; SEQ ID NOS:3, 4; and SEQ ID NOS:5, 6, herein (see International Patent Publication No. WO 93/19179). The present invention is
15 therefore particularly directed to additional members of the STAT family, including a murine gene encoding the 91 kD protein (SEQ ID NO:4) has been identified and sequenced. The nucleotide sequence (SEQ ID NO:7) and deduced amino acid sequence (SEQ ID NO:8) of the murine homolog of SEQ ID NO:4 are shown in FIGURE 1A-1C.

20

In a further embodiment, murine genes encoding homologs of the recognition factor have been successfully sequenced and cloned into plasmids. A gene in plasmid 13sf1 has the nucleotide sequence (SEQ ID NO:9) and deduced amino acid sequence (SEQ ID NO:10) as shown in FIGURE 2A-D. A gene in plasmid
25 19sf6 has the nucleotide sequence (SEQ ID NO:11) and deduced amino acid sequence (SEQ ID NO:12) shown in FIGURE 3A-E.

It is particularly noteworthy that the protein sequence of SEQ ID NO:2 and the sequence of the proteins of SEQ ID NO:4 and SEQ ID NO:6 derive, respectively,
30 from two different but related genes. Moreover, the protein sequence of FIGURE 1 (SEQ ID NO:8) derives from a murine gene that is analogous to the gene

encoding the protein of SEQ ID NO:4. Of further note is that the protein sequences of FIGURES 2 (SEQ ID NO:10) and 3 (SEQ ID NO:12) derive from two genes that are different from, but related to, the protein of FIGURE 1 (FIG ID NO:8). It is clear from these discoveries that a family of genes exists, and that
5 further family members likewise exist. Accordingly, as demonstrated herein, by use of hybridization techniques, additional such family members will be found.

Further, the capacity of such family members to function in the manner of the receptor recognition factors disclosed, herein may be assessed by determining
10 those ligand that cause the phosphorylation of the particular family members.

In its broadest aspect, the present invention extends to a receptor recognition factor implicated in the transcriptional stimulation of genes in target cells in response to the binding of a specific polypeptide ligand to its cellular receptor on
15 said target cell, said receptor recognition factor having the following characteristics:

- a) apparent direct interaction with the ligand-bound receptor complex and activation of one or more transcription factors capable of binding with a specific gene;
- 20 b) an activity demonstrably unaffected by the presence or concentration of second messengers;
- c) direct interaction with tyrosine kinase domains; and
- d) a perceived absence of interaction with G-proteins.

25 In a further aspect, the receptor recognition (STAT) protein forms a dimer upon activation by phosphorylation.

In a specific example, the receptor recognition factor represented by SEQ ID NO:4 possesses the added capability of acting as a translation protein and, in
30 particular, as a DNA binding protein in response to interferon- γ stimulation. This discovery presages an expanded role for the proteins in question, and other

proteins and like factors that have heretofore been characterized as receptor recognition factors. It is therefore apparent that a single factor may indeed provide the nexus between the liganded receptor at the cell surface and direct participation in DNA transcriptional activity in the nucleus. This pleiotypic factor

5 has the following characteristics:

- a) It interacts with an interferon- γ -bound receptor kinase complex;
- b) It is a tyrosine kinase substrate; and
- c) When phosphorylated, it serves as a DNA binding protein.

10 More particularly, the factor represented by SEQ ID NO:4 is interferon-dependent in its activity and is responsive to interferon stimulation, particularly that of interferon- γ . It has further been discovered that activation of the factor represented by SEQ ID NO:4 requires phosphorylation of tyrosine-701 of the protein. In particular, phosphorylation of tyrosine-701 is required for nuclear
15 transport, DNA binding, and transcription activation. Furthermore, tyrosine phosphorylation requires the presence of a functionally active SH2 domain in the protein. Preferably, such SH2 domain contains an amino acid residue corresponding to an arginine at position 602 of the protein.

20 In a still further aspect, the present invention extends to a receptor recognition factor interactive with a liganded interferon receptor, which receptor recognition factor possesses the following characteristics:

- a) it is present in cytoplasm;
- b) it undergoes tyrosine phosphorylation upon treatment of cells with IFN α
25 or IFN γ ;
- c) it activates transcription of an interferon stimulated gene;
- d) it stimulates either an ISRE-dependent or a gamma activated site (GAS)-dependent transcription *in vivo*;
- e) it interacts with IFN cellular receptors, and
30 f) it undergoes nuclear translocation upon stimulation of the IFN cellular receptors with IFN.

The factor of the invention represented by SEQ ID NO:4 appears to act in similar fashion to an earlier determined site-specific DNA binding protein that is interferon- γ dependent and that has been earlier called the γ activating factor (GAF). Specifically, interferon- γ -dependent activation of this factor occurs

5 without new protein synthesis and appears within minutes of interferon- γ treatment, achieves maximum extent between 15 and 30 minutes thereafter, and then disappears after 2-3 hours. These further characteristics of identification and action assist in the evaluation of the present factor for applications having both diagnostic and therapeutic significance.

10

In a particular embodiment, the present invention relates to all members of the herein disclosed family of receptor recognition factors, specifically the proteins whose sequences are represented by one or more of SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12.

15

The present invention also relates to a recombinant DNA molecule or cloned gene, or a degenerate variant thereof, which encodes a receptor recognition factor, or a fragment thereof, that possesses a molecular weight of about 113 kD and an amino acid sequence set forth in FIGURE 1 (SEQ ID NO:8). In yet another

20 embodiment, the receptor recognition factor has an amino acid sequence set forth in FIGURE 2 (SEQ ID NO:10); preferably a nucleic acid molecule, in particular a recombinant DNA molecule or cloned gene, encoding such receptor recognition factor has a nucleotide sequence or is complementary to a DNA sequence shown in FIGURE 2 (SEQ ID NO:9). In still another embodiment, the receptor

25 recognition factor has an amino acid sequence set forth in FIGURE 3 (SEQ ID NO:12); preferably a nucleic acid molecule, in particular a recombinant DNA molecule or cloned gene, encoding such receptor recognition factor has a nucleotide sequence or is complementary to a DNA sequence shown in FIGURE 3 (SEQ ID NO:11).

30

The human and murine DNA sequences of the receptor recognition factors of the present invention or portions thereof, may be prepared as probes to screen for complementary sequences and genomic clones in the same or alternate species. The present invention extends to probes so prepared that may be provided for
5 screening cDNA and genomic libraries for the receptor recognition factors. For example, the probes may be prepared with a variety of known vectors, such as the phage λ vector. The present invention also includes the preparation of plasmids including such vectors, and the use of the DNA sequences to construct vectors expressing antisense RNA or ribozymes which would attack the mRNAs of any or
10 all of the DNA sequences set forth in FIGURES 1, 2, and 3 (SEQ ID NOS:7, 9, and 11, respectively). Correspondingly, the preparation of antisense RNA and ribozymes are included herein.

The present invention also includes receptor recognition factor proteins having the
15 activities noted herein, and that display the amino acid sequences set forth and described above and selected from SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:12.

In a further embodiment of the invention, the full DNA sequence of the
20 recombinant DNA molecule or cloned gene so determined may be operatively linked to an expression control sequence which may be introduced into an appropriate host. The invention accordingly extends to unicellular hosts transformed with the cloned gene or recombinant DNA molecule comprising a DNA sequence encoding the present receptor recognition factor(s), and more
25 particularly, the complete DNA sequence determined from the sequences set forth above and in SEQ ID NO:7, SEQ ID NO:9 and SEQ ID NO:11.

According to other preferred features of certain preferred embodiments of the present invention, a recombinant expression system is provided to produce
30 biologically active animal or human receptor recognition factor.

- The present invention naturally contemplates several means for preparation of the recognition factor, including as illustrated herein known recombinant techniques, and the invention is accordingly intended to cover such synthetic preparations within its scope. The isolation of the cDNA amino acid sequences disclosed
- 5 herein facilitates the reproduction of the recognition factor by such recombinant techniques, and accordingly, the invention extends to expression vectors prepared from the disclosed DNA sequences for expression in host systems by recombinant DNA techniques, and to the resulting transformed hosts.
- 10 The invention includes an assay system for screening of potential drugs effective to modulate transcriptional activity of target mammalian cells by interrupting or potentiating the recognition factor or factors. In one instance, the test drug could be administered to a cellular sample with the ligand that activates the receptor recognition factor, or an extract containing the activated recognition factor, to
- 15 determine its effect upon the binding activity of the recognition factor to any chemical sample (including DNA), or to the test drug, by comparison with a control.

- The assay system could more importantly be adapted to identify drugs or other
- 20 entities that are capable of binding to the receptor recognition and/or transcription factors or proteins, either in the cytoplasm or in the nucleus, thereby inhibiting or potentiating transcriptional activity. Such assay would be useful in the development of drugs that would be specific against particular cellular activity, or that would potentiate such activity, in time or in level of activity. For example,
- 25 such drugs might be used to modulate cellular response to shock, or to treat other pathologies, as for example, in making IFN more potent against cancer.

- In yet a further embodiment, the invention contemplates antagonists of the activity of a receptor recognition factor (STAT). In particular, an agent or molecule that
- 30 inhibits dimerization (homodimerization or heterodimerization) can be used to block transcription activation effected by an activated, phosphorylated STAT

protein. In a specific embodiment, the antagonist can be a peptide having the sequence of a portion of an SH2 domain of a STAT protein, or the phosphotyrosine domain of a STAT protein, or both. If the peptide contains both regions, preferably the regions are located in tandem, more preferably with the SH2 domain portion N-terminal to the phosphotyrosine portion. In a specific example, *infra*, such peptides are shown to be capable of disrupting dimerization of STAT proteins.

The diagnostic utility of the present invention extends to the use of the present receptor recognition factors in assays to screen for tyrosine kinase inhibitors. Because the activity of the receptor recognition-transcriptional activation proteins described herein must maintain tyrosine phosphorylation, they can and presumably are dephosphorylated by specific tyrosine phosphatases. Blocking of the specific phosphatase is therefore an avenue of pharmacological intervention that would potentiate the activity of the receptor recognition proteins.

The present invention likewise extends to the development of antibodies against the receptor recognition factor(s), including naturally raised and recombinantly prepared antibodies. For example, the antibodies could be used to screen expression libraries to obtain the gene or genes that encode the receptor recognition factor(s). Such antibodies could include both polyclonal and monoclonal antibodies prepared by known genetic techniques, as well as bi-specific (chimeric) antibodies, and antibodies including other functionalities suiting them for additional diagnostic use conjunctive with their capability of modulating transcriptional activity.

In particular, antibodies against specifically phosphorylated factors can be selected and are included within the scope of the present invention for their particular ability in following activated protein. Thus, activity of the recognition factors or of the specific polypeptides believed to be causally connected thereto may therefore be followed directly by the assay techniques discussed later on, through

the use of an appropriately labeled quantity of the recognition factor or antibodies or analogs thereof.

Thus, the receptor recognition factors, their analogs and/or analogs, and any antagonists or antibodies that may be raised thereto, are capable of use in connection with various diagnostic techniques, including immunoassays, such as a radioimmunoassay, using for example, an antibody to the receptor recognition factor that has been labeled by either radioactive addition, reduction with sodium borohydride, or radioiodination.

10

In a further embodiment, the present invention relates to certain therapeutic methods which would be based upon the activity of the recognition factor(s), its (or their) subunits, or active fragments thereof, or upon agents or other drugs determined to possess the same activity. A first therapeutic method is associated with the prevention of the manifestations of conditions causally related to or following from the binding activity of the recognition factor or its subunits, and comprises administering an agent capable of modulating the production and/or activity of the recognition factor or subunits thereof, either individually or in mixture with each other in an amount effective to prevent the development of those conditions in the host. For example, drugs or other binding partners to the receptor recognition/transcription factors or proteins may be administered to inhibit or potentiate transcriptional activity, as in the potentiation of interferon in cancer therapy. Also, the blockade of the action of specific tyrosine phosphatases in the dephosphorylation of activated (phosphorylated) recognition/transcription factors or proteins presents a method for potentiating the activity of the receptor recognition factor or protein that would concomitantly potentiate therapies based on receptor recognition factor/protein activation.

25

More specifically, the therapeutic method generally referred to herein could include the method for the treatment of various pathologies or other cellular dysfunctions and derangements by the administration of pharmaceutical

30

compositions that may comprise effective inhibitors or enhancers of activation of the recognition factor or its subunits, or other equally effective drugs developed for instance by a drug screening assay prepared and used in accordance with a further aspect of the present invention. For example, drugs or other binding
5 partners to the receptor recognition/transcription factor or proteins, as represented by SEQ ID NO:8, 10, or 12, may be administered to inhibit or potentiate transcriptional activity, as in the potentiation of interferon in cancer therapy. Also, the blockade of the action of specific tyrosine phosphatases in the dephosphorylation of activated (phosphorylated) recognition/transcription factor or
10 protein presents a method for potentiating the activity of the receptor recognition factor or protein that would concomitantly potentiate therapies based on receptor recognition factor/protein activation. Correspondingly, the inhibition or blockade of the activation or binding of the recognition/transcription factor would affect MHC Class II expression and consequently, would promote immunosuppression.
15 Materials exhibiting this activity, as illustrated later on herein by staurosporine, may be useful in instances such as the treatment of autoimmune diseases and graft rejection, where a degree of immunosuppression is desirable.

In particular, the proteins of ISGF-3 whose sequences are presented in SEQ ID
20 NOS:8, 10, or 12 herein, their antibodies, agonists, antagonists, or active fragments thereof, could be prepared in pharmaceutical formulations for administration in instances wherein interferon therapy is appropriate, such as to treat chronic viral hepatitis, hairy cell leukemia, and for use of interferon in adjuvant therapy. The specificity of the receptor proteins hereof would make it
25 possible to better manage the aftereffects of current interferon therapy, and would thereby make it possible to apply interferon as a general antiviral agent.

Accordingly, it is a principal object of the present invention to provide a novel member of the family of receptor recognition factors, and subunits of such a novel
30 receptor recognition factor, in purified form that exhibits certain characteristics and activities associated with transcriptional promotion of cellular activity.

Is a particular object of the invention to provide fragments of such receptor recognition factors that inhibit activities of the factors.

It is a further object of the present invention to provide antibodies to the receptor
5 recognition factor and its subunits, and methods for their preparation, including recombinant means.

It is a further object of the present invention to provide a method for detecting the presence of the receptor recognition factor and its subunits in mammals in which
10 invasive, spontaneous, or idiopathic pathological states are suspected to be present.

It is a further object of the present invention to provide a method and associated assay system for screening substances such as drugs, agents and the like, potentially effective in either mimicking the activity or combating the adverse
15 effects of the recognition factor and/or its subunits in mammals.

It is a still further object of the present invention to provide a method for the treatment of mammals to control the amount or activity of the recognition factor or subunits thereof, so as to alter the adverse consequences of such presence or
20 activity, or where beneficial, to enhance such activity.

It is a still further object of the present invention to provide a method for the treatment of mammals to control the amount or activity of the recognition factor or its subunits, so as to treat or avert the adverse consequences of invasive,
25 spontaneous or idiopathic pathological states.

It is a still further object of the present invention to provide pharmaceutical compositions for use in therapeutic methods which comprise or are based upon the recognition factor, its subunits, their binding partner(s), or upon agents or drugs
30 that control the production, or that mimic or antagonize the activities of the recognition factors.

Other objects and advantages will become apparent to those skilled in the art from a review of the ensuing description which proceeds with reference to the following illustrative drawings.

5

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 depicts (A) the deduced amino acid sequence (SEQ ID NO:8) of and (B-C) the DNA sequence (SEQ ID NO:7) encoding the murine 91 kD intracellular receptor recognition factor.

10

FIGURE 2 depicts (A) the deduced amino acid sequence (SEQ ID NO:10) of and (B-D) the DNA sequence (SEQ ID NO:9) encoding the 13sf1 intracellular receptor recognition factor.

15 FIGURE 3 depicts (A) the deduced amino acid sequence (SEQ ID NO:12) of and (B-E) the DNA sequence (SEQ ID NO:11) encoding the 19sf6 intracellular receptor recognition factor.

FIGURE 4 presents identification of the phosphotyrosine residue in the 91 kD protein. (A) Tryptic phosphopeptide map of ^{32}P -91 kD protein from IFN- γ -treated FS2 cells. Phosphoamino acid analysis indicated that only peptide X contains phosphotyrosine (31). (B) Edman degradation of peptide X (32). The position of the PTH-P-Tyr marker detected by ultraviolet light is indicated. (C) Schematic diagram showing the site of the phosphotyrosine residue in the 91 kD protein.

25 HR, heptapeptide repeat; SH2, *Src* homology domain 2; and SH3, *Src* homology domain 3. (D) The synthetic peptide LDGPKGTYIKTELI (SEQ ID NO:13), which was phosphorylated with ^{32}P -labeled tyrosine, was digested with trypsin and analyzed by 2D peptide mapping either alone (left panel) or mixed with the same amount of ^{32}P -labeled peptide X (right panel). Ori, origin. The synthetic peptide
30 (10 μg) (obtained from Genetics) was incubated with 1 U of p45^{v-abl} (Oncogene Science), in 50 mM Hepes (pH 7.4), 0.1 mM EDTA, 0.015% Brij 35, 0.1 mM

ATP, 10 mM MgCl₂ and 2 μ Cl of [γ -³²P]ATP for 30 min. at 30°C. The ³²P-labeled peptide was subjected to electrophoresis at pH 3.5 on a thin layer chromatography plate and purified. Tryptic digestion of ³²P-labeled peptide was done as described (32).

5

Human FS2 cells were labeled with [³²P]orthophosphate (Du Pont) for 3 hours in phosphate-free medium and subsequently treated with IFN- γ for 10 min. Cell lysates were immunoprecipitated with antiserum to the COOH-terminal 35 amino acids of 91 kD (anti-91T) and separated by SDA-polyacrylamide gel

10 electrophoresis (PAGE) (7% gel). The ³²P-labeled 91 kD band was excised and subjected to tryptic mapping (31). Edman degradation was done as described (32, 33) with minor modifications. Peptide X (600 counts per minute) was taken through five cycles of Edman degradation. Samples from each cycle and an equivalent amount of untreated peptide X were analyzed by electrophoresis at pH
15 3.5. The PTH-P-Tyr marker was synthesized as described (31).

FIGURE 5 presents an analysis of phosphorylation of the 91 and 84 kD proteins in established cell lines. (A) Protein immunoblot analysis with antiserum to the 91 kD protein (anti-91) of whole-cell extracts from parental 2fTGH cells (lanes 1 and
20 4); mutant U3 cells lacking the 91 and 84 kD proteins (lanes 2 and 3); U3 cells expressing the 91 kD protein (C91, lane 6), the 84 kD protein (C84, lane 7), or the Tyr⁷⁰¹ mutant MNC-ty (Cty, lane 5). (B) Tryptic peptide map of the 84 kD protein. C84 cells were labeled with [³²P]orthophosphate for 3 hours and then treated with IFN- γ for 10 min.; immunoprecipitation with anti-91 and tryptic
25 peptide mapping of the ³²P-labeled 84-kDa protein was done as described (FIGURE 4). (C) Proteins in whole-cell lysates from 2fTGH (lanes 3, 4, 7 and 8) and Cty (lanes 1, 2, 5 and 6) cells were immunoprecipitated with anti-91T (31) and separated by SDA-PAGE (7% gel). The blot was then probed with a mAb to phosphotyrosine 4G10 (UBI, lanes 1 through 4). The blot was stripped and
30 reprobed with anti-91T (lanes 5 through 8). U3A cells (5 x 10⁵) (30) were transfected with 4 μ g of expression vector and 16 μ g of pBSK (Stratagene)

plasmid by the calcium phosphate procedure (35). Cells were selected in Dulbecco's modified Eagle's medium containing G418 (0.5 mg/ml) (Gibco, BRL). 48 hours after transfection, individual colonies were screened for the expression of appropriate proteins by protein immunoblotting. Cell lines were maintained in the presence of G418 (0.2 mg/ml). Expression vectors using the cytomegalovirus promoter and encoding the 91 or 84 kD protein were constructed by insertion of the cDNA into the NotI-BamHI cloning site of an expression vector pMNC (35). The TAT codon for Tyr⁷⁰¹ was changed to TTT by standard mutagenesis procedure with the polymerase chain reaction (PCR) (36, 37). The sequence was verified by DNA sequencing (U.S. Biochemical, Cleveland, Ohio). Molecular sizes are indicated to the left (A) or to the right (C) in kilodaltons.

FIGURE 6 presents data relating to DNA binding and nuclear localization of the 91 and 84 kD proteins. (A) DNA binding and translocation to the nucleus of the 91 and 84 kD proteins. Gel mobility-shift analysis of whole-cell extracts from Cty (lanes 1 and 2), 2fTGH (lanes 3 and 4), U3A (lanes 5 and 6), C91 (lanes 7 and 8), and C84 (lanes 9 and 10) cells treated with IFN- γ for 15 min (+) or untreated (-). A 21 nucleotide oligomer containing the GAS sequence from the Ly-6E gene (34) was labeled and used as a probe for shift assays as described (31). (B) Nuclear localization tested by immunofluorescence. Cells from stable cell lines C91 (a and b), C84 (c and d), and Cty (e and f) were stained with anti-91T (a,b,e, and f) and anti-91 (c and d) as described (31). Untreated, a, c, and e; IFN- γ for 30 min, b, d, and f.

FIGURE 7 presents an analysis of transcriptional activation. An oligonucleotide corresponding to the herpes simplex virus thymidine kinase (TK) promoter from -35 to +10 was fused to the HindIII site of pZLUC, a luciferase reporter construct (TK-LUC). One copy of the 91 kD binding site [a 21 nucleotide oligomer from the Ly-6E gene (34)] was inserted into the BamHI cloning site of TK-LUC (GAS-LUC). U3 cells were transfected by the calcium phosphate method as described (FIGURE 5) with 4 μ g of each construct. The cells were also transfected with 4

μ g of pMNC alone (35) (MNC) or pMNC encoding the 91 kD protein (MNC-91) or the 84 kD protein (MNC-84) or the Tyr⁷⁰¹ mutant of the 91 kD protein (MNC-ty). Lane 1, MNC-91 + GAS-LUC; lane 2, MNC-84 + GAS-LUC; lane 3, MNC + GAS-LUC; lane 4, MNC-ty + GAS-LUC; lane 4 MNC-91 + TK-LUC; and lane 6, GAS-LUC. Relative transfection efficiencies were monitored by inclusion of a β -galactosidase expression plasmid (pCMV β , Promega). Then, 36 hours after transfection, cells were treated with IFN- γ (5 ng/ml) for 6 hours, collected, and assayed for luciferase activities (Promega). (A) Data shown are taken from one representative experiment and represent the relative luciferase activity in cells treated with IFN- γ as compared with that from untreated cells (arbitrarily set to 1 U). (The luciferase assay was corrected for relative expression of a β -galactosidase). Each transfection was independently repeated at least three times. (B) Cell lysates from these same transfections were analyzed for the expression of proteins by protein immunoblotting with anti-91.

15

FIGURE 8 demonstrates that R⁶⁰² in the 91 kD protein SH2 domain is required for tyrosine phosphorylation. a) Western blot analysis of whole cell extracts from mutant U3A cell line (lane 3); parental 2fTGH cell line (lane 4); or U3A-derived cell lines transfected with an expression vector containing an R⁶⁰²->Leu⁶⁰² mutation (lanes 1 and 2). Antibody used was anti-91, which recognizes both the 91 and 84 kD proteins (15, 31). b) Immunoprecipitates with anti-91T antibody were subjected to 7.5% SDS-PAGE and probed with an anti-phosphotyrosine antibody. Mutagenesis was carried out by standard PCR procedure. The CGG codon for Arg⁶⁰² was mutated to CTG, which encodes Leu. Transfection and selection of stable cell lines was described in Figures 4-7 and Examples 3 and 4.

FIGURE 9. Determination of molecular weights of Stat91 and phospho Stat91 by native gel analysis. A) Western blot analysis of fractions from affinity purification. Extracts from human FS2 fibroblasts treated with IFN- γ (Ext), the unbound fraction (Flow), the fraction washed with Buffer AO.2 (AO.2), and the bound fraction eluted with buffer AO.8(AO.8) were immunoblotted with anti-91T.

30

B) Native gel analysis. Phosphorylated Stat91 (the AO.8 fraction from A) and unphosphorylated Stat91 (the Flow fraction from A) were analyzed on 4.5%, 5.5%, 6.5% and 7.5% native polyacrylamide gels followed by immunoblotting with anti-91T. The top of gels (TOP) and the migration position of bromophenol blue (BPB) are indicated. C) Ferguson plots. The relative mobilities (R_m) of the Stat91 and phospho Stat91 were obtained from Figure 1B (see Experimental Procedures). Closed circle: Chicken egg albumin (***) 45kD); Cross: Bovine serum albumin, monomer (66 kD); Open square: Bovine serum albumin, dimer (132 kD); Open circle: Urease, trimer (272 kD); Open triangle: Unphosphorylated Stat91; Closed triangle: Phosphorylated Stat91. D) Determination of molecular weights from the standard curve. The molecular weights of phosphorylated and unphosphorylated Stat91 proteins (indicated as closed and open arrows, respectively) were obtained by extrapolation of their retardation coefficients.

15 FIGURE 10. Determination of molecular weights by glycerol gradients.

A) Western blot analysis. Extracts from human Bud8 fibroblasts treated with IFN- γ (the rightmost lane) and every other fraction from fraction 16 to 34 were analyzed on 7.5% SDS-PAGE followed by immunoblotting with anti-91T. The peak of phosphorylated Stat91 (fraction 20) and the peak of unphosphorylated Stat91 (fraction 30) were indicated by a closed and open arrow, respectively. B) Mobility shift analysis. Every other fractions from the gradients were analyzed. C) Graphic representation of the data from A and B. Peak fraction numbers of protein standards are plotted versus their molecular weight. The position of peaks (of phosphorylated and unphosphorylated Stat91 protein are indicated by the closed and open arrows, respectively. Standards are ferritin (Fer, 440 kD), catalase (Cat, 232 kD), ferritin half unit (Fer 1/2, 220 kD), aldolase (Ald, 158 kD), bovine serum albumin (BSA, 68 kD).

FIGURE 11. Stat91 in cell extracts binds DNA as a dimer. A) Western blot analysis. Extracts from stable cell lines expressing either Stat84 (C84), or Stat91L (C91L) or both (Cmx) were analyzed on 7.5% SDS-PAGE followed by

immunoblotting with anti-91. B) Gel mobility shift analysis. Extracts from stable cell lines (Fig 3A) untreated (-) or treated with IFN- γ (+) were analyzed. The positions of Stat91 homodimer (91L), Stat84 homodimer (84), and the heterodimer (84*91) are indicated.

5

FIGURE 12. Formation of heterodimer by denaturation and renaturation.

Cytoplasmic (Left Panel) or nuclear extracts (Right Panel) from IFN- γ -treated cell lines expressing either Stat84 (C84) or Stat91 (C91) were analyzed by gel mobility shift assays. +: with addition; -: without addition; D/R: samples were subjected

10 to guanidinium hydrochloride denaturation and renaturation treatment.

FIGURE 13. Diagrammatic representation of dissociation and reassociation analysis.

15 FIGURE 14. Dissociation-reassociation analysis with peptides. Gel mobility shift analysis with IFN- γ treated nuclear extracts from cell lines expressing Stat91L (C91L, lane 15) or Stat84 (C84, lane 14) or mixture of both (lane 1-13, 16-18) in the presence of increasing concentrations of various peptides. 91-Y, unphosphorylated peptide from Stat91 (LDGPKGTYGYIKTELI) (SEQ ID NO:15);
20 91Y-p, phosphotyrosyl peptide from Stat91 (GY*IKTE) (SEQ ID NO:16); 113Y-p, phosphotyrosyl peptide with high binding affinity to Src SH2 domain (EPQY*EEIPIYL, Songyang et al., 1993, Cell 72:767-778) (SEQ ID NO:18). Final concentrations of peptides added: 1 μ M (lane 8), 4 μ M (lane 2,5, 11), 10 μ M (lane 9), 40 μ M (lane 3, 6, 10, 12, 14-18), 160 μ M (lane 4, 7, 13). +: with
25 addition; -: without addition. Right panel: antiserum tests for identity of gel-shift bands.

FIGURE 15. Dissociation-reassociation analysis with GST fusion proteins. A) SDS-PAGE (12%) analysis of purified GST fusion proteins as visualized by
30 Commassie blue. GST-91 SH3, native SH2 domain of Stat91; GST-91 mSH2, R⁶⁰² to L⁶⁰² mutant; GST-91 SH3, SH3 domain of Stat91; GST Src SH2, the SH2

domain of src protein. Same amounts (1 μ g) of each fusion proteins were loaded. Protein markers were run in lane 1 as indicated. B) Dissociation-reassociation analysis. Dissociating agents were GST fusion proteins purified from bacterial expression as shown above. Final concentrations of fusion proteins added are 0.5 μ M (lanes 2, 5, 8, 11, 14), 2.5 μ M (lanes 3, 6, 9, 12, 15) and 5 μ M (lanes 4, 7, 10, 13, 17, 18). +: with addition; -: without addition; FP: fusion proteins.

FIGURE 16. Comparison of Stat91 SH2 structure with known SH2 structures. The Stat91 sequence is disclosed herein (SEQ ID NO:4). The structures used for the other SH2s are Src (Waksman et al., 1992, Nature 358:646-653) (SEQ ID NO:19), Abl (Overduin et al., 1992, Proc. Natl. Acad. Sci. USA 89:11673-77 and 1992, Cell 70:697-704) (SEQ ID NO:20), Lck (Eck et al., 1993, Nature 362:87-91) (SEQ ID NO:21), and p85 α N (Booker et al., 1992, Nature 358:684-687) (SEQ ID NO:22). The alignment of the determined structures is by direct coordinate superimposition of the backbone structures. The names of secondary structural features and significant residues is based on the scheme of Eck et al., 1993. The boundaries and extents of the structure features are indicated by [---]. The starting numbers for the parent sequences are shown in parentheses. Experimentally determined structurally conserved regions are from Src, p85 α , and Abl (Cowburn, unpublished). The root mean square deviation of three-dimensionally aligned structures differs by less than 1 Angstrom for the backbone non-hydrogen atoms in the sections marked by the XXX.

DETAILED DESCRIPTION

25

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Maniatis, Fritsch & Sambrook, "Molecular Cloning: A Laboratory Manual" (1982); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover ed. 1985); "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid

Hybridization" [B.D. Hames & S.J. Higgins eds. (1985)]; "Transcription And Translation" [B.D. Hames & S.J. Higgins, eds. (1984)]; "Animal Cell Culture" [R.I. Freshney, ed. (1986)]; "Immobilized Cells And Enzymes" [IRL Press, (1986)]; B. Perbal, "A Practical Guide To Molecular Cloning" (1984).

5

Therefore, if appearing herein, the following terms shall have the definitions set out below.

The terms "receptor recognition factor", "receptor recognition-tyrosine kinase factor", "receptor recognition factor/tyrosine kinase substrate", "receptor recognition/transcription factor", "recognition factor", "recognition factor protein(s)", "signal transducers and activators of transcription", "STAT", and any variants not specifically listed, may be used herein interchangeably, and as used throughout the present application and claims refer to proteinaceous material including single or multiple proteins, and extends to those proteins having the amino acid sequence data described herein and presented in FIGURE 1 (SEQ ID NO:8), FIGURE 2 (SEQ ID NO:10), and in FIGURE 3 (SEQ ID NO:12), and the profile of activities set forth herein and in the Claims. Accordingly, proteins displaying substantially equivalent or altered activity are likewise contemplated.

20 These modifications may be deliberate, for example, such as modifications obtained through site-directed mutagenesis, or may be accidental, such as those obtained through mutations in hosts that are producers of the complex or its named subunits. Also, the terms "receptor recognition factor", "recognition factor", "recognition factor protein(s)", "signal transducers and activators of transcription", and "STAT" are intended to include within their scope proteins specifically recited herein as well as all substantially homologous analogs and allelic variations.

25

The amino acid residues described herein are preferred to be in the "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property of immunoglobulin-binding is retained by the polypeptide. NH₂ refers to the free amino group

30

present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide. In keeping with standard polypeptide nomenclature, *J. Biol. Chem.*, **243**:3552-59 (1969), abbreviations for amino acid residues are shown in the following Table of Correspondence:

5

TABLE OF CORRESPONDENCE

<u>SYMBOL</u>		<u>AMINO ACID</u>	
	<u>1-Letter</u>	<u>3-Letter</u>	
	Y	Tyr	tyrosine
10	G	Gly	glycine
	F	Phe	phenylalanine
	M	Met	methionine
	A	Ala	alanine
	S	Ser	serine
15	I	Ile	isoleucine
	L	Leu	leucine
	T	Thr	threonine
	V	Val	valine
	P	Pro	proline
20	K	Lys	lysine
	H	His	histidine
	Q	Gln	glutamine
	E	Glu	glutamic acid
	W	Trp	tryptophan
25	R	Arg	arginine
	D	Asp	aspartic acid
	N	Asn	asparagine
	C	Cys	cysteine

30 It should be noted that all amino-acid residue sequences are represented herein by formulae whose left and right orientation is in the conventional direction of amino-

terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino-acid residues. The above Table is presented to correlate the three-letter and one-letter notations which may appear alternately herein.

A "DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its either single stranded form, or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA).

A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell. A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a

cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to
5 initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT" boxes. Prokaryotic
10 promoters contain Shine-Dalgarno sequences in addition to the -10 and -35 consensus sequences. An "expression control sequence" is a DNA sequence that controls and regulates the transcription and translation of another DNA sequence, *e.g.*, and enhancer or suppressor element. A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA
15 polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence.

A DNA sequence is "operatively linked" to an expression control sequence when the expression control sequence controls and regulates the transcription and
20 translation of that DNA sequence. The term "operatively linked" includes having an appropriate start signal (*e.g.*, ATG) in front of the DNA sequence to be expressed and maintaining the correct reading frame to permit expression of the DNA sequence under the control of the expression control sequence and production of the desired product encoded by the DNA sequence. If a gene that
25 one desires to insert into a recombinant DNA molecule does not contain an appropriate start signal, such a start signal can be inserted in front of the gene.

The term "standard hybridization conditions" refers to salt and temperature conditions substantially equivalent to 5 x SSC and 65°C for both hybridization and
30 wash.

A "signal sequence" can be included before the coding sequence. This sequence encodes a signal peptide, N-terminal to the polypeptide, that communicates to the host cell to direct the polypeptide to the cell surface or secrete the polypeptide into the media, and this signal peptide is clipped off by the host cell before the protein
5 leaves the cell. Signal sequences can be found associated with a variety of proteins native to prokaryotes and eukaryotes.

The term "oligonucleotide", as used herein in referring to the probe of the present invention, is defined as a molecule comprised of two or more ribonucleotides,
10 preferably more than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide.

The term "primer" as used herein refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is
15 capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and pH. The primer may be either single-stranded or double-stranded and must be sufficiently
20 long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, source of primer and use of the method. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15-25 or more nucleotides, although it
25 may contain fewer nucleotides.

The primers herein are selected to be "substantially" complementary to different strands of a particular target DNA sequence. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore,
30 the primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment may be attached to the 5' end

of the primer, with the remainder of the primer sequence being complementary to the strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence of the strand to hybridize therewith and
5 thereby form the template for the synthesis of the extension product.

A cell has been "transformed" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of
10 the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated
15 by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A "clone" is a population of cells derived from a single cell or common ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth *in vitro* for many generations.

20

Two DNA sequences are "substantially homologous" when at least about 75% (preferably at least about 80%, and most preferably at least about 90 or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by comparing the sequences
25 using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Maniatis et al., *supra*; DNA Cloning, Vols. I & II, *supra*; Nucleic Acid Hybridization, *supra*.

30

A "heterologous" region of the DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. Another example of a heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., a cDNA where the genomic coding sequence contains introns, or synthetic sequences having codons different than the native gene). Allelic variations or naturally-occurring mutational events do not give rise to a heterologous region of DNA as defined herein.

An "antibody" is any immunoglobulin, including antibodies and fragments thereof, that binds a specific epitope. The term encompasses polyclonal, monoclonal, and chimeric antibodies, the last mentioned described in further detail in U.S. Patent Nos. 4,816,397 and 4,816,567. An "antibody combining site" is that structural portion of an antibody molecule comprised of heavy and light chain variable and hypervariable regions that specifically binds antigen. The phrase "antibody molecule" in its various grammatical forms as used herein contemplates both an intact immunoglobulin molecule and an immunologically active portion of an immunoglobulin molecule. Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contains the paratope, including those portions known in the art as Fab, Fab', F(ab')₂ and F(v), which portions are preferred for use in the therapeutic methods described herein. The phrase "monoclonal antibody" in its various grammatical forms refers to an antibody having only one species of antibody combining site capable of immunoreacting with a particular antigen. A monoclonal antibody thus typically displays a single binding affinity for any antigen with which it immunoreacts. A monoclonal antibody may therefore contain an antibody molecule having a plurality of antibody combining sites, each immunospecific for a different antigen; e.g., a bispecific (chimeric) monoclonal antibody.

The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. Preferably, as used herein, the term

5 "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.

10 The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to prevent, and preferably reduce by at least about 30 percent, more preferably by at least 50 percent, most preferably by at least 90 percent, a clinically significant change in the S phase activity of a target cellular mass, or other feature of pathology such as for example, elevated blood pressure, fever or
15 white cell count as may attend its presence and activity.

In its primary aspect, the present invention concerns the identification of novel receptor recognition factors, and the isolation and sequencing of a particular receptor recognition factor proteins, that are believed to be present in cytoplasm
20 and that serves as a signal transducer between a particular cellular receptor having bound thereto an equally specific polypeptide ligand, and the comparably specific transcription factor that enters the nucleus of the cell and interacts with a specific DNA binding site for the activation of the gene to promote the predetermined response to the particular polypeptide stimulus. The present disclosure confirms
25 that specific and individual receptor recognition factors exist that correspond to known stimuli such as tumor necrosis factor, nerve growth factor, platelet-derived growth factor and the like. Specific evidence of this is set forth herein with respect to the interferons α and γ (IFN α and IFN γ).

30 A further property of the receptor recognition factors (also termed herein signal transducers and activators of transcription -- STAT) is dimerization to form

homodimers or heterodimers upon activation by phosphorylation of tyrosine. In a specific embodiment, *infra*, Stat91 and Stat84 form homodimers and a Stat91-Stat84 heterodimer. Accordingly, the present invention is directed to such dimers, which can form spontaneously by phosphorylation of the STAT protein, or which
5 can be prepared synthetically by chemically cross-linking two like or unlike STAT proteins.

The present receptor recognition factor is likewise noteworthy in that it appears not to be demonstrably affected by fluctuations in second messenger activity and
10 concentration. The receptor recognition factor proteins appear to act as a substrate for tyrosine kinase domains, however do not appear to interact with G-proteins, and therefore do not appear to be second messengers.

A particular receptor recognition factor identified herein by SEQ ID NO:4, Stat91
15 or Stat1 α , has been determined to be present in cytoplasm and serves as a signal transducer and a specific transcription factor in response to IFN- γ stimulation that enters the nucleus of the cell and interacts directly with a specific DNA binding site for the activation of the gene to promote the predetermined response to the particular polypeptide stimulus. This particular factor also acts as a translation
20 protein and, in particular, as a DNA binding protein in response to interferon- γ stimulation. This factor is likewise noteworthy in that it has the following characteristics:

- a) It interacts with an interferon- γ -bound receptor kinase complex;
- b) It is a tyrosine kinase substrate; and
- 25 c) When phosphorylated, it serves as a DNA binding protein.

More particularly, the factor of SEQ ID NO:4 directly interacts with DNA after acquiring phosphate on tyrosine located at position 701 of the amino acid sequence. Also, interferon- γ -dependent activation of this factor occurs without
30 new protein synthesis and appears within minutes of interferon- γ treatment.

achieves maximum extent between 15 and 30 minutes thereafter, and then disappears after 2-3 hours.

Stat 91 is more particularly characterized by at least one of the following

5 additional characteristics:

- d) Phosphorylation of tyrosine-701 is required for nuclear transport;
- e) Phosphorylation of tyrosine-701 is required for DNA binding;
- f) Phosphorylation of tyrosine-701 is required for transcription

activation;

- 10 g) A functional SH2 domain is required for tyrosine-701 phosphorylation.

Yet a further property of the present factor is its ability to dimerize when phosphorylated. Accordingly, a further property of the receptor recognition

15 factors (also termed herein signal transducers and activators of transcription -- STAT) is dimerization to form homodimers or heterodimers upon activation by phosphorylation of tyrosine. In a specific embodiment, *infra*, Stat91 and Stat84 form homodimers and a Stat91-Stat84 heterodimer. Accordingly, the present invention is directed to such dimers, which can form spontaneously by

20 phosphorylation of the STAT protein, or which can be prepared synthetically by chemically cross-linking two like or unlike STAT proteins.

The present invention further relates to receptor recognition factors that are functionally active fragments, *e.g.*, as exemplified herein with fragments of the 91

25 kD receptor recognition factor, particularly such fragments that contain an amino acid residue corresponding to the tyrosine 701 residue, and preferably that contain a corresponding phosphotyrosine residue. In a different embodiment, the functionally active fragments further comprises the SH2 domain, particularly the SH2 domain that has a residue corresponding to an arginine-602 residue of the 91-

30 kD receptor recognition factor. It is envisioned that such functionally active receptor recognition factors comprise at least about 8 amino acid residues.

The invention contemplates inhibitory fragments of such receptor recognition proteins, *e.g.*, as exemplified herein with respect to the 91 kD protein. In one embodiment, the SH2 domain of the 91 kD protein can competitively inhibit phosphorylation of the whole protein or fragment thereof containing tyrosine 701.

- 5 In another embodiment, an inhibitory fragment can compete with the 91 kD protein for binding to a tyrosine kinase. Such an inhibitory fragment may contain a residue corresponding to tyrosine 701.

- In yet a further embodiment, the invention contemplates antagonists of the activity of a receptor recognition factor (STAT). In particular, an agent or molecule that inhibits dimerization (homodimerization or heterodimerization) can be used to block transcription activation effected by an activated, phosphorylated STAT protein. In a specific embodiment, the antagonist can be a peptide having the sequence of a portion of an SH2 domain of a STAT protein, or the
- 15 phosphotyrosine domain of a STAT protein, or both. If the peptide contains both regions, preferably the regions are located in tandem, more preferably with the SH2 domain portion N-terminal to the phosphotyrosine portion. In a specific example, *infra*, such peptides are shown to be capable of disrupting dimerization of STAT proteins.

20

- Subsequent to the filing of the initial applications directed to the present invention, the inventors have termed each member of the family of receptor recognition factors as a signal transducer and activator of transcription (STAT) protein. Each STAT protein is designated by the apparent molecular weight (*e.g.*, Stat113, Stat91, Stat84. etc.), or by the order in which it has been identified (*e.g.*, Stat1 α [Stat91], Stat1 β [Stat84], Stat2 [Stat113], Stat3 [a murine protein also termed 19sf6], and Stat4 [a murine STAT protein also termed 13sf1]). As will be readily appreciated by one of ordinary skill in the art, the choice of name has no effect on the intrinsic characteristics of the factors described herein, which were first
- 25
- 30 disclosed in International Patent Publication No. WO 93/19179, published 30 September 1993. The present inventors have chosen to adopt this newly derived

terminology herein as a convenience to the skilled artisan who is familiar with the subsequently published papers relating to the same, and in accordance with the proposal to harmonize the terminology for the novel class of proteins, and nucleic acids encoding the proteins, disclosed by the instant inventors. The terms

5 [molecular weight] kd receptor recognition factor, Stat[molecular weight], and Stat[number] are used herein interchangeably, and have the meanings given above. For example, the terms 91 kd protein, Stat91, and Stat1 α refer to the same protein, and in the appropriate context refer to the nucleic acid molecule encoding such protein.

10

As stated above, the present invention also relates to a recombinant DNA molecule or cloned gene, or a degenerate variant thereof, which encodes a receptor recognition factor, or a fragment thereof, that has a molecular weight of about 91 kD and the amino acid sequence set forth in FIGURE 1 (SEQ ID NO:8);

15 preferably a nucleic acid molecule, in particular a recombinant DNA molecule or cloned gene, encoding the 91 kD receptor recognition factor has a nucleotide sequence or is complementary to a DNA sequence shown in FIGURE 1 (SEQ ID NO:8). In yet another embodiment, the receptor recognition factor has an amino acid sequence set forth in FIGURE 2 (SEQ ID NO:10); preferably a nucleic acid

20 molecule, in particular a recombinant DNA molecule or cloned gene, encoding such receptor recognition factor has a nucleotide sequence or is complementary to a DNA sequence shown in FIGURE 2 (SEQ ID NO:9). In still another embodiment, the receptor recognition factor has an amino acid sequence set forth in FIGURE 3 (SEQ ID NO:12); preferably a nucleic acid molecule, in particular a

25 recombinant DNA molecule or cloned gene, encoding such receptor recognition factor has a nucleotide sequence or is complementary to a DNA sequence shown in FIGURE 3 (SEQ ID NO:11).

The possibilities both diagnostic and therapeutic that are raised by the existence of

30 the receptor recognition factor or factors, derive from the fact that the factors appear to participate in direct and causal protein-protein interaction between the

receptor that is occupied by its ligand, and those factors that thereafter directly interface with the gene and effect transcription and accordingly gene activation. As suggested earlier and elaborated further on herein, the present invention contemplates pharmaceutical intervention in the cascade of reactions in which the
5 receptor recognition factor is implicated, to modulate the activity initiated by the stimulus bound to the cellular receptor.

Thus, in instances where it is desired to reduce or inhibit the gene activity resulting from a particular stimulus or factor, an appropriate inhibitor of the
10 receptor recognition factor could be introduced to block the interaction of the receptor recognition factor with those factors causally connected with gene activation. Correspondingly, instances where insufficient gene activation is taking place could be remedied by the introduction of additional quantities of the receptor recognition factor or its chemical or pharmaceutical cognates, analogs, fragments
15 and the like.

As discussed earlier, the recognition factors or their binding partners or other ligands or agents exhibiting either mimicry or antagonism to the recognition factors or control over their production, may be prepared in pharmaceutical
20 compositions, with a suitable carrier and at a strength effective for administration by various means to a patient experiencing an adverse medical condition associated specific transcriptional stimulation for the treatment thereof. A variety of administrative techniques may be utilized, among them parenteral techniques such as subcutaneous, intravenous and intraperitoneal injections, catheterizations and the
25 like. Average quantities of the recognition factors or their subunits may vary and in particular should be based upon the recommendations and prescription of a qualified physician or veterinarian.

Also, antibodies including both polyclonal and monoclonal antibodies, and drugs
30 that modulate the production or activity of the recognition factors and/or their subunits may possess certain diagnostic applications and may for example, be

utilized for the purpose of detecting and/or measuring conditions such as viral infection or the like. For example, the recognition factor or its subunits may be used to produce both polyclonal and monoclonal antibodies to themselves in a variety of cellular media, by such well known techniques as immunization of
5 rabbit using Complete and Incomplete Freund's Adjuvant and the hybridoma technique utilizing, for example, fused mouse spleen lymphocytes and myeloma cells, respectively. These techniques have been described in numerous publications in great detail, *e.g.*, International Patent Publication WO 93/19179, and do not bear repeating here.

10

Likewise, small molecules that mimic or antagonize the activity(ies) of the receptor recognition factors of the invention may be discovered or synthesized, and may be used in diagnostic and/or therapeutic protocols.

15 As suggested earlier, the diagnostic method of the present invention comprises examining a cellular sample or medium by means of an assay including an effective amount of an antagonist to a receptor recognition factor/protein, such as an anti-recognition factor antibody, preferably an affinity-purified polyclonal antibody, and more preferably a mAb. In addition, it is preferable for the anti-
20 recognition factor antibody molecules used herein be in the form of Fab, Fab', F(ab')₂ or F(v) portions or whole antibody molecules. As previously discussed, patients capable of benefiting from this method include those suffering from cancer, a pre-cancerous lesion, a viral infection or other like pathological derangement. Methods for isolating the recognition factor and inducing anti-
25 recognition factor antibodies and for determining and optimizing the ability of anti-recognition factor antibodies to assist in the examination of the target cells are all well-known in the art.

The present invention further contemplates therapeutic compositions useful in
30 practicing the therapeutic methods of this invention. A subject therapeutic composition includes, in admixture, a pharmaceutically acceptable excipient

(carrier) and one or more of a receptor recognition factor, polypeptide analog thereof or fragment thereof, as described herein as an active ingredient. In a preferred embodiment, the composition comprises an antigen capable of modulating the specific binding of the present recognition factor within a target
5 cell.

The preparation of therapeutic compositions which contain polypeptides, analogs or active fragments as active ingredients is well understood in the art. Typically, such compositions are prepared as injectables, either as liquid solutions or
10 suspensions, however, solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The preparation can also be emulsified. The active therapeutic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like
15 and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents which enhance the effectiveness of the active ingredient.

A polypeptide, analog or active fragment can be formulated into the therapeutic
20 composition as neutralized pharmaceutically acceptable salt forms.

Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide or antibody molecule) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed
25 from the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

30 The therapeutic polypeptide-, analog- or active fragment-containing compositions are conventionally administered intravenously, as by injection of a unit dose, for

example. The term "unit dose" when used in reference to a therapeutic composition of the present invention refers to physically discrete units suitable as unitary dosage for humans, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; i.e., carrier, or vehicle.

The compositions are administered in a manner compatible with the dosage formulation, and in a therapeutically effective amount. The quantity to be administered depends on the subject to be treated, capacity of the subject's immune system to utilize the active ingredient, and degree of inhibition or neutralization of recognition factor binding capacity desired. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and are peculiar to each individual. However, suitable dosages may range from about 0.1 to 20, preferably about 0.5 to about 10, and more preferably one to several, milligrams of active ingredient per kilogram body weight of individual per day and depend on the route of administration. Suitable regimes for initial administration and booster shots are also variable, but are typified by an initial administration followed by repeated doses at one or more hour intervals by a subsequent injection or other administration. Alternatively, continuous intravenous infusion sufficient to maintain concentrations of ten nanomolar to ten micromolar in the blood are contemplated.

The therapeutic compositions may further include an effective amount of the factor/factor synthesis promoter antagonist or analog thereof, and one or more of the following active ingredients: an antibiotic, a steroid. Exemplary formulations are well known in the art, *e.g.*, as disclosed in International Patent Publication WO 93/19179.

Another feature of this invention is the expression of the DNA sequences disclosed herein. As is well known in the art, DNA sequences may be expressed by operatively linking them to an expression control sequence in an appropriate

expression vector and employing that expression vector to transform an appropriate unicellular host.

Such operative linking of a DNA sequence of this invention to an expression control sequence, of course, includes, if not already part of the DNA sequence, the provision of an initiation codon, ATG, in the correct reading frame upstream of the DNA sequence.

A wide variety of host/expression vector combinations may be employed in expressing the DNA sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and Synthetic DNA sequences. Suitable vectors include derivatives of SV40 and known bacterial plasmids, e.g., *E. coli* plasmids col E1, pCR1, pBR322, pMB9 and their derivatives, plasmids such as RP4; phage DNAs, e.g., the numerous derivatives of phage λ , e.g., NM989, and other phage DNA, e.g., M13 and Filamentous single stranded phage DNA; yeast plasmids such as the 2μ plasmid or derivatives thereof; vectors useful in eukaryotic cells, such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage DNA or other expression control sequences; and the like.

Any of a wide variety of expression control sequences -- sequences that control the expression of a DNA sequence operatively linked to it -- may be used in these vectors to express the DNA sequences of this invention. Such useful expression control sequences include, for example, the early or late promoters of SV40, CMV, vaccinia, polyoma or adenovirus, the *lac* system, the *trp* system, the *TAC* system, the *TRC* system, the *LTR* system, the major operator and promoter regions of phage λ , the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase (e.g., Pho5), the promoters of the yeast α -mating factors, and other

sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof.

A wide variety of unicellular host cells are also useful in expressing the DNA sequences of this invention. These hosts may include well known eukaryotic and prokaryotic hosts, such as strains of *E. coli*, *Pseudomonas*, *Bacillus*, *Streptomyces*, fungi such as yeasts, and animal cells, such as CHO, R1.1, B-W and L-M cells, African Green Monkey kidney cells (e.g., COS 1, COS 7, BSC1, BSC40, and BMT10), insect cells (e.g., Sf9), and human cells and plant cells in tissue culture.

Alternatively, a genes encoding a receptor recognition factor of the invention may be incorporated in a transgenic expression vector, e.g., one of the well known retroviral vectors, for *in vivo* or *ex vivo* transfection of cells for gene therapy.

It will be understood that not all vectors, expression control sequences and hosts will function equally well to express the DNA sequences of this invention. Neither will all hosts function equally well with the same expression system. However, one skilled in the art will be able to select the proper vectors, expression control sequences, and hosts without undue experimentation to accomplish the desired expression without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must function in it. The vector's copy number, the ability to control that copy number, and the expression of any other proteins encoded by the vector, such as antibiotic markers, will also be considered.

In selecting an expression control sequence, a variety of factors will normally be considered. These include, for example, the relative strength of the system, its controllability, and its compatibility with the particular DNA sequence or gene to be expressed, particularly as regards potential secondary structures. Suitable unicellular hosts will be selected by consideration of, e.g., their compatibility with

the chosen vector, their secretion characteristics, their ability to fold proteins correctly, and their fermentation requirements, as well as the toxicity to the host of the product encoded by the DNA sequences to be expressed, and the ease of purification of the expression products.

5

Considering these and other factors a person skilled in the art will be able to construct a variety of vector/expression control sequence/host combinations that will express the DNA sequences of this invention on fermentation or in large scale animal culture.

10

It is further intended that receptor recognition factor analogs may be prepared from nucleotide sequences of the protein complex/subunit derived within the scope of the present invention. Analogs, such as fragments, may be produced, for example, by pepsin digestion of receptor recognition factor material. Other
15 analogs, such as muteins, can be produced by standard site-directed mutagenesis of receptor recognition factor coding sequences. Analogs exhibiting "receptor recognition factor activity" such as small molecules, whether functioning as promoters or inhibitors, may be identified by known *in vivo* and/or *in vitro* assays.

20 As mentioned above, a DNA sequence encoding receptor recognition factor can be prepared synthetically rather than cloned. The DNA sequence can be designed with the appropriate codons for the receptor recognition factor amino acid sequence. In general, one will select preferred codons for the intended host if the sequence will be used for expression. The complete sequence is assembled from
25 overlapping oligonucleotides prepared by standard methods and assembled into a complete coding sequence. See, e.g., Edge, *Nature*, **292**:756 (1981); Nambair et al., *Science*, **223**:1299 (1984); Jay et al., *J. Biol. Chem.*, **259**:6311 (1984).

Synthetic DNA sequences allow convenient construction of genes which will
30 express receptor recognition factor analogs or "muteins". Alternatively, DNA encoding muteins can be made by site-directed mutagenesis of native receptor

recognition factor genes or cDNAs, and muteins can be made directly using conventional polypeptide synthesis.

5 A general method for site-specific incorporation of unnatural amino acids into proteins is described in Christopher J. Noren, Spencer J. Anthony-Cahill, Michael C. Griffith, Peter G. Schultz, *Science*, **244**:182-188 (April 1989). This method may be used to create analogs with unnatural amino acids.

10 The present invention extends to the preparation of antisense nucleotides and ribozymes that may be used to interfere with the expression of the receptor recognition proteins at the translational level. This approach utilizes antisense nucleic acid and ribozymes to block translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or cleaving it with a ribozyme. Antisense and ribozyme technology are well known in the art, and have been
15 described in many publications, *e.g.*, International Patent Publication WO 93/19179.

The present invention also relates to a variety of diagnostic applications, including methods for detecting the presence of stimuli such as the earlier referenced
20 polypeptide ligands, by reference to their ability to elicit the activities which are mediated by the present receptor recognition factor.

As mentioned earlier, the receptor recognition factor can be used to produce antibodies to itself by a variety of known techniques, and such antibodies could
25 then be isolated and utilized as in tests for the presence of particular transcriptional activity in suspect target cells. Many assay procedures, or formats, are well known in the art. The "competitive" procedure is described in U.S. Patent Nos. 3,654,090 and 3,850,752. The "sandwich" procedure, is described in U.S. Patent Nos. RE 31,006 and 4,016,043. Still other procedures are known such as the
30 "double antibody", or "DASP" procedure. In each instance, the receptor recognition factor forms complexes with one or more antibody(ies) or binding

partners and one member of the complex is labeled with a detectable label. The fact that a complex has formed and, if desired, the amount thereof, can be determined by known methods applicable to the detection of labels.

- 5 The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to ultraviolet light, and others. A number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine and auramine. The receptor recognition factor or its binding partner(s) can also be labeled with a radioactive
10 element or with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The preferred isotope may be selected from ^3H , ^{14}C , ^{32}P , ^{35}S , ^{36}Cl , ^{51}Cr , ^{57}Co , ^{58}Co , ^{59}Fe , ^{90}Y , ^{125}I , ^{131}I , and ^{186}Re . Enzyme labels are likewise useful, and can be detected by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric
15 or gasometric techniques.

- A particular assay system developed and utilized in accordance with the present invention, is known as a receptor assay. In a receptor assay, the material to be assayed is appropriately labeled and then certain cellular test colonies are
20 inoculated with a quantity of both the labeled and unlabeled material after which binding studies are conducted to determine the extent to which the labeled material binds to the cell receptors. In this way, differences in affinity between materials can be ascertained.

- 25 Accordingly, a purified quantity of the receptor recognition factor may be radiolabeled and combined, for example, with antibodies or other inhibitors thereto, after which binding studies would be carried out. Solutions would then be prepared that contain various quantities of labeled and unlabeled uncombined receptor recognition factor, and cell samples would then be inoculated and
30 thereafter incubated. The resulting cell monolayers are then washed, solubilized and then counted in a gamma counter for a length of time sufficient to yield a

standard error of $<5\%$. These data are then subjected to Scatchard analysis after which observations and conclusions regarding material activity can be drawn.

While the foregoing is exemplary, it illustrates the manner in which a receptor assay may be performed and utilized, in the instance where the cellular binding

5 ability of the assayed material may serve as a distinguishing characteristic.

An assay useful and contemplated in accordance with the present invention is known as a "cis/trans" assay. Briefly, this assay employs two genetic constructs, one of which is typically a plasmid that continually expresses a particular receptor
10 of interest when transfected into an appropriate cell line, and the second of which is a plasmid that expresses a reporter such as luciferase, under the control of a receptor/ligand complex. Thus, for example, if it is desired to evaluate a compound as a ligand for a particular receptor, one of the plasmids would be a construct that results in expression of the receptor in the chosen cell line, while the
15 second plasmid would possess a promoter linked to the luciferase gene in which the response element to the particular receptor is inserted. If the compound under test is an agonist for the receptor, the ligand will complex with the receptor, and the resulting complex will bind the response element and initiate transcription of the luciferase gene. The resulting chemiluminescence is then measured
20 photometrically, and dose response curves are obtained and compared to those of known ligands. The foregoing protocol is described in detail in U.S. Patent No. 4,981,784 and PCT International Publication No. WO 88/03168, for which purpose the artisan is referred.

25 In a further embodiment of this invention, commercial test kits suitable for use by a medical specialist may be prepared to determine the presence or absence of predetermined transcriptional activity or predetermined transcriptional activity capability in suspected target cells. In accordance with the testing techniques discussed above, one class of such kits will contain at least the labeled receptor
30 recognition factor or its binding partner, for instance an antibody specific thereto, and directions, of course, depending upon the method selected, e.g.,

"competitive", "sandwich", "DASP" and the like. The kits may also contain peripheral reagents such as buffers, stabilizers, etc.

- Accordingly, a test kit may be prepared for the demonstration of the presence or capability of cells for predetermined transcriptional activity, comprising:
- 5 (a) a predetermined amount of at least one labeled immunochemically reactive component obtained by the direct or indirect attachment of the present receptor recognition factor or a specific binding partner thereto, to a detectable label;
 - (b) other reagents; and
 - 10 (c) directions for use of said kit.

More specifically, the diagnostic test kit may comprise:

- (a) a known amount of the receptor recognition factor as described above (or a binding partner) generally bound to a solid phase to form an immunosorbent, or
15 in the alternative, bound to a suitable tag, or plural such end products, etc. (or their binding partners) one of each;
 - (b) if necessary, other reagents; and
 - (c) directions for use of said test kit.
- 20 In a further variation, the test kit may be prepared and used for the purposes stated above, which operates according to a predetermined protocol (e.g. "competitive", "sandwich", "double antibody", etc.), and comprises:
- (a) a labeled component which has been obtained by coupling the receptor recognition factor to a detectable label;
 - 25 (b) one or more additional immunochemical reagents of which at least one reagent is a ligand or an immobilized ligand, which ligand is selected from the group consisting of:
 - (i) a ligand capable of binding with the labeled component (a);
 - (ii) a ligand capable of binding with a binding partner of the labeled
30 component (a);

(iii) a ligand capable of binding with at least one of the component(s) to be determined; and

(iv) a ligand capable of binding with at least one of the binding partners of at least one of the component(s) to be determined;

5 and

(c) directions for the performance of a protocol for the detection and/or determination of one or more components of an immunochemical reaction between the receptor recognition factor and a specific binding partner thereto.

- 10 In accordance with the above, an assay system for screening potential drugs effective to modulate the activity of the receptor recognition factor may be prepared. The receptor recognition factor may be introduced into a test system, and the prospective drug may also be introduced into the resulting cell culture, and the culture thereafter examined to observe any changes in the transcriptional
- 15 activity of the cells, due either to the addition of the prospective drug alone, or due to the effect of added quantities of the known receptor recognition factor.

The present invention may be better understood by reference to the following Examples, which are provided by way of exemplification and not limitation.

20

EXAMPLE 1: IDENTIFICATION OF MURINE 91 KD PROTEIN

A fragment of the gene encoding the human 91 kD protein was used to screen a murine thymus and spleen cDNA library for homologous proteins. The screening

25 assay yielded a highly homologous gene encoding a murine polypeptide that is greater than 95% homologous to the human 91 kD protein. The nucleic acid and deduced amino acid sequence of the murine 91 kD protein are shown in Figure 1A-1C, and SEQ ID NO:7 (nucleotide sequence) and SEQ ID NO:8 (amino acid sequence).

30

EXAMPLE 2: ADDITIONAL MEMBERS OF
THE STAT PROTEIN FAMILY

Using a 300 nuclide fragment amplified by PCR from the SH2 region of the
5 murine 91kD protein gene, murine genes encoding two additional members of the
113-91 family of receptor recognition factor proteins were isolated from a murine
splenic/thymic cDNA library according to the method of Sambrook et al. (1989,
Molecular Cloning, A Laboratory Manual, 2nd. ed., Cold Spring Harbor Press:
Cold Spring Harbor, New York) constructed in the ZAP vector. Hybridization
10 was carried out at 42°C and washed at 42°C before the first exposure (Church and
Gilbert, 1984, Proc. Natl. Acad. Sci. USA 81:1991-95). Then the filters were
washed in 2X SSC, 0.1 % SDS at 65°C for a second exposure. Stat1 clones
survived the 65°C washing, whereas Stat3 and Stat4 clones were identified as
plaques that lost signals at 65°C. The plaques were purified and subcloned
15 according to Stratagene commercial protocols.

This probe was chosen to screen for other STAT family members because, while
Stat1 and Stat2 SH2 domains are quite similar over the entire 100 to 120 amino
acid region, only the amino terminal half of the STAT SH2 domains strongly
20 resemble the SH2 regions found in other proteins.

The two genes have been cloned into plasmids 13sf1 and 19sf6. The nucleotide
sequence, and deduced amino acid sequence, for the 13sf1 and 19sf6 genes are
shown in Figures 2 and 3, respectively. These proteins are alternatively termed
25 Stat4 and Stat3, respectively.

Comparison with the sequence of Stat91 (Stat1) and Stat113 (Stat2) shows several
highly conserved regions, including the putative SH3 and SH2 domains. The
conserved amino acid stretches likely point to conserved domains that enable these
30 proteins to carry out transcription activation functions. Stat3, like Stat1 (Stat91),
is widely expressed, while Stat4 expression is limited to the testes, thymus, and
spleen. Stat3 has been found to be activated as a DNA binding protein through

phosphorylation on tyrosine in cells treated with EGF or IL-6, but not after IFN- γ treatment.

Both the 13sf1 and 19sf6 genes share a significant homology with the genes
5 encoding the human and murine 91 kD protein. There is corresponding homology
between the deduced amino acid sequences of the 13sf1 and 19sf6 proteins and the
amino acid sequences of the human and murine 91 kD proteins, although not the
greater than 95 % amino acid homology that is found between the murine and
human 91 kD proteins. Thus, though clearly of the same family as the 91 kD
10 protein, the 13sf1 and 19sf6 genes encode distinct proteins.

The chromosomal locations of the murine STAT proteins (1-4) have been
determined: Stat1 and Stat4 are located in the centromeric region of mouse
chromosome 1 (corresponding to human 2q 32-34q); the two other genes are on
15 other chromosomes.

Southern analysis using probes derived from 13sf1 and 19sf6 on human genomic
libraries have established that genes corresponding to the murine 13sf1 and 19sf6
genes are found in humans.

20 Tissue distribution of mRNA expression of these genes was evaluated by Northern
hybridization analysis. The results of this distribution analysis are shown in the
following Table.

TABLE
DISTRIBUTION OF mRNA EXPRESSION OF 13sf1, 19sf6, 91 kD PROTEINS

ORGAN	13sf1	19sf6	91 KD
5 BRAIN	-	+	-
HEART	-	+++	-
KIDNEY	-	-	-
LIVER	-	+	+
LUNG	-	-	-
10 SPLEEN	+	+	++++
TESTIS	++++	++	N.A.
THYMUS	++	++	+++
EMBRYO (16d)	not found	found	found

- 15 Northern analysis demonstrates that there is variation in the tissue distribution of expression of the mRNAs encoded by these genes. The variation and tissue distribution indicates that the specific genes encode proteins that are responsive to different factors, as would be expected in accordance with the present invention. The actual ligand, the binding of which induces phosphorylation of the newly
- 20 discovered factors, will be readily determinable based on the tissue distribution evidence described above.

To determine whether the Stat3 and Stat4 proteins were present in cells, protein blots were carried out with antisera against each protein. The antisera were

25 obtained by subcloning amino acids 688 to 727 of Stat3 and 678 to 743 of Stat4 to pGEX1 λ (Pharmacia) by PCR with oligonucleotides based on the boundary sequence plus restriction sites (BamHI at the 5' end and EcoRI at the 3' end),

allowing for in-frame fusion with GST. One milligram of each antigen was used for the immunization and three booster injections were given 4 weeks apart. Anti-Stat3 and anti-Stat4 sera were used 1:1000 in Western blots using standard protocols. To avoid cross reactivity of the antisera, antibodies were raised against the C-terminal of Stat3 and Stat4, the less homologous region of the protein.

These proteins were unambiguously found in several tissues where the mRNA was known to be present. Protein expression was checked in several cell lines as well. A protein of 89 kD reactive with Stat4 antiserum was expressed in 70Z cells, a preB cell line, but not in many other cell lines. Stat3 was highly expressed, predominantly as a 97 kD protein, in 70Z, HT2 (a mouse helper T cell clone), and U937 (a macrophage-derived cell).

To prove that the full length functional cDNA clones of Stat3 and Stat4 were obtained, the open reading frames of each cDNA was independently (*i.e.*, separately) cloned into the Rc/CMV expression vector (Invitrogen) downstream of a CMV promoter. The resulting plasmids were transfected into COS1 cells and proteins were extracted 60 hrs post-transfection and examined by Western blot after electrophoresis. Untransfected COS1 cells expressed a low level of 97 kD Stat3 protein but did not express a detectable level of Stat4. Upon transfection of the Stat3-expressing plasmid, the 97 kD Stat3 was increased at least 10-fold. And 89 kD protein antigenically related to Stat3, found as a minor band in most cell line extracts, was also increased post-transfection. This protein therefore appears to represent another form of Stat3 protein, or an antigenically similar protein whose synthesis is stimulated by Stat3. Transfection with Stat4 led to the expression of a 89 kD reactive band indistinguishable in size from the p89 Stat4 found in 70Z cell extracts.

DISCUSSION

As mentioned earlier, the observation and conclusion underlying the present invention were crystallized from a consideration of the results of certain investigations with particular stimuli. Particularly, the present disclosure is illustrated by the results of work on protein factors that govern transcriptional control of IFN α -stimulated genes, as well as more recent data on the regulation of transcription of genes stimulated by IFN γ . The present disclosure is further illustrated by the identification of related genes encoding protein factors responsive to as yet unknown factors. It is expected that the murine 91 kD protein is responsive to IFN- γ .

For example, the above represents evidence that the 91 kD protein is the tyrosine kinase target when IFN γ is the ligand. Thus two different ligands acting through two different receptors both use these family members. With only a modest number of family members and combinatorial use in response to different ligands, this family of proteins becomes an even more likely possibility to represent a general link between ligand-occupied receptors and transcriptional control of specific genes in the nucleus.

It is proposed and shown by the foregoing that other members of the 113-91 protein family will be and have been identified as phosphorylation targets in response to other ligands. If as is believed, the tyrosine phosphorylation site on proteins in this family is conserved, one can then easily determine which family members are activated (phosphorylated), and likewise the particular extracellular polypeptide ligand to which that family member is responding. The modifications of these proteins (phosphorylation and dephosphorylation) enables the preparation and use of assays for determining the effectiveness of pharmaceuticals in potentiating or preventing intracellular responses to various polypeptides, and such assays are accordingly contemplated within the scope of the present invention.

Earlier work has concluded that DNA binding protein was activated in the cell cytoplasm in response to IFN- γ treatment and that this protein stimulated transcription of the GBP gene (10,14). In the present work, with the aid of antisera to proteins originally studied in connection with IFN- α gene stimulation

5 (7,12,15), the 91 kD ISGF-3 protein has been assigned a prominent role in IFN- γ gene stimulation as well. The evidence for this conclusion included: 1) antisera specific to the 91 kD protein affected the IFN- γ dependent gel-shift complex, and 2) A 91 kD protein could be cross-linked to the GAS IFN- γ activated site. 3) A 35 S-labeled 91 kD protein and a 91 kD immunoreactive protein specifically purified

10 with the gel-shift complex. 4) The 91 kD protein is an IFN- γ dependent tyrosine kinase substrate as indeed it had earlier proved to be in response to IFN- α (15). 5) The 91 kD protein but not the 113 kD protein moved to the nucleus in response to IFN- γ treatment. None of these experiments prove but do strongly suggest that the same 91 kD protein acts differently in different DNA binding complexes that

15 are triggered by either IFN- α or IFN- γ .

These results strongly support the hypothesis originated from studies on IFN- α that polypeptide cell surface receptors report their occupation by extracellular ligand to latent cytoplasmic proteins that after activation move to the nucleus to trigger

20 transcription (4,15,21). Furthermore, because cytoplasmic phosphorylation and factor activation is so rapid it appears likely that the functional receptor complexes contain tyrosine kinase activity. Since the IFN- γ receptor chain that has been cloned thus far (22) has no hint of possessing intrinsic kinase activity, perhaps some other molecule with tyrosine kinase activity couples with the IFN- γ receptor.

25 Two recent results with other receptors suggest possible parallels to the situation with the IFN receptors. The *trk* protein which has an intracellular tyrosine kinase domain, associates with the NGF receptor when that receptor is occupied (23). In addition, the *lck* protein, a member of the *src* family of tyrosine kinases, is co-precipitated with the T cell receptor (24). It is possible to predict that signal

30 transduction to the nucleus through these two receptors could involve latent cytoplasmic substrates that form part of activated transcription factors. In any

event, it seems possible that there are kinases like *trk* or *lck* associated with the IFN- γ receptor or with IFN- α receptor.

With regard to the effect of phosphorylation on the 91 kD protein, it was something of a surprise that after IFN- γ treatment the 91 kD protein becomes a DNA binding protein. Its role must be different in response to IFN- α treatment. Tyrosine is also phosphorylated on tyrosine and joins a complex with the 113 and 84 kD proteins but as judged by UV cross-linking studies (7), the 91 kD protein does not contact DNA.

10

In addition to becoming a DNA binding protein it is clear that the 91 kD protein is specifically translocated the nucleus in the wake of IFN- γ stimulation.

EXAMPLE 3: TYROSINE 701 IS PHOSPHORYLATED IN THE 91 kD PROTEIN

15

It has previously been shown that IFN- γ stimulates phosphorylation of the 91 kD protein. Thermolysin digestion of ^{32}P -labeled 91 kD protein from IFN- γ -treated cells yielded a single peptide labeled on tyrosine. The 91 kD protein contains 19 tyrosines (12), and to determine the location of the phosphorylated residue or residues, a tryptic digest of ^{32}P -labeled 91 kD protein from IFN- γ -treated cells (FIGURE 4A) was examined. IFN- γ induced phosphorylation of a single tryptic peptide (X) on tyrosine. Peptide X was recovered and stepwise Edman degradation done. The labeled phosphotyrosine was released in the fourth degradative cycle (FIGURE 4B). Computer alignment of all the potential tryptic peptides showed a single peptide (amino acids 698 to 703) in which tyrosine was the fourth amino acid, revealing this peptide as the major candidate for IFN- γ -stimulated tyrosine kinase action (FIGURE 4C). Note that the original sequence of the 91 kD protein omitted an 11 amino acid segment from residues 261 to 271. Thus, the putative phosphorylated peptide contained a single tyrosine at residue 701, confirming the expectation of phosphorylation at tyrosine 690 under the incorrect numbering system.

30

A synthetic peptide corresponding to amino acids 693 to 707 was prepared. This peptide was exposed to purified p43^{v-abl} protein kinase [Oncogene Science (27)] and [γ -³²P]adenosine triphosphate (ATP). Although labeling was inefficient, only tyrosine was phosphorylated. The labeled synthetic phosphopeptide was cleaved with trypsin, and the resulting peptide migrated identically with peptide X during 2D peptide mapping. Thus, we conclude that Tyr⁷⁰¹ is the single residue in the 91 kD protein that is tyrosine phosphorylated in response to IFN- γ .

EXAMPLE 4: FUNCTIONAL IMPORTANCE OF TYR⁷⁰¹ PHOSPHORYLATION

To test the functional importance of phosphorylation of Tyr⁷⁰¹, the TAT codon for tyrosine was changed to TTT, which encodes phenylalanine. The wild-type and mutant DNAs were inserted into an expression vector. The gene encoding the 91 kD protein produces two mRNAs with different 3' ends (12). The two mRNAs are translated to produce the 91 kD protein and the 84 kD protein, respectively. An expression vector containing complementary DNA (cDNA) encoding the 84 kD protein was also constructed.

These constructs were introduced by permanent transfection into U3A cells, which do not respond to IFN- α or IFN- γ (28, 29) because they do not express the 84 kD protein or the 91 kD protein. Full-length 91 kD protein restores the ability of these cells to respond to IFN- α and IFN- γ , as tested by IFN-induced accumulation of mRNA from endogenous genes. The 84 kD protein restores the accumulation of IFN- α -responsive mRNA but not IFN- γ -responsive mRNA (30).

Three cell lines were studied: C91 (expressing the 91 kD protein), Cty (expressing the 91 kD protein in which Tyr⁷⁰¹ was changed to Phe), and C84 (expressing the 84 kD protein) (FIGURE 5A). A monoclonal antibody (mAb) to phosphotyrosine was used to detect IFN- γ -dependent tyrosine phosphorylation on protein immunoblots. The mutant 91 kD protein was not phosphorylated on tyrosine in response to IFN- γ , whereas the 91 kD protein from either the wild-

type parental cell (2fTGH) or the C91 cell was phosphorylated on tyrosine when treated with IFN- γ (FIGURE 5C). This experiment confirmed that residue 701 is the sole site on the 91 kD that is phosphorylated on tyrosine in response to IFN- γ .

- 5 An experiment was performed to determine whether the 84 kD protein was phosphorylated on the same site as the 91 kD protein. C84 cells were labeled with ^{32}P and treated with IFN- γ ; the ^{32}P -labeled 84 kD protein was immunoprecipitated and cleaved with trypsin. The resulting tryptic phosphopeptides were analyzed by 2D phosphopeptide mapping (FIGURE 5B). A major spot was identified that
- 10 migrated similarly to peptide X from the 91 kD protein (FIGURE 4A). When mixed, the two peptides migrated identically. Thus, it was concluded that the 84 kD protein is also tyrosine phosphorylated on Tyr⁷⁰¹ in response to IFN- γ .

- The function of the 91 kD protein and the 84 kD proteins and the Tyr⁷⁰¹ \rightarrow Phe⁷⁰¹ mutant was tested in various steps in the signal transduction pathway that results in
- 15 IFN- γ -dependent gene activation. Removal of phosphate from the 91 kD protein phosphoprotein by calf intestinal phosphatase or inhibition of *in vivo* phosphorylation with staurosporine abolishes the 91 kD protein DNA binding activity. The IFN- γ -dependent DNA protein complex, GAF, was detected in the
- 20 wild-type parental cells (2fTGH) and in C91 cells (FIGURE 6A). The C84 cells also responded to IFN- γ , yielding a DNA-protein complex that migrated somewhat faster, as would be expected for a smaller protein (FIGURE 6A). In contrast, cells expressing the Tyr⁷⁰¹ mutant (Cty) failed to produce an IFN- γ -dependent DNA binding protein.

25

- IFN- γ -induced translocation to the nucleus was also tested. Immunofluorescence in C91 or C84 cells detected throughout the cell before IFN- γ treatment increased in the nucleus after IFN- γ treatment (FIGURE 6). In contrast, the Tyr⁷⁰¹ mutant protein did not move to the nucleus in response to IFN- γ , suggesting that
- 30 phosphorylation on Tyr⁷⁰¹ is required for the nuclear translocation of the 91 kD protein (FIGURE 6).

U3 cells were transiently transfected with the 91 and 84 kD proteins, and the Tyr⁷⁰¹ mutant protein, and the transcriptional response to IFN- γ was measured in these cells. A target gene was constructed containing luciferase as the reporter and bearing one copy of the binding site for the 91 kD phosphoprotein upstream of an RNA start site otherwise lacking promoter elements. Cells transfected with the target gene and the wild-type 91 kD protein expression vector showed a 5- to 10-fold stimulation of luciferase expression when treated with IFN- γ (FIGURE 7). The IFN- γ -dependent transcriptional activation required the presence of the 91 kD protein; IFN- γ did not enhance transcription in U3A cells transfected with the reporter vector alone or a vector lacking the GAS site. Cells transfected with the reporter vector and the Tyr⁷⁰¹ mutant did not respond to IFN- γ , suggesting a requirement for phosphorylation for gene activation. Protein immunoblot analysis indicated that the 91 kD, 84 kD, and Tyr⁷⁰¹ mutant proteins were expressed during the transient transfection (FIGURE 7). Similar experiments done in human kidney 293 cells support the same conclusion. The results with transient transfections are in accord with findings that in U3A cells accumulation of mRNA from endogenous cellular genes in response to IFN- γ requires the 91 kD protein (30). In those experiments, also, the 84 kD protein failed to direct the IFN- γ response.

20

EXAMPLE 5: THE ARG⁶⁰² RESIDUE IN THE 91KD SH2 DOMAIN IS REQUIRED FOR TYROSINE PHOSPHORYLATION

The 91 kD protein has a sequence from Try⁵⁷² to Pro⁶⁷⁰ that resembles SH2 domains (38), amino acid regions known bind tightly to tyrosine phosphates (39). Since ligand activated kinases often present a phosphotyrosine to a substrate, we tested the requirement for the SH2 domain in the 91 kD protein in ligand-mediated phosphorylation. The Arg¹⁵⁵ residue in the v-src SH2 domain is crucial for direct interaction between a phosphotyrosine residue in the v-src SH2 domain (40, 41) and Arg⁶⁰² of the kD protein is in a comparable position within the SH2 homology (38). We therefore changed the 91kD protein cDNA to encode Leu⁶⁰² instead of Arg⁶⁰² and inserted the new sequence into an expression vector. U3A cells, an

IFN- α and IFN- γ unresponsive cell line (29) which lacks the mRNA for the 91kD protein and 84kD proteins (30) were transfected with expression vectors. Two stable cell lines were selected that express the Arg⁶⁰²->Leu mutant protein. The mutant protein immunoprecipitated from these cell lines was not phosphorylated on tyrosine in response to IFN- γ (Figure 8b); thus a functional SH2 domain is required for the tyrosine phosphorylation of the 91kD protein suggesting that the kinase to which the substrate binds might in its active state have a tyrosine phosphate.

DISCUSSION

As mentioned earlier, the observation and conclusion underlying the present invention were crystallized from a consideration of the results of certain investigations with particular stimuli. Particularly, the present disclosure is illustrated by the results of work on protein factors that govern transcriptional control of IFN α -stimulated genes, as well as more recent data on the regulation of transcription of genes stimulated by IFN γ .

For example, the above represents evidence that the 91kD protein is the tyrosine kinase target when IFN γ is the ligand. Thus two different ligands acting through two different receptors both use these family members. With only a modest number of family members and combinatorial use in response to different ligands, this family of proteins becomes an even more likely possibility to represent a general link between ligand-occupied receptors and transcriptional control of specific genes in the nucleus.

It is proposed that other members of the 113-91 protein family will be identified as phosphorylation targets in response to other ligands. If as is believed, the tyrosine phosphorylation site on proteins in this family is conserved, one can then easily determine which family members are activated (phosphorylated), and likewise the particular extracellular polypeptide ligand to which that family member is

responding. The modifications of these proteins (phosphorylation and dephosphorylation) enables the preparation and use of assays for determining the effectiveness of pharmaceuticals in potentiating or preventing intracellular responses to various polypeptides, and such assays are accordingly contemplated
5 within the scope of the present invention.

Earlier work has concluded that DNA binding protein was activated in the cell cytoplasm in response to IFN- γ treatment and that this protein stimulated transcription of the GBP gene (10,14). In the present work, with the aid of
10 antisera to proteins originally studied in connection with IFN- α gene stimulation (7,12,15), the 91 kD ISGF-3 protein has been assigned a prominent role in IFN- γ gene stimulation as well. The evidence for this conclusion included: 1) antisera specific to the 91 kD protein affected the IFN- γ dependent gel-shift complex, and 2) A 91 kD protein could be cross-linked to the GAS IFN- γ activated site. 3) A
15 ³⁵S-labeled 91 kD protein and a 91 kD immunoreactive protein specifically purified with the gel-shift complex. 4) The 91 kD protein is an IFN- γ dependent tyrosine kinase substrate as indeed it had earlier proved to be in response to IFN- α (15). 5) The 91 kD protein but not the 113 kD protein moved to the nucleus in response to IFN- γ treatment. These experiments prove but do strongly suggest that the
20 same 91 kD protein acts differently in different DNA binding complexes that are triggered by either IFN- α or IFN- γ .

These results strongly support the hypothesis originated from studies on IFN- α that polypeptide cell surface receptors report their occupation by extracellular ligand to
25 latent cytoplasmic proteins that after activation move to the nucleus to trigger transcription (4,15,21). Furthermore, because cytoplasmic phosphorylation and factor activation is so rapid it appears likely that the functional receptor complexes contain tyrosine kinase activity. Since the IFN- γ receptor chain that has been cloned thus far (22) has no hint of possessing intrinsic kinase activity, perhaps
30 some other molecule with tyrosine kinase activity couples with the IFN- γ receptor. Two recent results with other receptors suggest possible parallels to the situation

with the IFN receptors. The *trk* protein which has an intracellular tyrosine kinase domain, associates with the NGF receptor when that receptor is occupied (23). In addition, the *lck* protein, a member of the *src* family of tyrosine kinases, is co-precipitated with the T cell receptor (24). It is possible to predict that signal transduction to the nucleus through these two receptors could involve latent cytoplasmic substrates that form part of activated transcription factors. In any event, it seems possible that there are kinases like *trk* or *lck* associated with the IFN- γ receptor or with IFN- α receptor.

- 10 With regard to the effect of phosphorylation on the 91 kD protein, it was something of a surprise that after IFN- γ treatment the 91 kD protein becomes a DNA binding protein. Its role must be different in response to IFN- α treatment. There it is also phosphorylated on tyrosine and joins a complex with the 113 and 84 kD proteins but as judged by UV cross-linking studies (7), the 91 kD protein does not contact DNA.

In addition to becoming a DNA binding protein it is clear that the 91 kD protein is specifically translocated the nucleus in the wake of IFN- γ stimulation. While the present work strongly implicates the 91 kD protein as important in the immediate IFN- γ transcriptional response of the GBP gene, two points should also be clear. First, it is not known whether the 91 kD protein acts on its own to activate transcription. Second, it is not known how widely used the 91 kD protein is in the immediate IFN- γ transcriptional response. Only a few genes have been studied that are activated immediately by IFN- γ without new protein synthesis. It is at present uncertain whether activation of these genes operates through the 91 kD binding site.

- The present examples demonstrate that phosphorylation of Tyr⁷⁰¹ on the 91 kD protein induces nuclear translocation and DNA binding of the protein.
- 30 Presumably, the phosphorylated 91 kD protein directly or indirectly activates transcription in response to IFN-8. This function of the phospho-91 kD protein

has been indirectly confirmed by the inability of a non-phosphorylated mutant 91 kD protein to induce transcription.

It was found that endogenous genes normally induced by IFN- γ cannot be induced in U3A cells complemented with the Tyr-Phe⁷⁰¹ mutant protein. However, U3A cells respond to IFN- α when transfected with either the 91 or 84 kD proteins. Thus, the 84 kD protein can fulfill the required role in the multimeric ISGF-3 complex induced by IFN- γ in which either the 84 or 91 kD protein joins with the 113 kD protein and a 48 kD DNA binding protein (30). Cells reconstituted with the Tyr-Phe⁷⁰¹ mutant protein cannot form ISGF-3 nor do IFN- α -induced mRNAs accumulate in such cells.

After IFN- γ treatment, the 84 kD protein acts in parallel with the 91 kD protein up to the point of gene activation: the 84 kD protein can be phosphorylated and translocated and binds to DNA. However, only the 91 kD protein acts by itself as a direct DNA binding protein capable of transcriptional activation. These results suggest that the 38 COOH-terminal amino acids of the 91 kD are essential for activation of transcription through a GAS site. It is possible that the 84 kD protein functions to regular activity of the 94 kD protein.

EXAMPLE 6: DIMERIZATION OF PHOSPHORYLATED STAT91

Stat91 (a 91 kD protein that acts as a signal transducer and activator of transcription) is inactive in the cytoplasm of untreated cells but is activated by phosphorylation on tyrosine in response to a number of polypeptide ligands including IFN- α and IFN- γ . This example reports that inactive Stat91 in the cytoplasm of untreated cells is a monomer and upon IFN- γ induced phosphorylation it forms a stable homodimer. The dimer is capable of binding to a specific DNA sequence directing transcription. Dissociation and reassociation assays show that dimerization of Stat91 is mediated through SH2-phosphotyrosyl peptide interactions. Dimerization involving SH2 recognition of specific

phosphotyrosyl peptides may well provide a prototype for interactions among family members of STAT proteins to form different transcription complexes and Jak2 for the IFN- γ pathway (42, 43, 44). These kinases themselves become tyrosine phosphorylated to carry out specific signaling events.

5

Materials and Methods

Cell Culture. Human 2fTGH, U3A cells were maintained in DMEM medium supplied with 10% bovine calf serum. U3A cell lines supplemented with various Stat91 protein constructs were maintained in 0.1 mg/ml G418 (Gibco, BRL). Stable cell lines were selected as described (45). IFN- γ (5 ng/ml, gift from Amgen) treatment of cells was for 15 min. unless otherwise noted.

Plasmid Constructions. Expression construct MNC-84 was made by insertion of the cDNA into the Not I-Bam HI cloning site of an expression vector PMNC (45, 35). MNC-91L was made by insertion of the Stat91 cDNA into the Not I -Bam HI cloning sites of pMNC without the stop codon at the end, resulting the production of a long form of Stat91 with a C-terminal tag of 34 amino acids encoded by PMNC vector.

20

GST fusion protein expression plasmids were constructed by the using the pGEX-2T vector (Pharmacia). GST-91SH2 encodes amino acids 573 to 672 of Stat91; GST-91mSH2 encodes amino acids 573 to 672 of Stat91 with an Arg-602- \rightarrow Leu-602 mutation; and GST-91SH3 encodes amino acids 506 to 564 of Stat91.

25

DNA Transfection. DNA transfection was carried by the calcium phosphate method, and stable cell lines were selected in Dulbecco's modified Eagle's medium containing G418 (0.5 mg/ml, Gibco), as described (45).

Preparation of Cell Extracts. Crude whole cell extracts were prepared as described (31). Cytoplasmic and nuclear extracts were prepared essentially as described (46).

- 5 *Affinity Purification.* Affinity purification with a biotinylated oligonucleotide was described (31). The sequence of the biotinylated GAS oligonucleotide was from the Ly6E gene promoter (34).

- Nondenaturing Polyacrylamide Gel Analysis.* A nondenatured protein molecular weight marker kit with a range of molecular weights from 14 to 545 kD was
10 obtained from Sigma. Determining molecular weights using nondenaturing polyacrylamide gel was carried out following the manufacturer's procedure, which is a modification of the methods of Bryan and Davis (47, 48). Phosphorylated and unphosphorylated Stat91 samples obtained from affinity purification using a
15 biotinylated GAS oligonucleotide (31) were resuspended in a buffer containing 10 mM Tris (pH 6.7), 16% glycerol, 0.04% bromphenol blue (BPB). The mixtures were analyzed on 4.5%, 5.5%, 6.5%, and 7.5.% native gels side by side with standard markers using a Bio-Rad mini-Protean II Cell electrophoresis system. Electrophoresis was stopped when the dye (BPB) reached the bottom of the gels.
20 The molecular size markers were revealed by Coomassie blue staining. Phosphorylated and unphosphorylated Stat91 samples were detected by immunoblotting with anti-91T.

- Glycerol Gradient Analysis.* Cells extracts (Bud 8) were mixed with protein
25 standards (Pharmacia) and subjected to centrifugation through preformed 10%-40% glycerol gradients for 40 hours at 40,000 rpm in an SW41 rotor as described (6).

- Gel Mobility Shift Assays.* Gel mobility shift assays were carried out as described
30 (34). An oligonucleotide corresponding to the GAS element from the human FcγRI receptor gene (Pearse et al. 1993) was synthesized and used for gel

mobility shift assays. The oligonucleotide has the following sequence:
5'GATCGAGATGTATTTCCAGAAAAG3' (SEQ ID NO:14).

Synthesis of Peptides. Solid phase peptide synthesis was used with either a
5 DuPont RAMPS multiple synthesizer or by manual synthesis. C-terminal amino
attached to Wang resin were obtained from DuPont/NEN. All amino acids were
coupled as the N-Fmoc pentafluorophenyl esters (Advanced Chemtech), except for
N-Fmoc, PO-dimethyl-L-phosphotyrosine (Bachem). Double couplings were used.
10 Cleavage from resin and deprotection used thioanisol/m-cresol/TFA/TMSBr at
4°C for 16 hr. Purification used C-18 column HPLC with 0.1% TFA/acetonitrile
gradients. Peptides were characterized by ¹H and ³¹P NMR, and by Mass Spec,
and were greater than 95% pure.

Guanidium Hydrochloride Treatment. Extracts were incubated with guanidium
15 hydrochloride (final concentration was 0.4 to 0.6 M) for two min. at room
temperature and then diluted with gel shift buffer (final concentration of guanidium
hydrochloride was 100 mM) and incubated at room temperature for 15 min. ³²P-
labeled GAS oligonucleotide probe was then added directly to the mixture followed
by gel mobility shift assay.

20 *Dissociation-reassociation Analysis.* Extracts were incubated with various
concentrations of peptides or fusion proteins, and ³²P-labeled GAS oligonucleotide
probe in gel shift buffer was then added to promote the formation of protein-
DNA complex followed by mobility shift analysis. This assay did not involve
25 guanidium hydrochloride treatment.

Preparation of Fusion Proteins. Bacterially expressed GST fusion proteins were
purified using standard techniques, as described in Birge et al., 1992. Fusion
proteins were quantified by O.D. absorbance at 280nm. Aliquotes were frozen
30 at -70°C.

Results

Detection of Ligand Induced Dimer Formation of Stat91 in Solution. In untreated cells, Stat91 is not phosphorylated on tyrosine. Treatment with IFN- γ leads
5 within minutes to tyrosine phosphorylation and activation of DNA binding capacity. The phosphorylated form migrates more slowly during electrophoresis under denaturing conditions affording a simple assay for the phosphoprotein (31).

To determine the native molecular weights of the phosphorylated and
10 unphosphorylated forms of Stat91, we separated them by affinity purification using a biotinylated deoxyoligonucleotide containing a GAS sequence (interferon gamma activation site) (Figure 9A). The separation of phosphorylated Stat91 from the unphosphorylated form was efficient as almost all detectable phosphorylated form could bind to the GAS site while unphosphorylated Stat91 remained unbound. To
15 determine the molecular weights of the purified phosphorylated Stat91 and unphosphorylated Stat91, samples of each were then subjected to electrophoresis through a set of nondenaturing gels containing various concentrations of acrylamide followed by Western blot analysis (Figure 9B). Native protein size markers (Sigma) were included in the analysis.

20 This technique was originally described by Bryan (48) and was recently used for dimer analysis (49). The logic of the technique is that increasing gel concentrations affect the migration of larger proteins more than smaller proteins, and the analysis is not affected by modifications such as protein phosphorylation
25 (49).

A function of the relative mobilities (R_m) was plotted versus the concentration of acrylamide for each sample to construct Ferguson plots (Figure 9C). The
30 logarithm of the retardation coefficient (calculated from Figure 9C) of each sample was then plotted against the logarithm of the relevant molecular weight range (Figure 9D). By extrapolation of its retardation coefficient (Figure 9D), the native

molecular weight of Stat91 from untreated cells was estimated to be approximately 95 kD, while tyrosine phosphorylated Stat91 was estimated to be about twice as large, or approximately 180 kD. Because the calculated molecular weight from amino acid sequence of Stat91 is 87 kD, and Stat91 migrates on denaturing SDA
5 gels with an apparent molecular weight of 91 kD (see *supra*, and refs. 12 and 45), we concluded that in solution, unphosphorylated Stat91 existed as a monomer while tyrosine phosphorylated Stat91 is a dimer.

We also employed glycerol gradient analysis to estimate the native molecular
10 weights of both phosphorylated and unphosphorylated Stat91 (Figure 10). Whole cell extract of fibroblast cells (Bud8) treated with IFN- γ were prepared and subjected to sedimentation through a 10-40% glycerol gradient. Fractions from the gradient were collected and analyzed by both immunoblotting and gel mobility
15 shift analysis (Figure 10A and 10B). As expected, two electrophoretic forms of Stat91 could be detected by immunoblotting (Figure 10A): the slow-migrating form (tyrosine phosphorylated) and the fast-migrating form (unphosphorylated; Figure 10A). The phosphorylated Stat91 sedimented more rapidly than the unphosphorylated form. Again, using molecular weight markers, the native
20 molecular weight of the unphosphorylated form of Stat91 appeared to be about 90 kD while the tyrosine phosphorylated form of Stat91 was about 180kD (Figure 10C), supporting the conclusion that unphosphorylated Stat91 existed as a monomer in solution while the tyrosine phosphorylated form exists as a dimer. When fractions from the glycerol gradients were analyzed by electrophoretic
25 mobility shift analysis (Figure 10B), the peak of the phosphorylated form of Stat91 correlated well with the DNA-binding activity of Stat91. Thus only the phosphorylated dimeric Stat91 has the sequence-specific DNA recognition capacity.

Stat91 Binds DNA as a Dimer. Long or short versions of DNA binding protein
30 can produce, respectively, a slower or a faster migrating band during gel retardation assays. Finding intermediate gel shift bands produced by mixing two

different sized species provides evidence of dimerization of the DNA binding proteins. Since Stat91 requires specific tyrosine phosphorylation in ligand-treated cells for its DNA binding, we sought evidence of formation of such heterodimers, first in transfected cells. An expression vector (MNC91L) encoding Stat91L, a recombinant form of Stat91 containing an additional 34 amino acid carboxyl terminal tag was generated. [The extra amino acids were encoded by a segment of DNA sequence from plasmid pMNC (see Materials and Methods).] A Stat84 expression vector (MNC84) was also available (45). From somatic cell genetic experiments, mutant human cell lines (U3) are known that lack the Stat91/84 mRNA and proteins (29,30). The U3 cells were therefore separately transfected with vectors encoding Stat84 (MNC84) or Stat91L (MNC91L) or a mixture of both vectors. Permanent transfectants expressing Stat84 (C84), Stat91L (C91L) or both proteins (Cmx) were isolated (Figure 11A).

Mobility shift analysis was performed with extracts from these stable cell lines (Figure 11B). Extracts of IFN- γ -treated C84 cells produced a faster migrating gel shift band than extracts of treated C91L cells. Most importantly, extracts from IFN- γ -treated Cmx cells expressing both Stat84 and Stat91L proteins formed an additional intermediate gel shift band. Anti-91, an antiserum against the C-terminal 38 amino acids of Stat91 (12) that are absent in Stat84, specifically removed the top two shift bands seen with the Cmx extracts. Anti-91, an antiserum against amino acids 609 to 716 (15) that recognizes both Stat91L and Stat84, proteins inhibited the binding of all three shift bands. Thus, the middle band formed by extracts of the Cmx cells is clearly identified as a heterodimer of Stat84 and Stat91L. We concluded that both Stat91 and Stat84 bind DNA as homodimers and, if present in the same cell, will form heterodimers.

We next wanted to detect the formation of dimers *in vitro*. When cytoplasmic or nuclear extracts of IFN- γ -treated C84 or C91L cells were mixed and analyzed (Figure 12), only the fast or slow migrating gel shift bands were observed. Thus it appeared that once formed *in vivo*, the dimers were stable. To promote the

formation of protein interchange between the subunits of the dimer, a mixture of either cytoplasmic or nuclear extracts of IFN- γ -treated C84 or C91L cells were subjected mild denaturation-renaturation treatment: extracts were made 0.5 M with respect to guanidium hydrochloride for two minutes and then diluted for

5 renaturation and subsequently used for gel retardation analysis. The formation of heterodimer was clearly detected after this treatment. When extracts from either C84 cells alone or C91L cells alone were subjected to the same treatment, the intermediate band did not form. The intermediate band was again proven by antiserum treatment to consist of Stat84/Stat91L dimer (data not shown).

10

This experiment defined conditions under which the dimer was stable, but also showed that dissociation and reassociation of the dimer *in vitro* was possible. Since guanidium hydrochloride is known to disrupt only non-covalent chemical bonds, it seemed that Stat91 (or Stat84) homodimerization was mediated through

15 non-covalent interactions.

Dimerization of Stat91 Involves Phosphotyrosyl Peptide and SH2 Interactions.

Based on the results described above, we devised a dissociation-reassociation assay in the absence of guanidium hydrochloride to explore the possible nature of

20 interactions involved in dimer formation (Figure 13). When the short and the long forms of a homodimer are mixed with a dissociating agent (*e.g.*, a peptide containing the putative dimerization domain), the subunits of the dimer should dissociate (in a concentration dependent fashion) due to the interaction of the agent with the dimerization domain(s) of the protein. When a specific DNA probe is

25 subsequently added to the mixture to drive the formation of a stable protein-DNA complex, the detection of any reassociated or remaining dimers can be assayed. In the presence of low concentration of the dissociating agent, addition of DNA to form the stable protein-DNA complex should lead to the detection of homodimers as well as heterodimers. At high concentration of the dissociating agent, subunits-

30 of the dimer may not be able to re-form and no DNA-protein complexes would be detected (Figure 13).

The Stat91 sequence contains an SH2 domain (amino acids 569 to 700, see discussion below), and we knew that Tyr-701 was the single phosphorylated tyrosine residue required for DNA binding activity (*supra*, 45). Furthermore, we have observed that phosphotyrosine at 10 mM, but not phosphoserine or phosphothreonine, could prevent the formation of Stat91-DNA complex. We therefore sought evidence that the dimerization of Stat91 involved specific SH2-phosphotyrosine interaction using the dissociation and reassociation assay.

In order to evaluate the role of the SH2-phosphotyrosine in dimerization, two peptides fragments of Stat91 corresponding to segments of the SH2 and phosphotyrosing domains of Stat91 were prepared: a non-phosphorylated peptide (91Y), LDGPKGTGYIKTELI (SEQ ID NO:15) (corresponding to amino acids 693-707), and a phosphotyrosyl peptide (91Y-p), GY*IKTE (SEQ ID NO:16) (representing residues 700-705).

Activated Stat84 or Stat91L was obtained from IFN- γ -treated C84 or C91L cells and mixed in the presence of various concentrations of the peptides followed by gel mobility shift analysis. The non-phosphorylated peptide had no effect on the presence of the two gel shift bands characteristic of Stat84 or Stat91L homodimers (Figure 14, lane 2-4). In contrast, the phosphorylated peptide (91Y-p) at the concentration of 4 μ M clearly promoted the exchange between the subunits of Stat84 dimers and Stat91L dimers to form heterodimers (Figure 14, lane 5). At a higher concentration (160 μ M), peptide 91Y-p but not the unphosphorylated peptide dissociated the dimers and blocked the formation of DNA protein complexes (Figure 14, lane 7).

When cells are treated with IFN- α both Stat91 (or 84) and Stat113 become phosphorylated (15). Antiserum to Stat113 can precipitate both Stat113 and Stat91 after IFN- α -treatment but not before, suggesting IFN- α dependent interaction of these two proteins, perhaps as a heterodimer (15).

- In Stat113, tyr-690 in the homologous position to Tyr-701 in Stat91 is the single target residue for phosphorylation. Amino acids downstream of the affected tyrosine residue show some homology between the two proteins. We therefore prepared a phosphotyrosyl peptide of Stat113 (113Y-p), KVN¹LQERRKY*LKHR (SEQ ID NO:17) [amino acids 681 to 694; (38)]. At concentrations similar to 91Y-p, 113Y-p also promoted the exchange of subunits between the Stat84 and Stat91L, while at a high concentration (40 μ M), 113Y-p prevented the gel shift bands almost completely (Figure 14, lane 8-10).
- 10 We prepared a phosphotyrosyl peptide (SrcY-p), EPQY*EEIPIYL (SEQ ID NO:18) which is known to interact with the Src SH2 domain with a high affinity (50). This peptide showed no effect on the Stat91 dimer formation (Figure 14, lane 11-13). Thus, it seems that Stat91 dimerization involves SH2 interaction with tyrosine residues in specific peptide sequence.
- 15 To test further the specificity of Stat91 dimerization mediated through specific-phosphotyrosyl-peptide SH2 interaction, a fusion product of glutathione-S-transferase with the Stat91-SH2 domain (GST-91SH2) was prepared (Figure 15A) and used in the *in vitro* dissociation reassociation assay. At concentrations of 0.5 to 5 μ M, the Stat91-SH2 domain promoted the formation of a heterodimer (Figure 20 15B, lanes 5-7). In contrast, neither GST alone, nor fusion products with a mutant (R⁶⁰²->L⁶⁰²) Stat91-SH2 domain (GST 91mSH2) that renders Stat91 non-functional *in vivo*, a Stat91 SH3 domain (GST-91SH3), nor the Src SH2 domain (GST-SrcSH2), induced the exchange of subunits between the Stat84 and Stat91L 25 homodimers (Figure 15B).

Discussion

- The initial sequence analysis of the Stat91 and Stat113 proteins revealed the presence of SH2 like domains (see 13,38). Further it was found that STAT 30 proteins themselves are phosphorylated on single tyrosine residues during their

activation (15,31). Single amino acid mutations either removing the Stat91 phosphorylation site, Tyr-701, or converting Arg-702 to Leu in the highly conserved "pocket" region of the SH2 domain abolished the activity of Stat91 (45). Thus it seemed highly likely that one possible role of the STAT SH2 domains would be to bind the phosphotyrosine residues in one of the JAK kinases.

Since the activated STATs have phosphotyrosine residues and SH2 domains, a second suggested role for SH2 domains was in protein-protein interactions within the STAT family. By two physical criteria -- electrophoresis in native gels and sedimentation on gradients -- Stat91 in untreated cells is a monomer and in treated cells is a dimer (Figures 9-11). Since phosphotyrosyl peptides from Stat91 or Stat113 and the SH2 domain of Stat91 could efficiently promote the formation of heterodimers between Stat91L and Stat84 in a disassociation and reassociation assay, we conclude that dimerization of Stat91 involves SH2-phosphotyrosyl peptide interactions.

The possibility of an SH2 domain in Stat91 was indicated initially by the presence of highly conserved amino acid stretches between the Stat91 and Stat113 sequences in the 569 to 700 residue region, several of which, especially the FLLR sequence in the amino terminal end of the region, are characteristic of -SH2 domains. The C-terminal half of the SH2 domains are less well conserved in general (39); this was also true for the STAT proteins compared to other proteins, although Stat91 and Stat113 are quite similar in this region (38, 13, Figure 16). The available structures of lck, src, abl, and p85a SH2's permit identification of structurally conserved regions (SCR's), and detailed alignment of amino acid sequences of several proteins (Figure 16) is based on these.

The characteristic W (in β A1) is preceded by hydrophilic residues and is followed by hydrophobic residues in Stat91, but alignment to the W seems justified, even if the small beta sheet of which the W is part is shifted in Stat91. The three positively charged residues contributing to the phosphotyrosyl binding site are at

the positions indicated as alphaA2, betaB5, and betaD5. Figure 16 shows an alignment which accomplishes this by insertions in the 'AA' and 'CD' regions. This is a different alignment from that previously suggested (38), and gives a satisfactory alignment in the (beta)D region, although, like the previous alignment, it is obviously considerably less similar to the other SH2's in the C-terminus.

This alignment suggests that the SH2 domain in the Stat91 would end in the vicinity of residue 700. In such an alignment, the Tyr-701 occurs almost immediately after the SH2 domain: a distance too short to allow an intramolecular phosphotyrosine -SH2 interaction. Since the data presented earlier strongly implicate that an SH2-phosphotyrosine interaction is involved in dimerization, such an interaction is likely to be between two phospho Stat91 subunits as a reciprocal pTyr -SH2 interaction.

The apparent stability of Stat91 dimer may be due to a high association rate coupled with a high dissociation rate of SH2-phosphotyrosyl peptide interactions as suggested (Felder et al., 1993, Mol. Cell Biol. 13:1449-1455) coupled with interactions between other domains of Stat91 that may contribute stability to the Stat91 dimer. Interference by homologous phosphopeptides with the -SH2-phosphotyrosine interaction would then lower stability sufficiently to allow complete dissociation and heterodimerization.

The dimer formation between phospho Stat91 is the first case in eukaryotes where dimer formation is regulated by phosphorylation, and the only one thus far dependent on tyrosine phosphorylation. We anticipate that dimerization with the STAT protein family will be important. It seems likely that in cells treated with IFN- α , there is Stat113-Stat91 interaction (15). This may well be mediated through SH2 and phosphotyrosyl peptide interactions as described above, leading to a complex (a probable dimer of Stat91-Stat113) which joins with a 48 kD DNA binding protein (a member of another family of DNA binding factors) to make a complex capable of binding to a different DNA site. Furthermore, two mouse

cDNAs which encode other STAT family members that have conserved the same general structure features observed in the Stat91 and Stat113 molecules have recently been cloned (see Example 2, *Supra*). Thus the specificity of STAT-containing complexes will almost surely be affected by which proteins are phosphorylated and then available for dimer formation.

The following is a list of references related to the above disclosure and particularly to the experimental procedures and discussions. The references are numbered to correspond to like number references that appear hereinabove.

- 10 1. Larner, A. C., Jonak, G., Cheng, Y. S., Korant, B., Knight, E. and Darnell, J. E., Jr. (1984). *Proc. Natl. Acad. Sci. USA* **81**:6733-6737; Larner, A. C., Chaudhuri, A. and Darnell, J. E. (1986). *J. Biol. Chem.* **261**:453-459.
- 15 2. Friedman, R. L., Manly, S. P., McMahon, M., Kerr, I. M. and Stark, G. R. (1984). *Cell* **38**:745-755.
3. Levy, D. E., Kessler, D. S., Pine, R., Reich, N. and Darnell, J. E. (1988). *Genes & Dev.* **2**:383-392.
- 20 4. Levy, D. E., Kessler, D. S., Pine, R., and Darnell, J. E. (1989). *Genes & Dev.* **3**:1362-1371.
- 25 5. Dale, T. C., Iman, A. M. A., Kerr, I. M. and Stark, G. R. (1989): *Proc. Natl. Acad. Sci.* **86**:1203-1207.
6. Kessler, D. S., Veals, S. A., Fu, X.-Y., and Levy, D. E. (1990). *Genes & Dev.* **4**:1753-1765.

7. Fu, X. -Y., Kessler, D. S., Veals, S. A., Levy, D. E. and Darnell, J. E. (1990). *Proc. Natl. Acad. Sci. USA* **87**:8555-8559.
8. Lew, D. J., Decker, T., and Darnell, J. E. (1989). *Mol. Cell. Biol.* **9**:5404-5411.
9. Decker, T., Lew, D. J., Cheng, Y.-S., Levy, D. E. and Darnell, J. E. (1989). *EMBO J.* **8**:2009-2014.
10. Decker, T., Lew, D. J., Mirkovitch, J. and Darnell, J. E., 1991. *EMBO J.* **10**:927-932.
11. Veals, S. A., Schindler, C. W., Fu, X.-Y., Leonard, D., Darnell, J. E. and Levy, D. E. (1992). *Mol. Cell. Biol.* **12**.
12. Schindler, C., Fu, X.-Y., Improt, T., Aebersold, R. and Darnell, J. E. (1992). *Proc. Natl. Acad. Sci. USA* **89**:7836-7389.
13. Fu, X.-Y., Schindler, C., Improt, T., Aebersold, R. and Darnell, J. E. (1992). *Proc. Natl. Acad. Sci. USA* **89**:7840-7389.
14. Lew, D. J., Decker, T. and Darnell, J. E. (1991). *Mol. Cell. Biol.* **11**:182-191.
15. Schindler, C., Shuai, K., Fu, X.-Y., Prezioso, V. and Darnell, J. E. (1992). *Science* **257**:809-812.
16. Garner, M. M. and Revan, A. (1981). *Nuc. Acids Res.* **9**:3047-3059; Fried, A., and Crothers, D. M. (1981) *ibid* 6505-6525.

17. Celis, J. E., Justessen, J., Madsen, P. S., Lovmand, J., Ratz, G. P. and Celis, A. (1987). *Leukemia* 1:800-813.
18. Chodosh, L. A., Carthew, R. W. and Sharp, P. A. (1986). *Mol. Cell Biol.* 6:4723-4733.
19. Reich, N. and Pfeffer, L. M. (1990). *Proc. Natl. Acad. Sci. USA* 87:8761-8765.
20. Kessler, D. S. and Levy, D. (1991). *J. Biol. Chem.* 266: 23471-23476.
21. Levy, D., and Darnell, J. E. (1990). *The New Biologist* 2:923-928.
22. Aguet, J. M., Denbie, Z. and Merlin, G. (1986). *Cell* 55:273-280.
23. Kaplan, D. R., Martin-Zanca, D. and Parada, L. F. (1991). *Nature* 350:158-160; Hempstead, G., Kapland, D., Martin-Zanca, D., Parada, L. F. and Chao, M. (1991). *Nature* 350:678-683.
24. Veillette, A., Bookman, M. A., Horak, E. M., and Bolen, J. B. (1988). *Cell* 55:301-308; Rudd, C. E. et al. (1988). *Proc. Natl. Acad. Sci. USA* 85:5190-5194.
25. Evans, R. K., Johnson, J. D. and Haley, B. E. (1986). *Proc. Natl. Acad. Sci. USA* 83:5382-5386.
26. Walaas, S. I. and Nairn, A. C. (1989). *J. of Mol. Neurosci.* 1:117-127.
28. Pellegrini, S., John, J., Shearer, M., Kerr, I.M., and Stark, G.R. (1989). *Mol. Cell. Biol.* 9:4605.

29. McKendry, R. et al. (1991). *Proc. Natl. Acad. Sci. U.S.A.* **88**:11455.
30. Muller, M. et al. (1993), *EMBO. J.*
- 5 31. Shuai, K., Schindler, C., Prezioso, V., and Darnell, J.E., Jr. (1992).
Science **258**:1808.
32. Boyle, W.J., van der Geer, and Hunter, T. (1991). *Methods Enzymol.*
202:110.
- 10 33. Walaas, S.I., and Nairn, A.C. (1989). *J. Mol. Neurosci.* **1**:117.
34. Khan, K.D. et al. (1993). *Proc. Natl. Acad. Sci. U.S.A.* **90**:6806.
- 15 35. Qufeshi, S.A. et al. (1991). *J. Biol. Chem.* **266**:20594.
36. Kawasaki, E., (1990). In *PRC Protocols: A Guide to Methods and Applications*. Innis, M., Gelfand, D., Sinisky, J., & White, T., Eds. (San Diego, CA: Academic Press), p. 119.
- 20 37. Brasier, A.R., Tata, J.E., and Habener, J.F. (1989).
Biotechniques **7**:1116.
38. Fu, X.-Y. (1992). *Cell* **70**:323-335.
- 25 39. Koch, C.A., Anderson, D. Moran, M.F., Ellis, C. and Pawson, T. (1991).
Science **252**:668-674.
40. Waksman, G. et al. (1992). *Nature* **358**:646-653.

41. Overduin, M. Rios, C.B., Mayer, B.J., Baltimore, D. and Cowburn, D.
(1992). *Cell* **70**:697-704.
42. Velazquez et al. (1992). *Cell* **70**:313.
- 5 43. Muller et al. (1993). *Nature* **366**:129-135.
44. Watling et al. (1993). *Nature* **366**:166.
- 10 45. Shuai, K., Stark, G.R., Kerr, I.M., and Darnell, J.E. (1993). *Science*
261:1744.
46. Dignam et al. (1983). *Nucl. Acids Res.* **11**:1475.
- 15 47. Davis, B.J. (1964). *Ann. N.Y. Acad. Sci.* **121**:404.
48. Bryan, J.K. (1977). *Anal. Biochem.* **78**:513.
49. Amster-Choder, O. and Wright, A. (1992). *Science* **257**:1395.
- 20 50. Songyang, Z., Shoelson, S.E., Chaudhuri, M., Gish, G., Pawson, T.,
Haser, W.G., King, F., Roberts, T., Ratnofsky, et al. (1993). *Cell*
72:767.
- 25 This invention may be embodied in other forms or carried out in other ways
without departing from the spirit or essential characteristics thereof. The present
disclosure is therefore to be considered as in all respects illustrative and not
restrictive, the scope of the invention being indicated by the appended Claims, and
all changes which come within the meaning and range of equivalency are intended
30 to be embraced therein.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: The Rockefeller University
- (ii) TITLE OF INVENTION: RECEPTOR RECOGNITION FACTORS, PROTEIN SEQUENCES AND METHODS OF USE THEREOF
- (iii) NUMBER OF SEQUENCES: 22
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Klauber & Jackson
 - (B) STREET: 411 Hackensack Avenue
 - (C) CITY: Hackensack
 - (D) STATE: New Jersey
 - (E) COUNTRY: USA
 - (F) ZIP: 07601
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: WO not yet assigned
 - (B) FILING DATE: 26-SEP-1994
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/212,185
 - (B) FILING DATE: 11-MAR-1994
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/212,184
 - (B) FILING DATE: 11-MAR-1994
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/126,588
 - (B) FILING DATE: 24-SEP-1993
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/126,595
 - (B) FILING DATE: 24-SEP-1993
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Jackson Esq., David A.
 - (B) REGISTRATION NUMBER: 26,742
 - (C) REFERENCE/DOCKET NUMBER: 600-1-073 PCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 201 487-5800
 - (B) TELEFAX: 201 343-1684
 - (C) TELEX: 133521

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 3268 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: both
 - (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
(B) CLONE: HeLa
- (ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 25..2577

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ACTGCAACCC TAATCAGAGC CCAA ATG GCG CAG TGG GAA ATG CTG CAG AAT	51
Met Ala Gln Trp Glu Met Leu Gln Asn	
1 5	
CTT GAC AGC CCC TTT CAG GAT CAG CTG CAC CAG CTT TAC TCG CAC AGC	99
Leu Asp Ser Pro Phe Gln Asp Gln Leu His Gln Leu Tyr Ser His Ser	
10 15 20 25	
CTC CTG CCT GTG GAC ATT CGA CAG TAC TTG GCT GTC TGG ATT GAA GAC	147
Leu Leu Pro Val Asp Ile Arg Gln Tyr Leu Ala Val Trp Ile Glu Asp	
30 35 40	
CAG AAC TGG CAG GAA GCT GCA CTT GGG AGT GAT GAT TCC AAG GCT ACC	195
Gln Asn Trp Gln Glu Ala Ala Leu Gly Ser Asp Asp Ser Lys Ala Thr	
45 50 55	
ATG CTA TTC TTC CAC TTC TTG GAT CAG CTG AAC TAT GAG TGT GGC CGT	243
Met Leu Phe Phe His Phe Leu Asp Gln Leu Asn Tyr Glu Cys Gly Arg	
60 65 70	
TGC AGC CAG GAC CCA GAG TCC TTG TTG CTG CAG CAC AAT TTG CGG AAA	291
Cys Ser Gln Asp Pro Glu Ser Leu Leu Leu Gln His Asn Leu Arg Lys	
75 80 85	
TTC TGC CGG GAC ATT CAG CCC TTT TCC CAG GAT CCT ACC CAG TTG GCT	339
Phe Cys Arg Asp Ile Gln Pro Phe Ser Gln Asp Pro Thr Gln Leu Ala	
90 95 100 105	
GAG ATG ATC TTT AAC CTC CTT CTG GAA GAA AAA AGA ATT TTG ATC CAG	387
Glu Met Ile Phe Asn Leu Leu Leu Glu Glu Lys Arg Ile Leu Ile Gln	
110 115 120	
GCT CAG AGG GCC CAA TTG GAA CAA GGA GAG CCA GTT CTC GAA ACA CCT	435
Ala Gln Arg Ala Gln Leu Glu Gln Gly Glu Pro Val Leu Glu Thr Pro	
125 130 135	
GTG GAG AGC CAG CAA CAT GAG ATT GAA TCC CGG ATC CTG GAT TTA AGG	483
Val Glu Ser Gln Gln His Glu Ile Glu Ser Arg Ile Leu Asp Leu Arg	
140 145 150	
GCT ATG ATG GAG AAG CTG GTA AAA TCC ATC AGC CAA CTG AAA GAC CAG	531
Ala Met Met Glu Lys Leu Val Lys Ser Ile Ser Gln Leu Lys Asp Gln	
155 160 165	
CAG GAT GTC TTC TGC TTC CGA TAT AAG ATC CAG GCC AAA GGG AAG ACA	579
Gln Asp Val Phe Cys Phe Arg Tyr Lys Ile Gln Ala Lys Gly Lys Thr	
170 175 180 185	

CCC TCT CTG GAC CCC CAT CAG ACC AAA GAG CAG AAG ATT CTG CAG GAA Pro Ser Leu Asp Pro His Gln Thr Lys Glu Gln Lys Ile Leu Gln Glu 190 195 200	627
ACT CTC AAT GAA CTG GAC AAA AGG AGA AAG GAG GTG CTG GAT GCC TCC Thr Leu Asn Glu Leu Asp Lys Arg Arg Lys Glu Val Leu Asp Ala Ser 205 210 215	675
AAA GCA CTG CTA GGC CGA TTA ACT ACC CTA ATC GAG CTA CTG CTG CCA Lys Ala Leu Leu Gly Arg Leu Thr Thr Leu Ile Glu Leu Leu Leu Pro 220 225 230	723
AAG TTG GAG GAG TGG AAG GCC CAG CAG CAA AAA GCC TGC ATC AGA GCT Lys Leu Glu Glu Trp Lys Ala Gln Gln Gln Lys Ala Cys Ile Arg Ala 235 240 245	771
CCC ATT GAC CAC GGG TTG GAA CAG CTG GAG ACA TGG TTC ACA GCT GGA Pro Ile Asp His Gly Leu Glu Gln Leu Glu Thr Trp Phe Thr Ala Gly 250 255 260 265	819
GCA AAG CTG TTG TTT CAC CTG AGG CAG CTG CTG AAG GAG CTG AAG GGA Ala Lys Leu Leu Phe His Leu Arg Gln Leu Leu Lys Glu Leu Lys Gly 270 275 280	867
CTG AGT TGC CTG GTT AGC TAT CAG GAT GAC CCT CTG ACC AAA GGG GTG Leu Ser Cys Leu Val Ser Tyr Gln Asp Asp Pro Leu Thr Lys Gly Val 285 290 295	915
GAC CTA CGC AAC GCC CAG GTC ACA GAG TTG CTA CAG CGT CTG CTC CAC Asp Leu Arg Asn Ala Gln Val Thr Glu Leu Leu Gln Arg Leu Leu His 300 305 310	963
AGA GCC TTT GTG GTA GAA ACC CAG CCC TGC ATG CCC CAA ACT CCC CAT Arg Ala Phe Val Val Glu Thr Gln Pro Cys Met Pro Gln Thr Pro His 315 320 325	1011
CGA CCC CTC ATC CTC AAG ACT GGC AGC AAG TTC ACC GTC CGA ACA AGG Arg Pro Leu Ile Leu Lys Thr Gly Ser Lys Phe Thr Val Arg Thr Arg 330 335 340 345	1059
CTG CTG GTG AGA CTC CAG GAA GGC AAT GAG TCA CTG ACT GTG GAA GTC Leu Leu Val Arg Leu Gln Glu Gly Asn Glu Ser Leu Thr Val Glu Val 350 355 360	1107
TCC ATT GAC AGG AAT CCT CCT CAA TTA CAA GGC TTC CGG AAG TTC AAC Ser Ile Asp Arg Asn Pro Pro Gln Leu Gln Gly Phe Arg Lys Phe Asn 365 370 375	1155
ATT CTG ACT TCA AAC CAG AAA ACT TTG ACC CCC GAG AAG GGG CAG AGT Ile Leu Thr Ser Asn Gln Lys Thr Leu Thr Pro Glu Lys Gly Gln Ser 380 385 390	1203
CAG GGT TTG ATT TGG GAC TTT GGT TAC CTG ACT CTG GTG GAG CAA CGT Gln Gly Leu Ile Trp Asp Phe Gly Tyr Leu Thr Leu Val Glu Gln Arg 395 400 405	1251
TCA GGT GGT TCA GGA AAG GGC AGC AAT AAG GGG CCA CTA GGT GTG ACA Ser Gly Gly Ser Gly Lys Gly Ser Asn Lys Gly Pro Leu Gly Val Thr 410 415 420 425	1299
GAG GAA CTG CAC ATC ATC AGC TTC ACG GTC AAA TAT ACC TAC CAG GGT Glu Glu Leu His Ile Ile Ser Phe Thr Val Lys Tyr Thr Tyr Gln Gly 430 435 440	1347
CTG AAG CAG GAG CTG AAA ACG GAC ACC CTC CCT GTG GTG ATT ATT TCC Leu Lys Gln Glu Leu Lys Thr Asp Thr Leu Pro Val Val Ile Ile Ser 445 450 455	1395

AAC ATG AAC CAG CTC TCA ATT GCC TGG GCT TCA GTT CTC TGG TTC AAT Asn Met Asn Gln Leu Ser Ile Ala Trp Ala Ser Val Leu Trp Phe Asn 460 465 470	1443
TTG CTC AGC CCA AAC CTT CAG AAC CAG CAG TTC TTC TCC AAC CCC CCC Leu Leu Ser Pro Asn Leu Gln Asn Gln Gln Phe Ser Asn Pro Pro 475 480 485	1491
AAG GCC CCC TGG AGC TTG CTG GGC CCT GCT CTC AGT TGG CAG TTC TCC Lys Ala Pro Trp Ser Leu Leu Gly Pro Ala Leu Ser Trp Gln Phe Ser 490 495 500 505	1539
TCC TAT GTT GGC CGA GGC CTC AAC TCA GAC CAG CTG AGC ATG CTG AGA Ser Tyr Val Gly Arg Gly Leu Asn Ser Asp Gln Leu Ser Met Leu Arg 510 515 520	1587
AAC AAG CTG TTC GGG CAG AAC TGT AGG ACT GAG GAT CCA TTA TTG TCC Asn Lys Leu Phe Gly Gln Asn Cys Arg Thr Glu Asp Pro Leu Leu Ser 525 530 535	1635
TGG GCT GAC TTC ACT AAG CGA GAG AGC CCT CCT GGC AAG TTA CCA TTC Trp Ala Asp Phe Thr Lys Arg Glu Ser Pro Pro Gly Lys Leu Pro Phe 540 545 550	1683
TGG ACA TGG CTG GAC AAA ATT CTG GAG TTG GTA CAT GAC CAC CTG AAG Trp Thr Trp Leu Asp Lys Ile Leu Glu Leu Val His Asp His Leu Lys 555 560 565	1731
GAT CTC TGG AAT GAT GGA CGC ATC ATG GGC TTT GTG AGT CGG AGC CAG Asp Leu Trp Asn Asp Gly Arg Ile Met Gly Phe Val Ser Arg Ser Gln 570 575 580 585	1779
GAG CGC CGG CTG CTG AAG AAG ACC ATG TCT GGC ACC TTT CTA CTG CGC Glu Arg Arg Leu Leu Lys Lys Thr Met Ser Gly Thr Phe Leu Leu Arg 590 595 600	1827
TTC AGT GAA TCG TCA GAA GGG GGC ATT ACC TGC TCC TGG GTG GAG CAC Phe Ser Glu Ser Ser Glu Gly Gly Ile Thr Cys Ser Trp Val Glu His 605 610 615	1875
CAG GAT GAT GAC AAG GTG CTC ATC TAC TCT GTG CAA CCG TAC ACG AAG Gln Asp Asp Asp Lys Val Leu Ile Tyr Ser Val Gln Pro Tyr Thr Lys 620 625 630	1923
GAG GTG CTG CAG TCA CTC CCG CTG ACT GAA ATC ATC CGC CAT TAC CAG Glu Val Leu Gln Ser Leu Pro Leu Thr Glu Ile Ile Arg His Tyr Gln 635 640 645	1971
TTG CTC ACT GAG GAG AAT ATA CCT GAA AAC CCA CTG CGC TTC CTC TAT Leu Leu Thr Glu Glu Asn Ile Pro Glu Asn Pro Leu Arg Phe Leu Tyr 650 655 660 665	2019
CCC CGA ATC CCC CGG GAT GAA GCT TTT GGG TGC TAC TAC CAG GAG AAA Pro Arg Ile Pro Arg Asp Glu Ala Phe Gly Cys Tyr Tyr Gln Glu Lys 670 675 680	2067
GTT AAT CTC CAG GAA CGG AGG AAA TAC CTG AAA CAC AGG CTC ATT GTG Val Asn Leu Gln Glu Arg Arg Lys Tyr Leu Lys His Arg Leu Ile Val 685 690 695	2115
GTC TCT AAT AGA CAG GTG GAT GAA CTG CAA CAA CCG CTG GAG CTT AAG Val Ser Asn Arg Gln Val Asp Glu Leu Gln Gln Pro Leu Glu Leu Lys 700 705 710	2163
CCA GAG CCA GAG CTG GAG TCA TTA GAG CTG GAA CTA GGG CTG GTG CCA Pro Glu Pro Glu Leu Glu Ser Leu Glu Leu Glu Leu Gly Leu Val Pro 715 720 725	2211

GAG CCA GAG CTC AGC CTG GAC TTA GAG CCA CTG CTG AAG GCA GGG CTG Glu Pro Glu Leu Ser Leu Asp Leu Glu Pro Leu Leu Lys Ala Gly Leu 730 735 740 745	2259
GAT CTG GGG CCA GAG CTA GAG TCT GTG CTG GAG TCC ACT CTG GAG CCT Asp Leu Gly Pro Glu Leu Glu Ser Val Leu Glu Ser Thr Leu Glu Pro 750 755 760	2307
GTG ATA GAG CCC ACA CTA TGC ATG GTA TCA CAA ACA GTG CCA GAG CCA Val Ile Glu Pro Thr Leu Cys Met Val Ser Gln Thr Val Pro Glu Pro 765 770 775	2355
GAC CAA GGA CCT GTA TCA CAG CCA GTG CCA GAG CCA GAT TTG CCC TGT Asp Gln Gly Pro Val Ser Gln Pro Val Pro Glu Pro Asp Leu Pro Cys 780 785 790	2403
GAT CTG AGA CAT TTG AAC ACT GAG CCA ATG GAA ATC TTC AGA AAC TGT Asp Leu Arg His Leu Asn Thr Glu Pro Met Glu Ile Phe Arg Asn Cys 795 800 805	2451
GTA AAG ATT GAA GAA ATC ATG CCG AAT GGT GAC CCA CTG TTG GCT GGC Val Lys Ile Glu Glu Ile Met Pro Asn Gly Asp Pro Leu Leu Ala Gly 810 815 820 825	2499
CAG AAC ACC GTG GAT GAG GTT TAC GTC TCC CGC CCC AGC CAC TTC TAC Gln Asn Thr Val Asp Glu Val Tyr Val Ser Arg Pro Ser His Phe Tyr 830 835 840	2547
ACT GAT GGA CCC TTG ATG CCT TCT GAC TTC TAGGAACCAC ATTTCTCTCTG Thr Asp Gly Pro Leu Met Pro Ser Asp Phe 845 850	2597
TTCTTTTCAT ATCTCTTTGC CCTTCCTACT CCTCATAGCA TGATATTGTT CTCCAAGGAT	2657
GGGAATCAGG CATGTGTCCC TTCCAAGCTG TGTTAACTGT TCAAACCTCAG GCCTGTGTGA	2717
CTCCATTGGG GTGAGAGGTG AAAGCATAAC ATGGGTACAG AGGGGACAAC AATGAATCAG	2777
AACAGATGCT GAGCCATAGG TCTAAATAGG ATCCTGGAGG CTGCCTGCTG TGCTGGGAGG	2837
TATAGGGGTC CTGGGGGCAG GCCAGGGCAG TTGACAGGTA CTTGGAGGGC TCAGGGCAGT	2897
GGCTTCTTTC CAGTATGGAA GGATTTCAAC ATTTTAATAG TTGGTTAGGC TAAACTGGTG	2957
CATACTGGCA TTGGCCTTGG TGGGGAGCAC AGACACAGGA TAGGACTCCA TTTCTTTCTT	3017
CCATTTCCTT ATGTCTAGGA TAACTTGCTT TCTTCTTTCC TTTACTCCTG GCTCAAGCCC	3077
TGAATTTCTT CTTTTCTTGC AGGGGTTGAG AGCTTTCTGC CTTAGCCTAC CATGTGAAAC	3137
TCTACCCTGA AGAAAGGGAT GGATAGGAAG TAGACCTCTT TTTCTTACCA GTCTCCTCCC	3197
CTACTCTGCC CCCTAAGCTG GCTGTACCTG TTCCTCCCC ATAAAATGAT CCTGCCAATC	3257
TAAAAA AAAA A	3268

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 851 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ala Gln Trp Glu Met Leu Gln Asn Leu Asp Ser Pro Phe Gln Asp
 1 5 10 15
 Gln Leu His Gln Leu Tyr Ser His Ser Leu Leu Pro Val Asp Ile Arg
 20 25 30
 Gln Tyr Leu Ala Val Trp Ile Glu Asp Gln Asn Trp Gln Glu Ala Ala
 35 40 45
 Leu Gly Ser Asp Asp Ser Lys Ala Thr Met Leu Phe Phe His Phe Leu
 50 55 60
 Asp Gln Leu Asn Tyr Glu Cys Gly Arg Cys Ser Gln Asp Pro Glu Ser
 65 70 75 80
 Leu Leu Leu Gln His Asn Leu Arg Lys Phe Cys Arg Asp Ile Gln Pro
 85 90 95
 Phe Ser Gln Asp Pro Thr Gln Leu Ala Glu Met Ile Phe Asn Leu Leu
 100 105 110
 Leu Glu Glu Lys Arg Ile Leu Ile Gln Ala Gln Arg Ala Gln Leu Glu
 115 120 125
 Gln Gly Glu Pro Val Leu Glu Thr Pro Val Glu Ser Gln Gln His Glu
 130 135 140
 Ile Glu Ser Arg Ile Leu Asp Leu Arg Ala Met Met Glu Lys Leu Val
 145 150 155 160
 Lys Ser Ile Ser Gln Leu Lys Asp Gln Gln Asp Val Phe Cys Phe Arg
 165 170 175
 Tyr Lys Ile Gln Ala Lys Gly Lys Thr Pro Ser Leu Asp Pro His Gln
 180 185 190
 Thr Lys Glu Gln Lys Ile Leu Gln Glu Thr Leu Asn Glu Leu Asp Lys
 195 200 205
 Arg Arg Lys Glu Val Leu Asp Ala Ser Lys Ala Leu Leu Gly Arg Leu
 210 215 220
 Thr Thr Leu Ile Glu Leu Leu Leu Pro Lys Leu Glu Glu Trp Lys Ala
 225 230 235 240
 Gln Gln Gln Lys Ala Cys Ile Arg Ala Pro Ile Asp His Gly Leu Glu
 245 250 255
 Gln Leu Glu Thr Trp Phe Thr Ala Gly Ala Lys Leu Leu Phe His Leu
 260 265 270
 Arg Gln Leu Leu Lys Glu Leu Lys Gly Leu Ser Cys Leu Val Ser Tyr
 275 280 285
 Gln Asp Asp Pro Leu Thr Lys Gly Val Asp Leu Arg Asn Ala Gln Val
 290 295 300
 Thr Glu Leu Leu Gln Arg Leu Leu His Arg Ala Phe Val Val Glu Thr
 305 310 315 320
 Gln Pro Cys Met Pro Gln Thr Pro His Arg Pro Leu Ile Leu Lys Thr
 325 330 335
 Gly Ser Lys Phe Thr Val Arg Thr Arg Leu Leu Val Arg Leu Gln Glu
 340 345 350
 Gly Asn Glu Ser Leu Thr Val Glu Val Ser Ile Asp Arg Asn Pro Pro

355 360 365
 Gln Leu Gln Gly Phe Arg Lys Phe Asn Ile Leu Thr Ser Asn Gln Lys
 370 375 380
 Thr Leu Thr Pro Glu Lys Gly Gln Ser Gln Gly Leu Ile Trp Asp Phe
 385 390 395 400
 Gly Tyr Leu Thr Leu Val Glu Gln Arg Ser Gly Gly Ser Gly Lys Gly
 405 410 415
 Ser Asn Lys Gly Pro Leu Gly Val Thr Glu Glu Leu His Ile Ile Ser
 420 425 430
 Phe Thr Val Lys Tyr Thr Tyr Gln Gly Leu Lys Gln Glu Leu Lys Thr
 435 440 445
 Asp Thr Leu Pro Val Val Ile Ile Ser Asn Met Asn Gln Leu Ser Ile
 450 455 460
 Ala Trp Ala Ser Val Leu Trp Phe Asn Leu Leu Ser Pro Asn Leu Gln
 465 470 475 480
 Asn Gln Gln Phe Phe Ser Asn Pro Pro Lys Ala Pro Trp Ser Leu Leu
 485 490 495
 Gly Pro Ala Leu Ser Trp Gln Phe Ser Ser Tyr Val Gly Arg Gly Leu
 500 505 510
 Asn Ser Asp Gln Leu Ser Met Leu Arg Asn Lys Leu Phe Gly Gln Asn
 515 520 525
 Cys Arg Thr Glu Asp Pro Leu Leu Ser Trp Ala Asp Phe Thr Lys Arg
 530 535 540
 Glu Ser Pro Pro Gly Lys Leu Pro Phe Trp Thr Trp Leu Asp Lys Ile
 545 550 555 560
 Leu Glu Leu Val His Asp His Leu Lys Asp Leu Trp Asn Asp Gly Arg
 565 570 575
 Ile Met Gly Phe Val Ser Arg Ser Gln Glu Arg Arg Leu Leu Lys Lys
 580 585 590
 Thr Met Ser Gly Thr Phe Leu Leu Arg Phe Ser Glu Ser Ser Glu Gly
 595 600 605
 Gly Ile Thr Cys Ser Trp Val Glu His Gln Asp Asp Lys Val Leu
 610 615 620
 Ile Tyr Ser Val Gln Pro Tyr Thr Lys Glu Val Leu Gln Ser Leu Pro
 625 630 635 640
 Leu Thr Glu Ile Ile Arg His Tyr Gln Leu Leu Thr Glu Glu Asn Ile
 645 650 655
 Pro Glu Asn Pro Leu Arg Phe Leu Tyr Pro Arg Ile Pro Arg Asp Glu
 660 665 670
 Ala Phe Gly Cys Tyr Tyr Gln Glu Lys Val Asn Leu Gln Glu Arg Arg
 675 680 685
 Lys Tyr Leu Lys His Arg Leu Ile Val Val Ser Asn Arg Gln Val Asp
 690 695 700
 Glu Leu Gln Gln Pro Leu Glu Leu Lys Pro Glu Pro Glu Leu Glu Ser
 705 710 715 720

Leu Glu Leu Glu Leu Gly Leu Val Pro Glu Pro Glu Leu Ser Leu Asp
 725 730 735
 Leu Glu Pro Leu Leu Lys Ala Gly Leu Asp Leu Gly Pro Glu Leu Glu
 740 745 750
 Ser Val Leu Glu Ser Thr Leu Glu Pro Val Ile Glu Pro Thr Leu Cys
 755 760 765
 Met Val Ser Gln Thr Val Pro Glu Pro Asp Gln Gly Pro Val Ser Gln
 770 775 780
 Pro Val Pro Glu Pro Asp Leu Pro Cys Asp Leu Arg His Leu Asn Thr
 785 790 795 800
 Glu Pro Met Glu Ile Phe Arg Asn Cys Val Lys Ile Glu Glu Ile Met
 805 810 815
 Pro Asn Gly Asp Pro Leu Leu Ala Gly Gln Asn Thr Val Asp Glu Val
 820 825 830
 Tyr Val Ser Arg Pro Ser His Phe Tyr Thr Asp Gly Pro Leu Met Pro
 835 840 845
 Ser Asp Phe
 850

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 3943 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: both
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

- (B) CLONE: Human Stat91

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 197..2449

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATTAAACCTC TCGCCGAGCC CCTCCGCAGA CTCTGCGCCG GAAAGTTTCA TTTGCTGTAT	60
GCCATCCTCG AGAGCTGTCT AGGTTAACGT TCGCACTCTG TGTATATAAC CTCGACAGTC	120
TTGGCACCTA ACGTGCTGTG CGTAGCTGCT CCTTTGGTTG AATCCCCAGG CCCTTGTTGG	180
GGCACAAGGT GGCAGG ATG TCT CAG TGG TAC GAA CTT CAG CAG CTT GAC	229
Met Ser Gln Trp Tyr Glu Leu Gln Gln Leu Asp	
1 5 10	
TCA AAA TTC CTG GAG CAG GTT CAC CAG CTT TAT GAT GAC AGT TTT CCC	277
Ser Lys Phe Leu Glu Gln Val His Gln Leu Tyr Asp Asp Ser Phe Pro	
15 20 25	

ATG GAA ATC AGA CAG TAC CTG GCA CAG TGG TTA GAA AAG CAA GAC TGG Met Glu Ile Arg Gln Tyr Leu Ala Gln Trp Leu Glu Lys Gln Asp Trp 30 35 40	325
GAG CAC GCT GCC AAT GAT GTT TCA TTT GCC ACC ATC CGT TTT CAT GAC Glu His Ala Ala Asn Asp Val Ser Phe Ala Thr Ile Arg Phe His Asp 45 50 55	373
CTC CTG TCA CAG CTG GAT GAT CAA TAT AGT CGC TTT TCT TTG GAG AAT Leu Leu Ser Gln Leu Asp Asp Gln Tyr Ser Arg Phe Ser Leu Glu Asn 60 65 70 75	421
AAC TTC TTG CTA CAG CAT AAC ATA AGG AAA AGC AAG CGT AAT CTT CAG Asn Phe Leu Leu Gln His Asn Ile Arg Lys Ser Lys Arg Asn Leu Gln 80 85 90	469
GAT AAT TTT CAG GAA GAC CCA ATC CAG ATG TCT ATG ATC ATT TAC AGC Asp Asn Phe Gln Glu Asp Pro Ile Gln Met Ser Met Ile Ile Tyr Ser 95 100 105	517
TGT CTG AAG GAA GAA AGG AAA ATT CTG GAA AAC GCC CAG AGA TTT AAT Cys Leu Lys Glu Glu Arg Lys Ile Leu Glu Asn Ala Gln Arg Phe Asn 110 115 120	565
CAG GCT CAG TCG GGG AAT ATT CAG AGC ACA GTG ATG TTA GAC AAA CAG Gln Ala Gln Ser Gly Asn Ile Gln Ser Thr Val Met Leu Asp Lys Gln 125 130 135	613
AAA GAG CTT GAC AGT AAA GTC AGA AAT GTG AAG GAC AAG GTT ATG TGT Lys Glu Leu Asp Ser Lys Val Arg Asn Val Lys Asp Lys Val Met Cys 140 145 150 155	661
ATA GAG CAT GAA ATC AAG AGC CTG GAA GAT TTA CAA GAT GAA TAT GAC Ile Glu His Glu Ile Lys Ser Leu Glu Asp Leu Gln Asp Glu Tyr Asp 160 165 170	709
TTC AAA TGC AAA ACC TTG CAG AAC AGA GAA CAC GAG ACC AAT GGT GTG Phe Lys Cys Lys Thr Leu Gln Asn Arg Glu His Glu Thr Asn Gly Val 175 180 185	757
GCA AAG AGT GAT CAG AAA CAA GAA CAG CTG TTA CTC AAG AAG ATG TAT Ala Lys Ser Asp Gln Lys Gln Glu Gln Leu Leu Leu Lys Lys Met Tyr 190 195 200	805
TTA ATG CTT GAC AAT AAG AGA AAG GAA GTA GTT CAC AAA ATA ATA GAG Leu Met Leu Asp Asn Lys Arg Lys Glu Val Val His Lys Ile Ile Glu 205 210 215	853
TTG CTG AAT GTC ACT GAA CTT ACC CAG AAT GCC CTG ATT AAT GAT GAA Leu Leu Asn Val Thr Glu Leu Thr Gln Asn Ala Leu Ile Asn Asp Glu 220 225 230 235	901
CTA GTG GAG TGG AAG CGG AGA CAG CAG AGC GCC TGT ATT GGG GGG CCG Leu Val Glu Trp Lys Arg Arg Gln Gln Ser Ala Cys Ile Gly Gly Pro 240 245 250	949
CCC AAT GCT TGC TTG GAT CAG CTG CAG AAC TGG TTC ACT ATA GTT GCG Pro Asn Ala Cys Leu Asp Gln Leu Gln Asn Trp Phe Thr Ile Val Ala 255 260 265	997
GAG AGT CTG CAG CAA GTT CGG CAG CAG CTT AAA AAG TTG GAG GAA TTG Glu Ser Leu Gln Gln Val Arg Gln Gln Leu Lys Lys Leu Glu Glu Leu 270 275 280	1045
GAA CAG AAA TAC ACC TAC GAA CAT GAC CCT ATC ACA AAA AAC AAA CAA Glu Gln Lys Tyr Thr Tyr Glu His Asp Pro Ile Thr Lys Asn Lys Gln 285 290 295	1093

GTG TTA TGG GAC CGC ACC TTC AGT CTT TTC CAG CAG CTC ATT CAG AGC Val Leu Trp Asp Arg Thr Phe Ser Leu Phe Gln Gln Leu Ile Gln Ser 300 305 310 315	1141
TCG TTT GTG GTG GAA AGA CAG CCC TGC ATG CCA ACG CAC CCT CAG AGG Ser Phe Val Val Glu Arg Gln Pro Cys Met Pro Thr His Pro Gln Arg 320 325 330	1189
CCG CTG GTC TTG AAG ACA GGG GTC CAG TTC ACT GTG AAG TTG AGA CTG Pro Leu Val Leu Lys Thr Gly Val Gln Phe Thr Val Lys Leu Arg Leu 335 340 345	1237
TTG GTG AAA TTG CAA GAG CTG AAT TAT AAT TTG AAA GTC AAA GTC TTA Leu Val Lys Leu Gln Glu Leu Asn Tyr Asn Leu Lys Val Lys Val Leu 350 355 360	1285
TTT GAT AAA GAT GTG AAT GAG AGA AAT ACA GTA AAA GGA TTT AGG AAG Phe Asp Lys Asp Val Asn Glu Arg Asn Thr Val Lys Gly Phe Arg Lys 365 370 375	1333
TTC AAC ATT TTG GGC ACG CAC ACA AAA GTG ATG AAC ATG GAG GAG TCC Phe Asn Ile Leu Gly Thr His Thr Lys Val Met Asn Met Glu Glu Ser 380 385 390 395	1381
ACC AAT GGC AGT CTG GCG GCT GAA TTT CGG CAC CTG CAA TTG AAA GAA Thr Asn Gly Ser Leu Ala Ala Glu Phe Arg His Leu Gln Leu Lys Glu 400 405 410	1429
CAG AAA AAT GCT GGC ACC AGA ACG AAT GAG GGT CCT CTC ATC GTT ACT Gln Lys Asn Ala Gly Thr Arg Thr Asn Glu Gly Pro Leu Ile Val Thr 415 420 425	1477
GAA GAG CTT CAC TCC CTT AGT TTT GAA ACC CAA TTG TGC CAG CCT GGT Glu Glu Leu His Ser Leu Ser Phe Glu Thr Gln Leu Cys Gln Pro Gly 430 435 440	1525
TTG GTA ATT GAC CTC GAG ACG ACC TCT CTG CCC GTT GTG GTG ATC TCC Leu Val Ile Asp Leu Glu Thr Thr Ser Leu Pro Val Val Val Ile Ser 445 450 455	1573
AAC GTC AGC CAG CTC CCG AGC GGT TGG GCC TCC ATC CTT TGG TAC AAC Asn Val Ser Gln Leu Pro Ser Gly Trp Ala Ser Ile Leu Trp Tyr Asn 460 465 470 475	1621
ATG CTG GTG GCG GAA CCC AGG AAT CTG TCC TTC TTC CTG ACT CCA CCA Met Leu Val Ala Glu Pro Arg Asn Leu Ser Phe Phe Leu Thr Pro Pro 480 485 490	1669
TGT GCA CGA TGG GCT CAG CTT TCA GAA GTG CTG AGT TGG CAG TTT TCT Cys Ala Arg Trp Ala Gln Leu Ser Glu Val Leu Ser Trp Gln Phe Ser 495 500 505	1717
TCT GTC ACC AAA AGA GGT CTC AAT GTG GAC CAG CTG AAC ATG TTG GGA Ser Val Thr Lys Arg Gly Leu Asn Val Asp Gln Leu Asn Met Leu Gly 510 515 520	1765
GAG AAG CTT CTT GGT CCT AAC GCC AGC CCC GAT GGT CTC ATT CCG TGG Glu Lys Leu Leu Gly Pro Asn Ala Ser Pro Asp Gly Leu Ile Pro Trp 525 530 535	1813
ACG ACG TTT TGT AAG GAA AAT ATA AAT GAT AAA AAT TTT CCC TTC TGG Thr Arg Phe Cys Lys Glu Asn Ile Asn Asp Lys Asn Phe Pro Phe Trp 540 545 550 555	1861
CTT TGG ATT GAA AGC ATC CTA GAA CTC ATT AAA AAA CAC CTG CTC CCT Leu Trp Ile Glu Ser Ile Leu Glu Leu Ile Lys Lys His Leu Leu Pro 560 565 570	1909

CTC TGG AAT GAT GGG TGC ATC ATG GGC TTC ATC AGC AAG GAG CGA GAG Leu Trp Asn Asp Gly Cys Ile Met Gly Phe Ile Ser Lys Glu Arg Glu 575 580 585	1957
CGT GCC CTG TTG AAG GAC CAG CAG CCG GGG ACC TTC CTG CTG CGG TTC Arg Ala Leu Leu Lys Asp Gln Gln Pro Gly Thr Phe Leu Leu Arg Phe 590 595 600	2005
AGT GAG AGC TCC CGG GAA GGG GCC ATC ACA TTC ACA TGG GTG GAG CGG Ser Glu Ser Ser Arg Glu Gly Ala Ile Thr Phe Thr Trp Val Glu Arg 605 610 615	2053
TCC CAG AAC GGA GGC GAA CCT GAC TTC CAT GCG GTT GAA CCC TAC ACG Ser Gln Asn Gly Gly Glu Pro Asp Phe His Ala Val Glu Pro Tyr Thr 620 625 630 635	2101
AAG AAA GAA CTT TCT GCT GTT ACT TTC CCT GAC ATC ATT CGC AAT TAC Lys Lys Glu Leu Ser Ala Val Thr Phe Pro Asp Ile Ile Arg Asn Tyr 640 645 650	2149
AAA GTC ATG GCT GCT GAG AAT ATT CCT GAG AAT CCC CTG AAG TAT CTG Lys Val Met Ala Ala Glu Asn Ile Pro Glu Asn Pro Leu Lys Tyr Leu 655 660 665	2197
TAT CCA AAT ATT GAC AAA GAC CAT GCC TTT GGA AAG TAT TAC TCC AGG Tyr Pro Asn Ile Asp Lys Asp His Ala Phe Gly Lys Tyr Tyr Ser Arg 670 675 680	2245
CCA AAG GAA GCA CCA GAG CCA ATG GAA CTT GAT GGC CCT AAA GGA ACT Pro Lys Glu Ala Pro Glu Pro Met Glu Leu Asp Gly Pro Lys Gly Thr 685 690 695	2293
GGA TAT ATC AAG ACT GAG TTG ATT TCT GTG TCT GAA GTT CAC CCT TCT Gly Tyr Ile Lys Thr Glu Leu Ile Ser Val Ser Glu Val His Pro Ser 700 705 710 715	2341
AGA CTT CAG ACC ACA GAC AAC CTG CTC CCC ATG TCT CCT GAG GAG TTT Arg Leu Gln Thr Thr Asp Asn Leu Leu Pro Met Ser Pro Glu Glu Phe 720 725 730	2389
GAC GAG GTG TCT CGG ATA GTG GGC TCT GTA GAA TTC GAC AGT ATG ATG Asp Glu Val Ser Arg Ile Val Gly Ser Val Glu Phe Asp Ser Met Met 735 740 745	2437
AAC ACA GTA TAGAGCATGA ATTTTTTTCA TCTTCTCTGG CGACAGTTTT Asn Thr Val 750	2486
CCTTCTCATC TGTGATTCCC TCCTGCTACT CTGTTCTTTC ACATCCTGTG TTTCTAGGGA	2546
AATGAAAGAA AGGCCAGCAA ATTCGCTGCA ACCTGTTGAT AGCAAGTGAA TTTTCTCTA	2606
ACTCAGAAAC ATCAGTTACT CTGAAGGGCA TCATGCATCT TACTGAAGGT AAAATTGAAA	2666
GGCATTCTCT GAAGAGTGGG TTTCACAAGT GAAAAACATC CAGATACACC CAAAGTATCA	2726
GGACGAGAAT GAGGGTCCTT TGGGAAAGGA GAAGTTAAGC AACATCTAGC AAATGTTATG	2786
CATAAAGTCA GTGCCAACT GTTATAGGTT GTTGGATAAA TCAGTGGTTA TTTAGGGAAC	2846
TGCTTGACGT AGGAACGGTA AATTTCTGTG GGAGAATTCT TACATGTTTT CTTTGCTTTA	2906
AGTGTAAGTGC GCAGTTTTCC ATTGGTTTAC CTGTGAAATA GTTCAAAGCC AAGTTTATAT	2966
ACAATTATAT CAGTCCTCTT TCAAAGGTAG CCATCATGGA TCTGGTAGGG GGAAAATGTG	3026
TATTTTATTA CATCTTTCAC ATTGGCTATT TAAAGACAAA GACAAATTCT GTTTCTTGAG	3086

AAGAGAACAT TTCCAAATTC ACAAGTTGTG TTTGATATCC AAAGCTGAAT ACATTCTCCT 3146
 TTCATCTTGG TCACATACAA TTATTTTAC AGTCTCCCA AGGGAGTTAG GCTATTCACA 3206
 ACCACTCATT CAAAAGTTGA AATTAACCAT AGATGTAGAT AAACTCAGAA ATTTAATTCA 3266
 TGTTCCTTAA ATGGGCTACT TTGTCCTTTT TGTATTAGG GTGGTATTTA GTCTATTAGC 3326
 CACAAAATTG GGAAAGGAGT AGAAAAAGCA GTAAGTGACA ACTTGAATAA TACACCAGAG 3386
 ATAATATGAG AATCAGATCA TTTCAAACT CATTTCCTAT GTAAGTGCAT TGAGAACTGC 3446
 ATATGTTTCG CTGATATATG TGTTTTTCAC ATTTGCGAAT GGTTCATTTC TCTCTCCTGT 3506
 ACTTTTCCCA GACACTTTTT TGAGTGGATG ATGTTTCGTG AAGTATACTG TATTTTACC 3566
 TTTTTCCTTC CTTATCACTG ACACAAAAG TAGATTAAGA GATGGGTTTG ACAAGTTCT 3626
 TCCCTTTTAC ATACTGCTGT CTATGTGGCT GTATCTTGT TTTCCACTAC TGCTACCACA 3686
 ACTATATTAT CATGCAAATG CTGTATTCTT CTTTGGTGGA GATAAAGATT TCTTGAGTTT 3746
 TGTTTTAAAA TTAAAGCTAA AGTATCTGTA TTGCATTAAA TATAATATCG ACACAGTGC 3806
 TTCCGTGGCA CTGCATACAA TCTGAGGCTT CCTCTCTCAG TTTTATATA GATGGCGAGA 3866
 ACCTAAGTTT CAGTTGATT TACAATTGAA ATGACTAAAA AACAAAGAAG ACAACATTAA 3926
 AAACAATATT GTTCTA 3943

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 750 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Ser Gln Trp Tyr Glu Leu Gln Gln Leu Asp Ser Lys Phe Leu Glu
 1 5 10 15
 Gln Val His Gln Leu Tyr Asp Asp Ser Phe Pro Met Glu Ile Arg Gln
 20 25 30
 Tyr Leu Ala Gln Trp Leu Glu Lys Gln Asp Trp Glu His Ala Ala Asn
 35 40 45
 Asp Val Ser Phe Ala Thr Ile Arg Phe His Asp Leu Leu Ser Gln Leu
 50 55 60
 Asp Asp Gln Tyr Ser Arg Phe Ser Leu Glu Asn Asn Phe Leu Leu Gln
 65 70 75 80
 His Asn Ile Arg Lys Ser Lys Arg Asn Leu Gln Asp Asn Phe Gln Glu
 85 90 95
 Asp Pro Ile Gln Met Ser Met Ile Ile Tyr Ser Cys Leu Lys Glu Glu
 100 105 110
 Arg Lys Ile Leu Glu Asn Ala Gln Arg Phe Asn Gln Ala Gln Ser Gly
 115 120 125

Asn Ile Gln Ser Thr Val Met Leu Asp Lys Gln Lys Glu Leu Asp Ser
 130 135 140
 Lys Val Arg Asn Val Lys Asp Lys Val Met Cys Ile Glu His Glu Ile
 145 150 155 160
 Lys Ser Leu Glu Asp Leu Gln Asp Glu Tyr Asp Phe Lys Cys Lys Thr
 165 170 175
 Leu Gln Asn Arg Glu His Glu Thr Asn Gly Val Ala Lys Ser Asp Gln
 180 185 190
 Lys Gln Glu Gln Leu Leu Leu Lys Lys Met Tyr Leu Met Leu Asp Asn
 195 200 205
 Lys Arg Lys Glu Val Val His Lys Ile Ile Glu Leu Leu Asn Val Thr
 210 215 220
 Glu Leu Thr Gln Asn Ala Leu Ile Asn Asp Glu Leu Val Glu Trp Lys
 225 230 235 240
 Arg Arg Gln Gln Ser Ala Cys Ile Gly Gly Pro Pro Asn Ala Cys Leu
 245 250 255
 Asp Gln Leu Gln Asn Trp Phe Thr Ile Val Ala Glu Ser Leu Gln Gln
 260 265 270
 Val Arg Gln Gln Leu Lys Lys Leu Glu Glu Leu Glu Gln Lys Tyr Thr
 275 280 285
 Tyr Glu His Asp Pro Ile Thr Lys Asn Lys Gln Val Leu Trp Asp Arg
 290 295 300
 Thr Phe Ser Leu Phe Gln Gln Leu Ile Gln Ser Ser Phe Val Val Glu
 305 310 315 320
 Arg Gln Pro Cys Met Pro Thr His Pro Gln Arg Pro Leu Val Leu Lys
 325 330 335
 Thr Gly Val Gln Phe Thr Val Lys Leu Arg Leu Leu Val Lys Leu Gln
 340 345 350
 Glu Leu Asn Tyr Asn Leu Lys Val Lys Val Leu Phe Asp Lys Asp Val
 355 360 365
 Asn Glu Arg Asn Thr Val Lys Gly Phe Arg Lys Phe Asn Ile Leu Gly
 370 375 380
 Thr His Thr Lys Val Met Asn Met Glu Glu Ser Thr Asn Gly Ser Leu
 385 390 395 400
 Ala Ala Glu Phe Arg His Leu Gln Leu Lys Glu Gln Lys Asn Ala Gly
 405 410 415
 Thr Arg Thr Asn Glu Gly Pro Leu Ile Val Thr Glu Glu Leu His Ser
 420 425 430
 Leu Ser Phe Glu Thr Gln Leu Cys Gln Pro Gly Leu Val Ile Asp Leu
 435 440 445
 Glu Thr Thr Ser Leu Pro Val Val Val Ile Ser Asn Val Ser Gln Leu
 450 455 460
 Pro Ser Gly Trp Ala Ser Ile Leu Trp Tyr Asn Met Leu Val Ala Glu
 465 470 475 480

Pro Arg Asn Leu Ser Phe Phe Leu Thr Pro Pro Cys Ala Arg Trp Ala
 485 490 495
 Gln Leu Ser Glu Val Leu Ser Trp Gln Phe Ser Ser Val Thr Lys Arg
 500 505 510
 Gly Leu Asn Val Asp Gln Leu Asn Met Leu Gly Glu Lys Leu Leu Gly
 515 520 525
 Pro Asn Ala Ser Pro Asp Gly Leu Ile Pro Trp Thr Arg Phe Cys Lys
 530 535 540
 Glu Asn Ile Asn Asp Lys Asn Phe Pro Phe Trp Leu Trp Ile Glu Ser
 545 550 555 560
 Ile Leu Glu Leu Ile Lys Lys His Leu Leu Pro Leu Trp Asn Asp Gly
 565 570 575
 Cys Ile Met Gly Phe Ile Ser Lys Glu Arg Glu Arg Ala Leu Leu Lys
 580 585 590
 Asp Gln Gln Pro Gly Thr Phe Leu Leu Arg Phe Ser Glu Ser Ser Arg
 595 600 605
 Glu Gly Ala Ile Thr Phe Thr Trp Val Glu Arg Ser Gln Asn Gly Gly
 610 615 620
 Glu Pro Asp Phe His Ala Val Glu Pro Tyr Thr Lys Lys Glu Leu Ser
 625 630 635 640
 Ala Val Thr Phe Pro Asp Ile Ile Arg Asn Tyr Lys Val Met Ala Ala
 645 650 655
 Glu Asn Ile Pro Glu Asn Pro Leu Lys Tyr Leu Tyr Pro Asn Ile Asp
 660 665 670
 Lys Asp His Ala Phe Gly Lys Tyr Tyr Ser Arg Pro Lys Glu Ala Pro
 675 680 685
 Glu Pro Met Glu Leu Asp Gly Pro Lys Gly Thr Gly Tyr Ile Lys Thr
 690 695 700
 Glu Leu Ile Ser Val Ser Glu Val His Pro Ser Arg Leu Gln Thr Thr
 705 710 715 720
 Asp Asn Leu Leu Pro Met Ser Pro Glu Glu Phe Asp Glu Val Ser Arg
 725 730 735
 Ile Val Gly Ser Val Glu Phe Asp Ser Met Met Asn Thr Val
 740 745 750

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 2607 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: both
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 197..2335

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATTAAACCTC TCGCCGAGCC CCTCCGAGAG CTCTGCGCCG GAAAGTTTCA TTTGCTGTAT	60
GCCATCCTCG AGAGCTGTCT AGGTTAACGT TCGCACTCTG TGTATATAAC CTCGACAGTC	120
TTGGCACCTA ACGTGCTGTG CGTAGCTGCT CCTTTGGTTG AATCCCCAGG CCCTTGTTGG	180
GGCACAAGGT GGCAGG ATG TCT CAG TGG TAC GAA CTT CAG CAG CTT GAC	229
Met Ser Gln Trp Tyr Glu Leu Gln Gln Leu Asp	
1 5 10	
TCA AAA TTC CTG GAG CAG GTT CAC CAG CTT TAT GAT GAC AGT TTT CCC	277
Ser Lys Phe Leu Glu Gln Val His Gln Leu Tyr Asp Asp Ser Phe Pro	
15 20 25	
ATG GAA ATC AGA CAG TAC CTG GCA CAG TGG TTA GAA AAG CAA GAC TGG	325
Met Glu Ile Arg Gln Tyr Leu Ala Gln Trp Leu Glu Lys Gln Asp Trp	
30 35 40	
GAG CAC GCT GCC AAT GAT GTT TCA TTT GCC ACC ATC CGT TTT CAT GAC	373
Glu His Ala Ala Asn Asp Val Ser Phe Ala Thr Ile Arg Phe His Asp	
45 50 55	
CTC CTG TCA CAG CTG GAT GAT CAA TAT AGT CGC TTT TCT TTG GAG AAT	421
Leu Leu Ser Gln Leu Asp Asp Gln Tyr Ser Arg Phe Ser Leu Glu Asn	
60 65 70 75	
AAC TTC TTG CTA CAG CAT AAC ATA AGG AAA AGC AAG CGT AAT CTT CAG	469
Asn Phe Leu Leu Gln His Asn Ile Arg Lys Ser Lys Arg Asn Leu Gln	
80 85 90	
GAT AAT TTT CAG GAA GAC CCA ATC CAG ATG TCT ATG ATC ATT TAC AGC	517
Asp Asn Phe Gln Glu Asp Pro Ile Gln Met Ser Met Ile Ile Tyr Ser	
95 100 105	
TGT CTG AAG GAA GAA AGG AAA ATT CTG GAA AAC GCC CAG AGA TTT AAT	565
Cys Leu Lys Glu Glu Arg Lys Ile Leu Glu Asn Ala Gln Arg Phe Asn	
110 115 120	
CAG GCT CAG TCG GGG AAT ATT CAG AGC ACA GTG ATG TTA GAC AAA CAG	613
Gln Ala Gln Ser Gly Asn Ile Gln Ser Thr Val Met Leu Asp Lys Gln	
125 130 135	
AAA GAG CTT GAC AGT AAA GTC AGA AAT GTG AAG GAC AAG GTT ATG TGT	661
Lys Glu Leu Asp Ser Lys Val Arg Asn Val Lys Asp Lys Val Met Cys	
140 145 150 155	
ATA GAG CAT GAA ATC AAG AGC CTG GAA GAT TTA CAA GAT GAA TAT GAC	709
Ile Glu His Glu Ile Lys Ser Leu Glu Asp Leu Gln Asp Glu Tyr Asp	
160 165 170	
TTC AAA TGC AAA ACC TTG CAG AAC AGA GAA CAC GAG ACC AAT GGT GTG	757
Phe Lys Cys Lys Thr Leu Gln Asn Arg Glu His Glu Thr Asn Gly Val	
175 180 185	
GCA AAG AGT GAT CAG AAA CAA GAA CAG CTG TTA CTC AAG AAG ATG TAT	805
Ala Lys Ser Asp Gln Lys Gln Glu Gln Leu Leu Leu Lys Lys Met Tyr	
190 195 200	

TTA ATG CTT GAC AAT AAG AGA AAG GAA GTA GTT CAC AAA ATA ATA GAG Leu Met Leu Asp Asn Lys Arg Lys Glu Val Val His Lys Ile Ile Glu 205 210 215	853
TTG CTG AAT GTC ACT GAA CTT ACC CAG AAT GCC CTG ATT AAT GAT GAA Leu Leu Asn Val Thr Glu Leu Thr Gln Asn Ala Leu Ile Asn Asp Glu 220 225 230 235	901
CTA GTG GAG TGG AAG CGG AGA CAG CAG AGC GCC TGT ATT GGG GGG CCG Leu Val Glu Trp Lys Arg Arg Gln Gln Ser Ala Cys Ile Gly Gly Pro 240 245 250	949
CCC AAT GCT TGC TTG GAT CAG CTG CAG AAC TGG TTC ACT ATA GTT GCG Pro Asn Ala Cys Leu Asp Gln Leu Gln Asn Trp Phe Thr Ile Val Ala 255 260 265	997
GAG AGT CTG CAG CAA GTT CGG CAG CAG CTT AAA AAG TTG GAG GAA TTG Glu Ser Leu Gln Gln Val Arg Gln Gln Leu Lys Lys Leu Glu Glu Leu 270 275 280	1045
GAA CAG AAA TAC ACC TAC GAA CAT GAC CCT ATC ACA AAA AAC AAA CAA Glu Gln Lys Tyr Thr Tyr Glu His Asp Pro Ile Thr Lys Asn Lys Gln 285 290 295	1093
GTG TTA TGG GAC CGC ACC TTC AGT CTT TTC CAG CAG CTC ATT CAG AGC Val Leu Trp Asp Arg Thr Phe Ser Leu Phe Gln Gln Leu Ile Gln Ser 300 305 310 315	1141
TCG TTT GTG GTG GAA AGA CAG CCC TGC ATG CCA ACG CAC CCT CAG AGG Ser Phe Val Val Glu Arg Gln Pro Cys Met Pro Thr His Pro Gln Arg 320 325 330	1189
CCG CTG GTC TTG AAG ACA GGG GTC CAG TTC ACT GTG AAG TTG AGA CTG Pro Leu Val Leu Lys Thr Gly Val Gln Phe Thr Val Lys Leu Arg Leu 335 340 345	1237
TTG GTG AAA TTG CAA GAG CTG AAT TAT AAT TTG AAA GTC AAA GTC TTA Leu Val Lys Leu Gln Glu Leu Asn Tyr Asn Leu Lys Val Lys Val Leu 350 355 360	1285
TTT GAT AAA GAT GTG AAT GAG AGA AAT ACA GTA AAA GGA TTT AGG AAG Phe Asp Lys Asp Val Asn Glu Arg Asn Thr Val Lys Gly Phe Arg Lys 365 370 375	1333
TTC AAC ATT TTG GGC ACG CAC ACA AAA GTG ATG AAC ATG GAG GAG TCC Phe Asn Ile Leu Gly Thr His Thr Lys Val Met Asn Met Glu Glu Ser 380 385 390 395	1381
ACC AAT GGC AGT CTG GCG GCT GAA TTT CGG CAC CTG CAA TTG AAA GAA Thr Asn Gly Ser Leu Ala Ala Glu Phe Arg His Leu Gln Leu Lys Glu 400 405 410	1429
CAG AAA AAT GCT GGC ACC AGA ACG AAT GAG GGT CCT CTC ATC GTT ACT Gln Lys Asn Ala Gly Thr Arg Thr Asn Glu Gly Pro Leu Ile Val Thr 415 420 425	1477
GAA GAG CTT CAC TCC CTT AGT TTT GAA ACC CAA TTG TGC CAG CCT GGT Glu Glu Leu His Ser Leu Ser Phe Glu Thr Gln Leu Cys Gln Pro Gly 430 435 440	1525
TTG GTA ATT GAC CTC GAG ACG ACC TCT CTG CCC GTT GTG GTG ATC TCC Leu Val Ile Asp Leu Glu Thr Ser Leu Pro Val Val Val Ile Ser 445 450 455	1573
AAC GTC AGC CAG CTC CCG AGC GGT TGG GCC TCC ATC CTT TGG TAC AAC Asn Val Ser Gln Leu Pro Ser Gly Trp Ala Ser Ile Leu Trp Tyr Asn 460 465 470 475	1621

ATG CTG GTG GCG GAA CCC AGG AAT CTG TCC TTC TTC CTG ACT CCA CCA Met Leu Val Ala Glu Pro Arg Asn Leu Ser Phe Phe Leu Thr Pro Pro 480 485 490	1669
TGT GCA CGA TGG GCT CAG CTT TCA GAA GTG CTG AGT TGG CAG TTT TCT Cys Ala Arg Trp Ala Gln Leu Ser Glu Val Leu Ser Trp Gln Phe Ser 495 500 505	1717
TCT GTC ACC AAA AGA GGT CTC AAT GTG GAC CAG CTG AAC ATG TTG GGA Ser Val Thr Lys Arg Gly Leu Asn Val Asp Gln Leu Asn Met Leu Gly 510 515 520	1765
GAG AAG CTT CTT GGT CCT AAC GCC AGC CCC GAT GGT CTC ATT CCG TGG Glu Lys Leu Leu Gly Pro Asn Ala Ser Pro Asp Gly Leu Ile Pro Trp 525 530 535	1813
ACG AGG TTT TGT AAG GAA AAT ATA AAT GAT AAA AAT TTT CCC TTC TGG Thr Arg Phe Cys Lys Glu Asn Ile Asn Asp Lys Asn Phe Pro Phe Trp 540 545 550 555	1861
CTT TGG ATT GAA AGC ATC CTA GAA CTC ATT AAA AAA CAC CTG CTC CCT Leu Trp Ile Glu Ser Ile Leu Glu Leu Ile Lys Lys His Leu Leu Pro 560 565 570	1909
CTC TGG AAT GAT GGG TGC ATC ATG GGC TTC ATC AGC AAG GAG CGA GAG Leu Trp Asn Asp Gly Cys Ile Met Gly Phe Ile Ser Lys Glu Arg Glu 575 580 585	1957
CGT GCC CTG TTG AAG GAC CAG CAG CCG GGG ACC TTC CTG CTG CGG TTC Arg Ala Leu Leu Lys Asp Gln Gln Pro Gly Thr Phe Leu Leu Arg Phe 590 595 600	2005
AGT GAG AGC TCC CGG GAA GGG GCC ATC ACA TTC ACA TGG GTG GAG CGG Ser Glu Ser Ser Arg Glu Gly Ala Ile Thr Phe Thr Trp Val Glu Arg 605 610 615	2053
TCC CAG AAC GGA GGC GAA CCT GAC TTC CAT GCG GTT GAA CCC TAC ACG Ser Gln Asn Gly Gly Glu Pro Asp Phe His Ala Val Glu Pro Tyr Thr 620 625 630 635	2101
AAG AAA GAA CTT TCT GCT GTT ACT TTC CCT GAC ATC ATT CGC AAT TAC Lys Lys Glu Leu Ser Ala Val Thr Phe Pro Asp Ile Ile Arg Asn Tyr 640 645 650	2149
AAA GTC ATG GCT GCT GAG AAT ATT CCT GAG AAT CCC CTG AAG TAT CTG Lys Val Met Ala Ala Glu Asn Ile Pro Glu Asn Pro Leu Lys Tyr Leu 655 660 665	2197
TAT CCA AAT ATT GAC AAA GAC CAT GCC TTT GGA AAG TAT TAC TCC AGG Tyr Pro Asn Ile Asp Lys Asp His Ala Phe Gly Lys Tyr Tyr Ser Arg 670 675 680	2245
CCA AAG GAA GCA CCA GAG CCA ATG GAA CTT GAT GGC CCT AAA GGA ACT Pro Lys Glu Ala Pro Glu Pro Met Glu Leu Asp Gly Pro Lys Gly Thr 685 690 695	2293
GGA TAT ATC AAG ACT GAG TTG ATT TCT GTG TCT GAA GTG TAAGTGAACA Gly Tyr Ile Lys Thr Glu Leu Ile Ser Val Ser Glu Val 700 705 710	2342
CAGAAGAGTG ACATGTTTAC AAACCTCAAG CCAGCCTTGC TCCTGGCTGG GGCCTGTTGA	2402
AGATGCTTGT ATTTTACTTT TCCATTGTAA TTGCTATCGC CATCACAGCT GAACTTGTTG	2462
AGATCCCCGT GTTACTGCCT ATCAGCATT TACTACTTTA AAAAAAAAAA AAAAGCCAA	2522
AAACCAAATT TGTATTTAAG GTATATAAAT TTTCCCAAAA CTGATACCCT TTGAAAAAGT	2582

ATAAATAAAA TGAGCAAAAG TTGAA

2607

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 712 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Ser Gln Trp Tyr Glu Leu Gln Gln Leu Asp Ser Lys Phe Leu Glu
 1 5 10 15
 Gln Val His Gln Leu Tyr Asp Asp Ser Phe Pro Met Glu Ile Arg Gln
 20 25 30
 Tyr Leu Ala Gln Trp Leu Glu Lys Gln Asp Trp Glu His Ala Ala Asn
 35 40 45
 Asp Val Ser Phe Ala Thr Ile Arg Phe His Asp Leu Leu Ser Gln Leu
 50 55 60
 Asp Asp Gln Tyr Ser Arg Phe Ser Leu Glu Asn Asn Phe Leu Leu Gln
 65 70 75 80
 His Asn Ile Arg Lys Ser Lys Arg Asn Leu Gln Asp Asn Phe Gln Glu
 85 90 95
 Asp Pro Ile Gln Met Ser Met Ile Ile Tyr Ser Cys Leu Lys Glu Glu
 100 105 110
 Arg Lys Ile Leu Glu Asn Ala Gln Arg Phe Asn Gln Ala Gln Ser Gly
 115 120 125
 Asn Ile Gln Ser Thr Val Met Leu Asp Lys Gln Lys Glu Leu Asp Ser
 130 135 140
 Lys Val Arg Asn Val Lys Asp Lys Val Met Cys Ile Glu His Glu Ile
 145 150 155 160
 Lys Ser Leu Glu Asp Leu Gln Asp Glu Tyr Asp Phe Lys Cys Lys Thr
 165 170 175
 Leu Gln Asn Arg Glu His Glu Thr Asn Gly Val Ala Lys Ser Asp Gln
 180 185 190
 Lys Gln Glu Gln Leu Leu Leu Lys Lys Met Tyr Leu Met Leu Asp Asn
 195 200 205
 Lys Arg Lys Glu Val Val His Lys Ile Ile Glu Leu Leu Asn Val Thr
 210 215 220
 Glu Leu Thr Gln Asn Ala Leu Ile Asn Asp Glu Leu Val Glu Trp Lys
 225 230 235 240
 Arg Arg Gln Gln Ser Ala Cys Ile Gly Gly Pro Pro Asn Ala Cys Leu
 245 250 255
 Asp Gln Leu Gln Asn Trp Phe Thr Ile Val Ala Glu Ser Leu Gln Gln
 260 265 270
 Val Arg Gln Gln Leu Lys Lys Leu Glu Glu Leu Glu Gln Lys Tyr Thr
 275 280 285

Tyr Glu His Asp Pro Ile Thr Lys Asn Lys Gln Val Leu Trp Asp Arg
 290 295 300
 Thr Phe Ser Leu Phe Gln Gln Leu Ile Gln Ser Ser Phe Val Val Glu
 305 310 315 320
 Arg Gln Pro Cys Met Pro Thr His Pro Gln Arg Pro Leu Val Leu Lys
 325 330 335
 Thr Gly Val Gln Phe Thr Val Lys Leu Arg Leu Leu Val Lys Leu Gln
 340 345 350
 Glu Leu Asn Tyr Asn Leu Lys Val Lys Val Leu Phe Asp Lys Asp Val
 355 360 365
 Asn Glu Arg Asn Thr Val Lys Gly Phe Arg Lys Phe Asn Ile Leu Gly
 370 375 380
 Thr His Thr Lys Val Met Asn Met Glu Glu Ser Thr Asn Gly Ser Leu
 385 390 395 400
 Ala Ala Glu Phe Arg His Leu Gln Leu Lys Glu Gln Lys Asn Ala Gly
 405 410 415
 Thr Arg Thr Asn Glu Gly Pro Leu Ile Val Thr Glu Glu Leu His Ser
 420 425 430
 Leu Ser Phe Glu Thr Gln Leu Cys Gln Pro Gly Leu Val Ile Asp Leu
 435 440 445
 Glu Thr Thr Ser Leu Pro Val Val Val Ile Ser Asn Val Ser Gln Leu
 450 455 460
 Pro Ser Gly Trp Ala Ser Ile Leu Trp Tyr Asn Met Leu Val Ala Glu
 465 470 475 480
 Pro Arg Asn Leu Ser Phe Phe Leu Thr Pro Pro Cys Ala Arg Trp Ala
 485 490 495
 Gln Leu Ser Glu Val Leu Ser Trp Gln Phe Ser Ser Val Thr Lys Arg
 500 505 510
 Gly Leu Asn Val Asp Gln Leu Asn Met Leu Gly Glu Lys Leu Leu Gly
 515 520 525
 Pro Asn Ala Ser Pro Asp Gly Leu Ile Pro Trp Thr Arg Phe Cys Lys
 530 535 540
 Glu Asn Ile Asn Asp Lys Asn Phe Pro Phe Trp Leu Trp Ile Glu Ser
 545 550 555 560
 Ile Leu Glu Leu Ile Lys Lys His Leu Leu Pro Leu Trp Asn Asp Gly
 565 570 575
 Cys Ile Met Gly Phe Ile Ser Lys Glu Arg Glu Arg Ala Leu Leu Lys
 580 585 590
 Asp Gln Gln Pro Gly Thr Phe Leu Leu Arg Phe Ser Glu Ser Ser Arg
 595 600 605
 Glu Gly Ala Ile Thr Phe Thr Trp Val Glu Arg Ser Gln Asn Gly Gly
 610 615 620
 Glu Pro Asp Phe His Ala Val Glu Pro Tyr Thr Lys Lys Glu Leu Ser
 625 630 635 640

Ala	Val	Thr	Phe	Pro	Asp	Ile	Ile	Arg	Asn	Tyr	Lys	Val	Met	Ala	Ala
				645					650						655
Glu	Asn	Ile	Pro	Glu	Asn	Pro	Leu	Lys	Tyr	Leu	Tyr	Pro	Asn	Ile	Asp
			660					665					670		
Lys	Asp	His	Ala	Phe	Gly	Lys	Tyr	Tyr	Ser	Arg	Pro	Lys	Glu	Ala	Pro
		675					680					685			
Glu	Pro	Met	Glu	Leu	Asp	Gly	Pro	Lys	Gly	Thr	Gly	Tyr	Ile	Lys	Thr
		690				695					700				
Glu	Leu	Ile	Ser	Val	Ser	Glu	Val								
705						710									

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 2277 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: both
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Mouse

(vii) IMMEDIATE SOURCE:

- (B) CLONE: Murine Stat91

(ix) FEATURE:

- FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 5..2251

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CAGG	ATG	TCA	CAG	TGG	TTC	GAG	CTT	CAG	CAG	CTG	GAC	TCC	AAG	TTC	CTG	49
Met	Ser	Gln	Trp	Phe	Glu	Leu	Gln	Gln	Leu	Asp	Ser	Lys	Phe	Leu	15	
1				5						10						
GAG	CAG	GTC	CAC	CAG	CTG	TAC	GAT	GAC	AGT	TTC	CCC	ATG	GAA	ATC	AGA	97
Glu	Gln	Val	His	Gln	Leu	Tyr	Asp	Asp	Ser	Phe	Pro	Met	Glu	Ile	Arg	
				20					25					30		
CAG	TAC	CTG	GCC	CAG	TGG	CTG	GAA	AAG	CAA	GAC	TGG	GAG	CAC	GCT	GCC	145
Gln	Tyr	Leu	Ala	Gln	Trp	Leu	Glu	Lys	Gln	Asp	Trp	Glu	His	Ala	Ala	
			35					40					45			
TAT	GAT	GTC	TCG	TTT	GCG	ACC	ATC	CGC	TTC	CAT	GAC	CTC	CTC	TCA	CAG	193
Tyr	Asp	Val	Ser	Phe	Ala	Thr	Ile	Arg	Phe	His	Asp	Leu	Leu	Ser	Gln	
		50					55					60				
CTG	GAC	GAC	CAG	TAC	AGC	CGC	TTT	TCT	CTG	GAG	AAT	AAT	TTC	TTG	TTG	241
Leu	Asp	Asp	Gln	Tyr	Ser	Arg	Phe	Ser	Leu	Glu	Asn	Asn	Phe	Leu	Leu	
	65					70					75					
CAG	CAC	AAC	ATA	CGG	AAA	AGC	AAG	CGT	AAT	CTC	CAG	GAT	AAC	TTC	CAA	285
Gln	His	Asn	Ile	Arg	Lys	Ser	Lys	Arg	Asn	Leu	Gln	Asp	Asn	Phe	Gln	
80					85					90					95	

GAA GAT CCC GTA CAG ATG TCC ATG ATC ATC TAC AAC TGT CTG AAG GAA Glu Asp Pro Val Gln Met Ser Met Ile Ile Tyr Asn Cys Leu Lys Glu 100 105 110	337
GAA AGG AAG ATT TTG GAA AAT GCC CAA AGA TTT AAT CAG GCC CAG GAG Glu Arg Lys Ile Leu Glu Asn Ala Gln Arg Phe Asn Gln Ala Gln Glu 115 120 125	385
GGA AAT ATT CAG AAC ACT GTG ATG TTA GAT AAA CAG AAG GAG CTG GAC Gly Asn Ile Gln Asn Thr Val Met Leu Asp Lys Gln Lys Glu Leu Asp 130 135 140	433
AGT AAA GTC AGA AAT GTG AAG GAT CAA GTC ATG TGC ATA GAG CAG GAA Ser Lys Val Arg Asn Val Lys Asp Gln Val Met Cys Ile Glu Gln Glu 145 150 155	481
ATC AAG ACC CTA GAA GAA TTA CAA GAT GAA TAT GAC TTT AAA TGC AAA Ile Lys Thr Leu Glu Glu Leu Gln Asp Glu Tyr Asp Phe Lys Cys Lys 160 165 170 175	529
ACC TCT CAG AAC AGA GAA GGT GAA GCC AAT GGT GTG GCG AAG AGC GAC Thr Ser Gln Asn Arg Glu Gly Glu Ala Asn Gly Val Ala Lys Ser Asp 180 185 190	577
CAA AAA CAG GAA CAG CTG CTG CTC CAC AAG ATG TTT TTA ATG CTT GAC Gln Lys Gln Gln Gln Leu Leu Leu His Lys Met Phe Leu Met Leu Asp 195 200 205	625
AAT AAG AGA AAG GAG ATA ATT CAC AAA ATC AGA GAG TTG CTG AAT TCC Asn Lys Arg Lys Glu Ile Ile His Lys Ile Arg Glu Leu Leu Asn Ser 210 215 220	673
ATC GAG CTC ACT CAG AAC ACT CTG ATT AAT GAC GAG CTC GTG GAG TGG Ile Glu Leu Thr Gln Asn Thr Leu Ile Asn Asp Glu Leu Val Glu Trp 225 230 235	721
AAG CGA AGG CAG CAG AGC GCC TGC ATC GGG GGA CCG CCC AAC GCC TGC Lys Arg Arg Gln Gln Ser Ala Cys Ile Gly Gly Pro Pro Asn Ala Cys 240 245 250 255	769
CTG GAT CAG CTG CAA ACG TGG TTC ACC ATT GTT GCA GAG ACC CTG CAG Leu Asp Gln Leu Gln Thr Trp Phe Thr Ile Val Ala Glu Thr Leu Gln 260 265 270	817
CAG ATC CGT CAG CAG CTT AAA AAG CTG GAG GAG TTG GAA CAG AAA TTC Gln Ile Arg Gln Gln Leu Lys Lys Leu Glu Glu Leu Glu Gln Lys Phe 275 280 285	865
ACC TAT GAG CCC GAC CCT ATT ACA AAA AAC AAG CAG GTG TTG TCA GAT Thr Tyr Glu Pro Asp Pro Ile Thr Lys Asn Lys Gln Val Leu Ser Asp 290 295 300	913
CGA ACC TTC CTC CTC TTC CAG CAG CTC ATT CAG AGC TCC TTC GTG GTA Arg Thr Phe Leu Leu Phe Gln Gln Leu Ile Gln Ser Ser Phe Val Val 305 310 315	961
GAA CGA CAG CCG TGC ATG CCC ACT CAC CCG CAG AGG CCC CTG GTC TTG Glu Arg Gln Pro Cys Met Pro Thr His Pro Gln Arg Pro Leu Val Leu 320 325 330 335	1009
AAG ACT GGG GTA CAG TTC ACT GTC AAG TCG AGA CTG TTG GTG AAA TTG Lys Thr Gly Val Gln Phe Thr Val Lys Ser Arg Leu Leu Val Lys Leu 340 345 350	1057
CAA GAG TCG AAT CTA TTA ACG AAA GTG AAA TGT CAC TTT GAC AAA GAT Gln Glu Ser Asn Leu Leu Thr Lys Val Lys Cys His Phe Asp Lys Asp 355 360 365	1105

GTG AAC GAG AAA AAC ACA GTT AAA GGA TTT CGG AAG TTC AAC ATC TTG Val Asn Glu Lys Asn Thr Val Lys Gly Phe Arg Lys Phe Asn Ile Leu 370 375 380	1153
GGT ACG CAC ACA AAA GTG ATG AAC ATG GAA GAA TCC ACC AAC GGA AGT Gly Thr His Thr Lys Val Met Asn Met Glu Glu Ser Thr Asn Gly Ser 385 390 395	1201
CTG GCA GCT GAG CTC CGA CAC CTG CAA CTG AAG GAA CAG AAA AAC GCT Leu Ala Ala Glu Leu Arg His Leu Gln Leu Lys Glu Gln Lys Asn Ala 400 405 410 415	1249
GGG AAC AGA ACT AAT GAG GGG CCT CTC ATT GTC ACC GAA GAA CTT CAC Gly Asn Arg Thr Asn Glu Gly Pro Leu Ile Val Thr Glu Glu Leu His 420 425 430	1297
TCT CTT AGC TTT GAA ACC CAG TTG TGC CAG CCA GGC TTG GTG ATT GAC Ser Leu Ser Phe Glu Thr Gln Leu Cys Gln Pro Gly Leu Val Ile Asp 435 440 445	1345
CTG GAG ACC ACC TCT CTT CCT GTC GTG GTG ATC TCC AAC GTC AGC CAG Leu Glu Thr Thr Ser Leu Pro Val Val Val Ile Ser Asn Val Ser Gln 450 455 460	1393
CTC CCC AGT GGC TGG GCG TCT ATC CTG TGG TAC AAC ATG CTG GTG ACA Leu Pro Ser Gly Trp Ala Ser Ile Leu Trp Tyr Asn Met Leu Val Thr 465 470 475	1441
GAG CCC AGG AAT CTC TCC TTC TTC CTG AAC CCC CCG TGC GCG TGG TGG Glu Pro Arg Asn Leu Ser Phe Phe Leu Asn Pro Pro Cys Ala Trp Trp 480 485 490 495	1489
TCC CAG CTC TCA GAG GTG TTG AGT TGG CAG TTT TCA TCA GTC ACC AAG Ser Gln Leu Ser Glu Val Leu Ser Trp Gln Phe Ser Ser Val Thr Lys 500 505 510	1537
AGA GGT CTG AAC GCA GAC CAG CTG AGC ATG CTG GGA GAG AAG CTG CTG Arg Gly Leu Asn Ala Asp Gln Leu Ser Met Leu Gly Glu Lys Leu Leu 515 520 525	1585
GGC CCT AAT GCT GGC CCT GAT GGT CTT ATT CCA TGG ACA AGG TTT TGT Gly Pro Asn Ala Gly Pro Asp Gly Leu Ile Pro Trp Thr Arg Phe Cys 530 535 540	1633
AAG GAA AAT ATT AAT GAT AAA AAT TTC TCC TTC TGG CCT TGG ATT GAC Lys Glu Asn Ile Asn Asp Lys Asn Phe Ser Phe Trp Pro Trp Ile Asp 545 550 555	1681
ACC ATC CTA GAG CTC ATT AAG AAC GAC CTG CTG TGC CTC TGG AAT GAT Thr Ile Leu Glu Leu Ile Lys Asn Asp Leu Leu Cys Leu Trp Asn Asp 560 565 570 575	1729
GGG TGC ATT ATG GGC TTC ATC AGC AAG GAG CGA GAA CGC GCT CTG CTC Gly Cys Ile Met Gly Phe Ile Ser Lys Glu Arg Glu Arg Ala Leu Leu 580 585 590	1777
AAG GAC CAG CAG CCA GGG ACG TTC CTG CTT AGA TTC AGT GAG AGC TCC Lys Asp Gln Pro Gly Thr Phe Leu Leu Arg Phe Ser Glu Ser Ser 595 600 605	1825
CGG GAA GGG GCC ATC ACA TTC ACA TGG GTG GAA CGG TCC CAG AAC GGA Arg Glu Gly Ala Ile Thr Phe Thr Trp Val Glu Arg Ser Gln Asn Gly 610 615 620	1873
GGT GAA CCT GAC TTC CAT GCC GTG GAG CCC TAC ACG AAA AAA GAA CTT Gly Glu Pro Asp Phe His Ala Val Glu Pro Tyr Thr Lys Lys Glu Leu 625 630 635	1921

TCA GCT GTT ACT TTC CCA GAT ATT ATT CGC AAC TAC AAA GTC ATG GCT 1969
 Ser Ala Val Thr Phe Pro Asp Ile Ile Arg Asn Tyr Lys Val Met Ala
 640 645 650 655
 GCC GAG AAC ATA CCA GAG AAT CCC CTG AAG TAT CTG TAC CCC AAT ATT 2017
 Ala Glu Asn Ile Pro Glu Asn Pro Leu Lys Tyr Leu Tyr Pro Asn Ile
 660 665 670
 GAC AAA GAC CAC GCC TTT GGG AAG TAT TAT TCC AGA CCA AAG GAA GCA 2065
 Asp Lys Asp His Ala Phe Gly Lys Tyr Tyr Ser Arg Pro Lys Glu Ala
 675 680 685
 CCA GAA CCG ATG GAG CTT GAC GAC CCT AAG CGA ACT GGA TAC ATC AAG 2113
 Pro Glu Pro Met Glu Leu Asp Asp Pro Lys Arg Thr Gly Tyr Ile Lys
 690 695 700
 ACT GAG TTG ATT TCT GTG TCT GAA GTC CAC CCT TCT AGA CTT CAG ACC 2161
 Thr Glu Leu Ile Ser Val Ser Glu Val His Pro Ser Arg Leu Gln Thr
 705 710 715
 ACA GAC AAC CTG CTT CCC ATG TCT CCA GAG GAG TTT GAT GAG ATG TCC 2209
 Thr Asp Asn Leu Leu Pro Met Ser Pro Glu Glu Phe Asp Glu Met Ser
 720 725 730 735
 CGG ATA GTG GGC CCC GAA TTT GAC AGT ATG ATG AGC ACA GTA 2251
 Arg Ile Val Gly Pro Glu Phe Asp Ser Met Met Ser Thr Val
 740 745
 TAAACACGAA TTTCTCTCTG GCGACA 2277

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 749 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met Ser Gln Trp Phe Glu Leu Gln Gln Leu Asp Ser Lys Phe Leu Glu
 1 5 10 15
 Gln Val His Gln Leu Tyr Asp Asp Ser Phe Pro Met Glu Ile Arg Gln
 20 25 30
 Tyr Leu Ala Gln Trp Leu Glu Lys Gln Asp Trp Glu His Ala Ala Tyr
 35 40 45
 Asp Val Ser Phe Ala Thr Ile Arg Phe His Asp Leu Leu Ser Gln Leu
 50 55 60
 Asp Asp Gln Tyr Ser Arg Phe Ser Leu Glu Asn Asn Phe Leu Leu Gln
 65 70 75 80
 His Asn Ile Arg Lys Ser Lys Arg Asn Leu Gln Asp Asn Phe Gln Glu
 85 90 95
 Asp Pro Val Gln Met Ser Met Ile Ile Tyr Asn Cys Leu Lys Glu Glu
 100 105 110
 Arg Lys Ile Leu Glu Asn Ala Gln Arg Phe Asn Gln Ala Gln Glu Gly
 115 120 125

Asn Ile Gln Asn Thr Val Met Leu Asp Lys Gln Lys Glu Leu Asp Ser
 130 135 140
 Lys Val Arg Asn Val Lys Asp Gln Val Met Cys Ile Glu Gln Glu Ile
 145 150 155 160
 Lys Thr Leu Glu Glu Leu Gln Asp Glu Tyr Asp Phe Lys Cys Lys Thr
 165 170 175
 Ser Gln Asn Arg Glu Gly Glu Ala Asn Gly Val Ala Lys Ser Asp Gln
 180 185 190
 Lys Gln Glu Gln Leu Leu Leu His Lys Met Phe Leu Met Leu Asp Asn
 195 200 205
 Lys Arg Lys Glu Ile Ile His Lys Ile Arg Glu Leu Leu Asn Ser Ile
 210 215 220
 Glu Leu Thr Gln Asn Thr Leu Ile Asn Asp Glu Leu Val Glu Trp Lys
 225 230 235 240
 Arg Arg Gln Gln Ser Ala Cys Ile Gly Gly Pro Pro Asn Ala Cys Leu
 245 250 255
 Asp Gln Leu Gln Thr Trp Phe Thr Ile Val Ala Glu Thr Leu Gln Gln
 260 265 270
 Ile Arg Gln Gln Leu Lys Lys Leu Glu Glu Leu Glu Gln Lys Phe Thr
 275 280 285
 Tyr Glu Pro Asp Pro Ile Thr Lys Asn Lys Gln Val Leu Ser Asp Arg
 290 295 300
 Thr Phe Leu Leu Phe Gln Gln Leu Ile Gln Ser Ser Phe Val Val Glu
 305 310 315 320
 Arg Gln Pro Cys Met Pro Thr His Pro Gln Arg Pro Leu Val Leu Lys
 325 330 335
 Thr Gly Val Gln Phe Thr Val Lys Ser Arg Leu Leu Val Lys Leu Gln
 340 345 350
 Glu Ser Asn Leu Leu Thr Lys Val Lys Cys His Phe Asp Lys Asp Val
 355 360 365
 Asn Glu Lys Asn Thr Val Lys Gly Phe Arg Lys Phe Asn Ile Leu Gly
 370 375 380
 Thr His Thr Lys Val Met Asn Met Glu Glu Ser Thr Asn Gly Ser Leu
 385 390 395 400
 Ala Ala Glu Leu Arg His Leu Gln Leu Lys Glu Gln Lys Asn Ala Gly
 405 410 415
 Asn Arg Thr Asn Glu Gly Pro Leu Ile Val Thr Glu Glu Leu His Ser
 420 425 430
 Leu Ser Phe Glu Thr Gln Leu Cys Gln Pro Gly Leu Val Ile Asp Leu
 435 440 445
 Glu Thr Thr Ser Leu Pro Val Val Val Ile Ser Asn Val Ser Gln Leu
 450 455 460
 Pro Ser Gly Trp Ala Ser Ile Leu Trp Tyr Asn Met Leu Val Thr Glu
 465 470 475 480

Pro Arg Asn Leu Ser Phe Phe Leu Asn Pro Pro Cys Ala Trp Trp Ser
 485 490 495
 Gln Leu Ser Glu Val Leu Ser Trp Gln Phe Ser Ser Val Thr Lys Arg
 500 505 510
 Gly Leu Asn Ala Asp Gln Leu Ser Met Leu Gly Glu Lys Leu Leu Gly
 515 520 525
 Pro Asn Ala Gly Pro Asp Gly Leu Ile Pro Trp Thr Arg Phe Cys Lys
 530 535 540
 Glu Asn Ile Asn Asp Lys Asn Phe Ser Phe Trp Pro Trp Ile Asp Thr
 545 550 555 560
 Ile Leu Glu Leu Ile Lys Asn Asp Leu Leu Cys Leu Trp Asn Asp Gly
 565 570 575
 Cys Ile Met Gly Phe Ile Ser Lys Glu Arg Glu Arg Ala Leu Leu Lys
 580 585 590
 Asp Gln Gln Pro Gly Thr Phe Leu Leu Arg Phe Ser Glu Ser Ser Arg
 595 600 605
 Glu Gly Ala Ile Thr Phe Thr Trp Val Glu Arg Ser Gln Asn Gly Gly
 610 615 620
 Glu Pro Asp Phe His Ala Val Glu Pro Tyr Thr Lys Lys Glu Leu Ser
 625 630 635 640
 Ala Val Thr Phe Pro Asp Ile Ile Arg Asn Tyr Lys Val Met Ala Ala
 645 650 655
 Glu Asn Ile Pro Glu Asn Pro Leu Lys Tyr Leu Tyr Pro Asn Ile Asp
 660 665 670
 Lys Asp His Ala Phe Gly Lys Tyr Tyr Ser Arg Pro Lys Glu Ala Pro
 675 680 685
 Glu Pro Met Glu Leu Asp Asp Pro Lys Arg Thr Gly Tyr Ile Lys Thr
 690 695 700
 Glu Leu Ile Ser Val Ser Glu Val His Pro Ser Arg Leu Gln Thr Thr
 705 710 715 720
 Asp Asn Leu Leu Pro Met Ser Pro Glu Glu Phe Asp Glu Met Ser Arg
 725 730 735
 Ile Val Gly Pro Glu Phe Asp Ser Met Met Ser Thr Val
 740 745

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2375 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: both
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Mouse

(vii) IMMEDIATE SOURCE:
 (A) LIBRARY: splenic/thymic
 (B) CLONE: Murine 13sf1

(ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 34..2277

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

TGCCACTACC TGGACGGAGA GAGAGAGAGC AGC ATG TCT CAG TGG AAT CAA GTC	54
Met Ser Gln Trp Asn Gln Val	
1 5	
CAA CAA TTA GAA ATC AAG TTT TTG GAG CAA GTA GAT CAG TTC TAT GAT	102
Gln Gln Leu Glu Ile Lys Phe Leu Glu Gln Val Asp Gln Phe Tyr Asp	
10 15 20	
GAC AAC TTT CCT ATG GAA ATC CGG CAT CTG CTA GCT CAG TGG ATT GAG	150
Asp Asn Phe Pro Met Glu Ile Arg His Leu Leu Ala Gln Trp Ile Glu	
25 30 35	
ACT CAA GAC TGG GAA GTA GCT TCT AAC AAT GAA ACT ATG GCA ACA ATT	198
Thr Gln Asp Trp Glu Val Ala Ser Asn Asn Glu Thr Met Ala Thr Ile	
40 45 50 55	
CTG CTT CAA AAC TTA CTA ATA CAA TTG GAT GAA CAG TTG GGG CGG GTT	246
Leu Leu Gln Asn Leu Leu Ile Gln Leu Asp Glu Gln Leu Gly Arg Val	
60 65 70	
TCC AAA GAA AAA AAT CTG CTA TTG ATT CAC AAT CTA AAG AGA ATT AGA	294
Ser Lys Glu Lys Asn Leu Leu Leu Ile His Asn Leu Lys Arg Ile Arg	
75 80 85	
AAA GTT CTT CAG GGC AAG TTT CAT GGA AAT CCA ATG CAT GTA GCT GTG	342
Lys Val Leu Gln Gly Lys Phe His Gly Asn Pro Met His Val Ala Val	
90 95 100	
GTA ATT TCA AAT TGC TTA AGG GAA GAG AGG AGA ATA TTG GCT GCA GCC	390
Val Ile Ser Asn Cys Leu Arg Glu Glu Arg Arg Ile Leu Ala Ala Ala	
105 110 115	
AAC ATG CCT ATC CAG GGA CCT CTG GAG AAA TCC TTA CAG AGT TCT TCA	438
Asn Met Pro Ile Gln Gly Pro Leu Glu Lys Ser Leu Gln Ser Ser Ser	
120 125 130 135	
GTT TCT GAA AGA CAA AGG AAT GTG GAA CAC AAA GTG TCT GCC ATT AAA	486
Val Ser Glu Arg Gln Arg Asn Val Glu His Lys Val Ser Ala Ile Lys	
140 145 150	
AAC AGT GTG CAG ATG ACA GAA CAA GAT ACC AAA TAC TTA GAA GAC CTG	534
Asn Ser Val Gln Met Thr Glu Gln Asp Thr Lys Tyr Leu Glu Asp Leu	
155 160 165	
CAA GAT GAG TTT GAC TAC AGG TAT AAA ACA ATT CAG ACA ATG GAT CAG	582
Gln Asp Glu Phe Asp Tyr Arg Tyr Lys Thr Ile Gln Thr Met Asp Gln	
170 175 180	
GGT GAC AAA AAC AGT ATC CTG GTG AAC CAG GAA GTT TTG ACA CTG CTG	630
Gly Asp Lys Asn Ser Ile Leu Val Asn Gln Glu Val Leu Thr Leu Leu	
185 190 195	
CAA GAA ATG CTT AAT AGT CTG GAC TTC AAG AGA AAG GAA GCA CTC AGT	678
Gln Glu Met Leu Asn Ser Leu Asp Phe Lys Arg Lys Glu Ala Leu Ser	
200 205 210 215	

AAG ATG ACG CAG ATA GTG AAC GAG ACA GAC CTG CTC ATG AAC AGC ATG Lys Met Thr Gln Ile Val Asn Glu Thr Asp Leu Leu Met Asn Ser Met 220 225 230	726
CTT CTA GAA GAG CTG CAG GAC TGG AAA AAG CGG CAC AGG ATT GCC TGC Leu Leu Glu Glu Leu Gln Asp Trp Lys Lys Arg His Arg Ile Ala Cys 235 240 245	774
ATT GGT GGC CCG CTC CAC AAT GGG CTG GAC CAG CTT CAG AAC TGC TTT Ile Gly Gly Pro Leu His Asn Gly Leu Asp Gln Leu Gln Asn Cys Phe 250 255 260	822
ACC CTA CTG GCA GAG AGT CTT TTC CAA CTC AGA CAG CAA CTG GAG AAA Thr Leu Leu Ala Glu Ser Leu Phe Gln Leu Arg Gln Gln Leu Glu Lys 265 270 275	870
CTA CAG GAG CAA TCT ACT AAA ATG ACC TAT GAA GGG GAT CCC ATC CCT Leu Gln Glu Gln Ser Thr Lys Met Thr Tyr Glu Gly Asp Pro Ile Pro 280 285 290 295	918
GCT CAA AGA GCA CAC CTC CTG GAA AGA GCT ACC TTC CTG ATC TAC AAC Ala Gln Arg Ala His Leu Leu Glu Arg Ala Thr Phe Leu Ile Tyr Asn 300 305 310	966
CTT TTC AAG AAC TCA TTT GTG GTC GAG CGA CAC GCA TGC ATG CCA ACG Leu Phe Lys Asn Ser Phe Val Val Glu Arg His Ala Cys Met Pro Thr 315 320 325	1014
CAC CCT CAG AGG CCG ATG GTA CTT AAA ACC CTC ATT CAG TTC ACT GTA His Pro Gln Arg Pro Met Val Leu Lys Thr Leu Ile Gln Phe Thr Val 330 335 340	1062
AAA CTG AGA TTA CTA ATA AAA TTG CCG GAA CTA AAC TAT CAG GTG AAA Lys Leu Arg Leu Leu Ile Lys Leu Pro Glu Leu Asn Tyr Gln Val Lys 345 350 355	1110
GTA AAG GCG TCC ATT GAC AAG AAT GTT TCA ACT CTA AGC AAT AGA AGA Val Lys Ala Ser Ile Asp Lys Asn Val Ser Thr Leu Ser Asn Arg Arg 360 365 370 375	1158
TTT GTG CTT TGT GGA ACT CAC GTC AAA GCT ATG TCC AGT GAG GAA TCT Phe Val Leu Cys Gly Thr His Val Lys Ala Met Ser Ser Glu Glu Ser 380 385 390	1206
TCC AAT GGG AGC CTC TCA GTG GAG TTA GAC ATT GCA ACC CAA GGA GAT Ser Asn Gly Ser Leu Ser Val Glu Leu Asp Ile Ala Thr Gln Gly Asp 395 400 405	1254
GAA GTG CAG TAC TGG AGT AAA GGA AAC GAG GGC TGC CAC ATG GTG ACA Glu Val Gln Tyr Trp Ser Lys Gly Asn Glu Gly Cys His Met Val Thr 410 415 420	1302
GAG GAG TTG CAT TCC ATA ACC TTT GAG ACC CAG ATC TGC CTC TAT GGC Glu Glu Leu His Ser Ile Thr Phe Glu Thr Gln Ile Cys Leu Tyr Gly 425 430 435	1350
CTC ACC ATT AAC CTA GAG ACC AGC TCA TTA CCT GTC GTG ATG ATT TCT Leu Thr Ile Asn Leu Glu Thr Ser Ser Leu Pro Val Val Met Ile Ser 440 445 450 455	1398
AAT GTC AGC CAA CTA CCT AAT GCA TGG GCA TCC ATC ATT TGG TAC AAT Asn Val Ser Gln Leu Pro Asn Ala Trp Ala Ser Ile Ile Trp Tyr Asn 460 465 470	1446
GTA TCA ACT AAC GAC TCC CAG AAC TTG GTT TTC TTT AAT AAC CCT CCA Val Ser Thr Asn Asp Ser Gln Asn Leu Val Phe Phe Asn Asn Pro Pro 475 480 485	1494

TCT GTC ACT TTG GGC CAA CTC CTG GAA GTG ATG AGC TGG CAA TTT TCA Ser Val Thr Leu Gly Gln Leu Leu Glu Val Met Ser Trp Gln Phe Ser 490 495 500	1542
TCC TAT GTC GGT CGT GGC CTT AAT TCA GAG CAG CTC AAC ATG CTG GCA Ser Tyr Val Gly Arg Gly Leu Asn Ser Glu Gln Leu Asn Met Leu Ala 505 510 515	1590
GAG AAG CTC ACA GTT CAG TCT AAC TAC AAT GAT GGT CAC CTC ACC TGG Glu Lys Leu Thr Val Gln Ser Asn Tyr Asn Asp Gly His Leu Thr Trp 520 525 530 535	1638
GCC AAG TTC TGC AAG GAA CAT TTG CCT GGC AAA ACA TTT ACC TTC TGG Ala Lys Phe Cys Lys Glu His Leu Pro Gly Lys Thr Phe Thr Phe Trp 540 545 550	1686
ACT TGG CTT GAA GCA ATA TTG GAC CTA ATT AAA AAA CAT ATT CTT CCC Thr Trp Leu Glu Ala Ile Leu Asp Leu Ile Lys Lys His Ile Leu Pro 555 560 565	1734
CTC TGG ATT GAT GGG TAC ATC ATG GGA TTT GTT AGT AAA GAG AAG GAA Leu Trp Ile Asp Gly Tyr Ile Met Gly Phe Val Ser Lys Glu Lys Glu 570 575 580	1782
CGG CTT CTG CTC AAA GAT AAA ATG CCT GGG ACA TTT TTG TTA AGA TTC Arg Leu Leu Leu Lys Asp Lys Met Pro Gly Thr Phe Leu Leu Arg Phe 585 590 595	1830
AGT GAG AGC CAT CTT GGA GGG ATA ACC TTC ACC TGG GTG GAC CAA TCT Ser Glu Ser His Leu Gly Gly Ile Thr Phe Thr Trp Val Asp Gln Ser 600 605 610 615	1878
GAA AAT GGA GAA GTG AGA TTC CAC TCT GTA GAA CCC TAC AAC AAA GGG Glu Asn Gly Glu Val Arg Phe His Ser Val Glu Pro Tyr Asn Lys Gly 620 625 630	1926
AGA CTG TCG GCT CTG GCC TTC GCT GAC ATC CTG CGA GAC TAC AAG GTT Arg Leu Ser Ala Leu Ala Phe Ala Asp Ile Leu Arg Asp Tyr Lys Val 635 640 645	1974
ATC ATG GCT GAA AAC ATC CCT GAA AAC CCT CTG AAG TAC CTC TAC CCT Ile Met Ala Glu Asn Ile Pro Glu Asn Pro Leu Lys Tyr Leu Tyr Pro 650 655 660	2022
GAC ATT CCC AAA GAC AAA GCC TTT GGC AAA CAC TAC AGC TCC CAG CCG Asp Ile Pro Lys Asp Lys Ala Phe Gly Lys His Tyr Ser Ser Gln Pro 665 670 675	2070
TGC GAA GTC TCA AGA CCA ACC GAA CGG GGA GAC AAG GGT TAC GTC CCC Cys Glu Val Ser Arg Pro Thr Glu Arg Gly Asp Lys Gly Tyr Val Pro 680 685 690 695	2118
TCT GTT TTT ATC CCC ATT TCA ACA ATC CGA AGC GAT TCC ACG GAG CCA Ser Val Phe Ile Pro Ile Ser Thr Ile Arg Ser Asp Ser Thr Glu Pro 700 705 710	2166
CAA TCT CCT TCA GAC CTT CTC CCC ATG TCT CCA AGT GCA TAT GCT GTG Gln Ser Pro Ser Asp Leu Leu Pro Met Ser Pro Ser Ala Tyr Ala Val 715 720 725	2214
CTG AGA GAA AAC CTG AGC CCA ACG ACA ATT GAA ACT GCA ATG AAT TCC Leu Arg Glu Asn Leu Ser Pro Thr Thr Ile Glu Thr Ala Met Asn Ser 730 735 740	2262
CCA TAT TCT GCT GAA TGACGGTGCA AACGGACACT TTAAAGAAGG AAGCAGATGA Pro Tyr Ser Ala Glu 745	2317

AACTGGAGAG TGTCTTTAC CATAGATCAC AATTTATTC TTCGGCTTG TAAATACC

2375

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 748 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Ser Gln Trp Asn Gln Val Gln Gln Leu Glu Ile Lys Phe Leu Glu
 1 5 10 15
 Gln Val Asp Gln Phe Tyr Asp Asp Asn Phe Pro Met Glu Ile Arg His
 20 25 30
 Leu Leu Ala Gln Trp Ile Glu Thr Gln Asp Trp Glu Val Ala Ser Asn
 35 40 45
 Asn Glu Thr Met Ala Thr Ile Leu Leu Gln Asn Leu Leu Ile Gln Leu
 50 55 60
 Asp Glu Gln Leu Gly Arg Val Ser Lys Glu Lys Asn Leu Leu Ile
 65 70 75 80
 His Asn Leu Lys Arg Ile Arg Lys Val Leu Gln Gly Lys Phe His Gly
 85 90 95
 Asn Pro Met His Val Ala Val Val Ile Ser Asn Cys Leu Arg Glu Glu
 100 105 110
 Arg Arg Ile Leu Ala Ala Ala Asn Met Pro Ile Gln Gly Pro Leu Glu
 115 120 125
 Lys Ser Leu Gln Ser Ser Ser Val Ser Glu Arg Gln Arg Asn Val Glu
 130 135 140
 His Lys Val Ser Ala Ile Lys Asn Ser Val Gln Met Thr Glu Gln Asp
 145 150 155 160
 Thr Lys Tyr Leu Glu Asp Leu Gln Asp Glu Phe Asp Tyr Arg Tyr Lys
 165 170 175
 Thr Ile Gln Thr Met Asp Gln Gly Asp Lys Asn Ser Ile Leu Val Asn
 180 185 190
 Gln Glu Val Leu Thr Leu Leu Gln Glu Met Leu Asn Ser Leu Asp Phe
 195 200 205
 Lys Arg Lys Glu Ala Leu Ser Lys Met Thr Gln Ile Val Asn Glu Thr
 210 215 220
 Asp Leu Leu Met Asn Ser Met Leu Leu Glu Glu Leu Gln Asp Trp Lys
 225 230 235 240
 Lys Arg His Arg Ile Ala Cys Ile Gly Gly Pro Leu His Asn Gly Leu
 245 250 255
 Asp Gln Leu Gln Asn Cys Phe Thr Leu Leu Ala Glu Ser Leu Phe Gln
 260 265 270
 Leu Arg Gln Gln Leu Glu Lys Leu Gln Glu Gln Ser Thr Lys Met Thr
 275 280 285

Tyr Glu Gly Asp Pro Ile Pro Ala Gln Arg Ala His Leu Leu Glu Arg
 290 295 300
 Ala Thr Phe Leu Ile Tyr Asn Leu Phe Lys Asn Ser Phe Val Val Glu
 305 310 315 320
 Arg His Ala Cys Met Pro Thr His Pro Gln Arg Pro Met Val Leu Lys
 325 330 335
 Thr Leu Ile Gln Phe Thr Val Lys Leu Arg Leu Leu Ile Lys Leu Pro
 340 345 350
 Glu Leu Asn Tyr Gln Val Lys Val Lys Ala Ser Ile Asp Lys Asn Val
 355 360 365
 Ser Thr Leu Ser Asn Arg Arg Phe Val Leu Cys Gly Thr His Val Lys
 370 375 380
 Ala Met Ser Ser Glu Glu Ser Ser Asn Gly Ser Leu Ser Val Glu Leu
 385 390 395 400
 Asp Ile Ala Thr Gln Gly Asp Glu Val Gln Tyr Trp Ser Lys Gly Asn
 405 410 415
 Glu Gly Cys His Met Val Thr Glu Glu Leu His Ser Ile Thr Phe Glu
 420 425 430
 Thr Gln Ile Cys Leu Tyr Gly Leu Thr Ile Asn Leu Glu Thr Ser Ser
 435 440 445
 Leu Pro Val Val Met Ile Ser Asn Val Ser Gln Leu Pro Asn Ala Trp
 450 455 460
 Ala Ser Ile Ile Trp Tyr Asn Val Ser Thr Asn Asp Ser Gln Asn Leu
 465 470 475 480
 Val Phe Phe Asn Asn Pro Pro Ser Val Thr Leu Gly Gln Leu Leu Glu
 485 490 495
 Val Met Ser Trp Gln Phe Ser Ser Tyr Val Gly Arg Gly Leu Asn Ser
 500 505 510
 Glu Gln Leu Asn Met Leu Ala Glu Lys Leu Thr Val Gln Ser Asn Tyr
 515 520 525
 Asn Asp Gly His Leu Thr Trp Ala Lys Phe Cys Lys Glu His Leu Pro
 530 535 540
 Gly Lys Thr Phe Thr Phe Trp Thr Trp Leu Glu Ala Ile Leu Asp Leu
 545 550 555 560
 Ile Lys Lys His Ile Leu Pro Leu Trp Ile Asp Gly Tyr Ile Met Gly
 565 570 575
 Phe Val Ser Lys Glu Lys Glu Arg Leu Leu Leu Lys Asp Lys Met Pro
 580 585 590
 Gly Thr Phe Leu Leu Arg Phe Ser Glu Ser His Leu Gly Gly Ile Thr
 595 600 605
 Phe Thr Trp Val Asp Gln Ser Glu Asn Gly Glu Val Arg Phe His Ser
 610 615 620
 Val Glu Pro Tyr Asn Lys Gly Arg Leu Ser Ala Leu Ala Phe Ala Asp
 625 630 635 640

Ile Leu Arg Asp Tyr Lys Val Ile Met Ala Glu Asn Ile Pro Glu Asn
645 650 655
Pro Leu Lys Tyr Leu Tyr Pro Asp Ile Pro Lys Asp Lys Ala Phe Gly
660 665 670
Lys His Tyr Ser Ser Gln Pro Cys Glu Val Ser Arg Pro Thr Glu Arg
675 680 685
Gly Asp Lys Gly Tyr Val Pro Ser Val Phe Ile Pro Ile Ser Thr Ile
690 695 700
Arg Ser Asp Ser Thr Glu Pro Gln Ser Pro Ser Asp Leu Leu Pro Met
705 710 715 720
Ser Pro Ser Ala Tyr Ala Val Leu Arg Glu Asn Leu Ser Pro Thr Thr
725 730 735
Ile Glu Thr Ala Met Asn Ser Pro Tyr Ser Ala Glu
740 745

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2869 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Mouse

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: splenic/thymic
- (B) CLONE: Murine 19sf6

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 69..2378

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GCCGCGACCA GCCAGGCCCG CCAGTCGGGC TCAGCCCGGA GACAGTCGAG ACCCCTGACT 60
GCAGCAGG ATG GCT CAG TGG AAC CAG CTG CAG CAG CTG GAC ACA CGC TAC 110
Met Ala Gln Trp Asn Gln Leu Gln Gln Leu Asp Thr Arg Tyr
1 5 10
CTG AAG CAG CTG CAC CAG CTG TAC AGC GAC ACC TTC CCC ATG GAG CTG 158
Leu Lys Gln Leu His Gln Leu Tyr Ser Asp Thr Phe Pro Met Glu Leu
15 20 25 30
CGG CAG TTC CTG GCA CCT TGG ATT GAG AGT CAA GAC TGG GCA TAT GCA 206
Arg Gln Phe Leu Ala Pro Trp Ile Glu Ser Gln Asp Trp Ala Tyr Ala
35 40 45
GCC AGC AAA GAG TCA CAT GCC ACG TTG GTG TTT CAT AAT CTC TTG GGT 254
Ala Ser Lys Glu Ser His Ala Thr Leu Val Phe His Asn Leu Leu Gly
50 55 60

GAA ATT GAC CAG CAA TAT AGC CGA TTC CTG CAA GAG TCC AAT GTC CTC 302
 Glu Ile Asp Gln Gln Tyr Ser Arg Phe Leu Gln Glu Ser Asn Val Leu
 65 70 75

TAT CAG CAC AAC CTT CGA AGA ATC AAG CAG TTT CTG CAG AGC AGG TAT 350
 Tyr Gln His Asn Leu Arg Arg Ile Lys Gln Phe Leu Gln Ser Arg Tyr
 80 85 90

CTT GAG AAG CCA ATG GAA ATT GCC CGG ATC GTG GCC CGA TGC CTG TGG 398
 Leu Glu Lys Pro Met Glu Ile Ala Arg Ile Val Ala Arg Cys Leu Trp
 95 100 105 110

GAA GAG TCT CGC CTC CTC CAG ACG GCA GCC ACG GCA GCC CAG CAA GGG 446
 Glu Glu Ser Arg Leu Leu Gln Thr Ala Ala Thr Ala Ala Gln Gln Gly
 115 120 125

GGC CAG GCC AAC CAC CCA ACA GCC GCC GTA GTG ACA GAG AAG CAG CAG 494
 Gly Gln Ala Asn His Pro Thr Ala Ala Val Val Thr Glu Lys Gln Gln
 130 135 140

ATG TTG GAG CAG CAT CTT CAG GAT GTC CGG AAG CGA GTG CAG GAT CTA 542
 Met Leu Glu Gln His Leu Gln Asp Val Arg Lys Arg Val Gln Asp Leu
 145 150 155

GAA CAG AAA ATG AAG GTG GTG GAG AAC CTC CAG GAC GAC TTT GAT TTC 590
 Glu Gln Lys Met Lys Val Val Glu Asn Leu Gln Asp Asp Phe Asp Phe
 160 165 170

AAC TAC AAA ACC CTC AAG AGC CAA GGA GAC ATG CAG GAT CTG AAT GGA 638
 Asn Tyr Lys Thr Leu Lys Ser Gln Gly Asp Met Gln Asp Leu Asn Gly
 175 180 185 190

AAC AAC CAG TCT GTG ACC AGA CAG AAG ATG CAG CAG CTG GAA CAG ATG 686
 Asn Asn Gln Ser Val Thr Arg Gln Lys Met Gln Gln Leu Glu Gln Met
 195 200 205

CTC ACA GCC CTG GAC CAG ATG CGG AGA AGC ATT GTG AGT GAG CTG GCG 734
 Leu Thr Ala Leu Asp Gln Met Arg Arg Ser Ile Val Ser Glu Leu Ala
 210 215 220

GGG CTC TTG TCA GCA ATG GAG TAC GTG CAG AAG ACA CTG ACT GAT GAA 782
 Gly Leu Leu Ser Ala Met Glu Tyr Val Gln Lys Thr Leu Thr Asp Glu
 225 230 235

GAG CTG GCT GAC TGG AAG AGG CGG CCA GAG ATC GCG TGC ATC GGA GGC 830
 Glu Leu Ala Asp Trp Lys Arg Arg Pro Glu Ile Ala Cys Ile Gly Gly
 240 245 250

CCT CCC AAC ATC TGC CTG GAC CGT CTG GAA AAC TGG ATA ACT TCA TTA 878
 Pro Pro Asn Ile Cys Leu Asp Arg Leu Glu Asn Trp Ile Thr Ser Leu
 255 260 265 270

GCA GAA TCT CAA CTT CAG ACC CGC CAA CAA ATT AAG AAA CTG GAG GAG 926
 Ala Glu Ser Gln Leu Gln Thr Arg Gln Gln Ile Lys Lys Leu Glu Glu
 275 280 285

CTG CAG CAG AAA GTG TCC TAC AAG GGC GAC CCT ATC GTG CAG CAC CGG 974
 Leu Gln Gln Lys Val Ser Tyr Lys Gly Asp Pro Ile Val Gln His Arg
 290 295 300

CCC ATG CTG GAG GAG AGG ATC GTG GAG CTG TTC AGA AAC TTA ATG AAG 1022
 Pro Met Leu Glu Glu Arg Ile Val Glu Leu Phe Arg Asn Leu Met Lys
 305 310 315

AGT GCC TTC GTG GTG GAG CGG CAG CCC TGC ATG CCC ATG CAC CCG GAC 1070
 Ser Ala Phe Val Val Glu Arg Gln Pro Cys Met Pro Met His Pro Asp
 320 325 330

CGG CCC TTA GTC ATC AAG ACT GGT GTC CAG TTT ACC ACG AAA GTC AGG Arg Pro Leu Val Ile Lys Thr Gly Val Gln Phe Thr Thr Lys Val Arg 335 340 345 350	1118
TTG CTG GTC AAA TTT CCT GAG TTG AAT TAT CAG CTT AAA ATT AAA GTG Leu Leu Val Lys Phe Pro Glu Leu Asn Tyr Gln Leu Lys Ile Lys Val 355 360 365	1166
TGC ATT GAT AAA GAC TCT GGG GAT GTT GCT GCC CTC AGA GGG TCT CGG Cys Ile Asp Lys Asp Ser Gly Asp Val Ala Ala Leu Arg Gly Ser Arg 370 375 380	1214
AAA TTT AAC ATT CTG GGC ACG AAC ACA AAA GTG ATG AAC ATG GAG GAG Lys Phe Asn Ile Leu Gly Thr Asn Thr Lys Val Met Asn Met Glu Glu 385 390 395	1262
TCT AAC AAC GGC AGC CTG TCT GCA GAG TTC AAG CAC CTG ACC CTT AGG Ser Asn Asn Gly Ser Leu Ser Ala Glu Phe Lys His Leu Thr Leu Arg 400 405 410	1310
GAG CAG AGA TGT GGG AAT GGA GGC CGT GCC AAT TGT GAT GCC TCC TTG Glu Gln Arg Cys Gly Asn Gly Gly Arg Ala Asn Cys Asp Ala Ser Leu 415 420 425 430	1358
ATC GTG ACT GAG GAG CTG CAC CTG ATC ACC TTC GAG ACT GAG GTG TAC Ile Val Thr Glu Glu Leu His Leu Ile Thr Phe Glu Thr Glu Val Tyr 435 440 445	1406
CAC CAA GGC CTC AAG ATT GAC CTA GAG ACC CAC TCC TTG CCA GTT GTG His Gln Gly Leu Lys Ile Asp Leu Glu Thr His Ser Leu Pro Val Val 450 455 460	1454
GTG ATC TCC AAC ATC TGT CAG ATG CCA AAT GCT TGG GCA TCA ATC CTG Val Ile Ser Asn Ile Cys Gln Met Pro Asn Ala Trp Ala Ser Ile Leu 465 470 475	1502
TGG TAT AAC ATG CTG ACC AAT AAC CCC AAG AAC GTG AAC TTC TTC ACT Trp Tyr Asn Met Leu Thr Asn Asn Pro Lys Asn Val Asn Phe Phe Thr 480 485 490	1550
AAG CCG CCA ATT GGA ACC TGG GAC CAA GTG GCC GAG GTG CTC AGC TGG Lys Pro Pro Ile Gly Thr Trp Asp Gln Val Ala Glu Val Leu Ser Trp 495 500 505 510	1598
CAG TTC TCG TCC ACC ACC AAG CGA GGG CTG AGC ATC GAG CAG CTG ACA Gln Phe Ser Ser Thr Thr Lys Arg Gly Leu Ser Ile Glu Gln Leu Thr 515 520 525	1646
ACG CTG GCT GAG AAG CTC CTA GGG CCT GGT GTG AAC TAC TCA GGG TGT Thr Leu Ala Glu Lys Leu Leu Gly Pro Gly Val Asn Tyr Ser Gly Cys 530 535 540	1694
CAG ATC ACA TGG GCT AAA TTC TGC AAA GAA AAC ATG GCT GGC AAG GGC Gln Ile Thr Trp Ala Lys Phe Cys Lys Glu Asn Met Ala Gly Lys Gly 545 550 555	1742
TTC TCC TTC TGG GTC TGG CTA GAC AAT ATC ATC GAC CTT GTG AAA AAG Phe Ser Phe Trp Val Trp Leu Asp Asn Ile Ile Asp Leu Val Lys Lys 560 565 570	1790
TAT ATC TTG GCC CTT TGG AAT GAA GGG TAC ATC ATG GGT TTC ATC AGC Tyr Ile Leu Ala Leu Trp Asn Glu Gly Tyr Ile Met Gly Phe Ile Ser 575 580 585 590	1838
AAG GAG CGG GAG CGG GCC ATC CTA AGC ACA AAG CCC CCG GGC ACC TTC Lys Glu Arg Glu Arg Ala Ile Leu Ser Thr Lys Pro Pro Gly Thr Phe 595 600 605	1886

CTA CTG CGC TTC AGC GAG AGC AGC AAA GAA GGA GGG GTC ACT TTC ACT	1934
Leu Leu Arg Phe Ser Glu Ser Ser Lys Glu Gly Gly Val Thr Phe Thr	
610 615 620	
TGG GTG GAA AAG GAC ATC AGT GGC AAG ACC CAG ATC CAG TCT GTA GAG	1982
Trp Val Glu Lys Asp Ile Ser Gly Lys Thr Gln Ile Gln Ser Val Glu	
625 630 635	
CCA TAC ACC AAG CAG CAG CTG AAC AAC ATG TCA TTT GCT GAA ATC ATC	2030
Pro Tyr Thr Lys Gln Gln Leu Asn Asn Met Ser Phe Ala Glu Ile Ile	
640 645 650	
ATG GGC TAT AAG ATC ATG GAT GCG ACC AAC ATC CTG GTG TCT CCA CTT	2078
Met Gly Tyr Lys Ile Met Asp Ala Thr Asn Ile Leu Val Ser Pro Leu	
655 660 665 670	
GTC TAC CTC TAC CCC GAC ATT CCC AAG GAG GAG GCA TTT GGA AAG TAC	2126
Val Tyr Leu Tyr Pro Asp Ile Pro Lys Glu Glu Ala Phe Gly Lys Tyr	
675 680 685	
TGT AGG CCC GAG AGC CAG GAG CAC CCC GAA GCC GAC CCA GGT AGT GCT	2174
Cys Arg Pro Glu Ser Gln Glu His Pro Glu Ala Asp Pro Gly Ser Ala	
690 695 700	
GCC CCG TAC CTG AAG ACC AAG TTC ATC TGT GTG ACA CCA ACG ACC TGC	2222
Ala Pro Tyr Leu Lys Thr Lys Phe Ile Cys Val Thr Pro Thr Thr Cys	
705 710 715	
AGC AAT ACC ATT GAC CTG CCG ATG TCC CCC CGC ACT TTA GAT TCA TTG	2270
Ser Asn Thr Ile Asp Leu Pro Met Ser Pro Arg Thr Leu Asp Ser Leu	
720 725 730	
ATG CAG TTT GGA AAT AAC GGT GAA GGT GCT GAG CCC TCA GCA GGA GGG	2318
Met Gln Phe Gly Asn Asn Gly Glu Gly Ala Glu Pro Ser Ala Gly Gly	
735 740 745 750	
CAG TTT GAG TCG CTC ACG TTT GAC ATG GAT CTG ACC TCG GAG TGT GCT	2366
Gln Phe Glu Ser Leu Thr Phe Asp Met Asp Leu Thr Ser Glu Cys Ala	
755 760 765	
ACC TCC CCC ATG TGAGGAGCTG AAACCAGAAG CTGCAGAGAC GTGACTTGAG	2418
Thr Ser Pro Met	
770	
ACACCTGCCC CGTGCTCCAC CCCTAAGCAG CCGAACCCCA TATCGTCTGA AACTCCTAAC	2478
TTTGTGGTTC CAGATTTTTT TTTTAAATT CCTACTTCTG CTATCTTTGG GCAATCTGGG	2538
CACTTTTTAA AAGAGAGAAA TGAGTGAGTG TGGGTGATAA ACTGTTATGT AAAGAGGAGA	2598
GACCTCTGAG TCTGGGGATG GGGCTGAGAG CAGAAGGGAG GCAAAGGGGA ACACCTCCTG	2658
TCCTGCCCCG CTGCCCTCCT TTTTCAGCAG CTCGGGGGTT GGTGTGTTAGA CAAGTGCCCTC	2718
CTGGTGCCCA TGGCTACCTG TTGCCCCACT CTGTGAGCTG ATACCCCATC CTGGGAACCTC	2778
CTGGCTCTGC ACTTTCAACC TTGCTAATAT CCACATAGAA GCTAGGACTA AGCCCAGGAG	2838
GTTCTCTTT AAATTAAAAA AAAAAAAAAA A	2869

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 770 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met Ala Gln Trp Asn Gln Leu Gln Gln Leu Asp Thr Arg Tyr Leu Lys
 1 5 10 15
 Gln Leu His Gln Leu Tyr Ser Asp Thr Phe Pro Met Glu Leu Arg Gln
 20 25 30
 Phe Leu Ala Pro Trp Ile Glu Ser Gln Asp Trp Ala Tyr Ala Ala Ser
 35 40 45
 Lys Glu Ser His Ala Thr Leu Val Phe His Asn Leu Leu Gly Glu Ile
 50 55 60
 Asp Gln Gln Tyr Ser Arg Phe Leu Gln Glu Ser Asn Val Leu Tyr Gln
 65 70 75 80
 His Asn Leu Arg Arg Ile Lys Gln Phe Leu Gln Ser Arg Tyr Leu Glu
 85 90 95
 Lys Pro Met Glu Ile Ala Arg Ile Val Ala Arg Cys Leu Trp Glu Glu
 100 105 110
 Ser Arg Leu Leu Gln Thr Ala Ala Thr Ala Ala Gln Gln Gly Gly Gln
 115 120 125
 Ala Asn His Pro Thr Ala Ala Val Val Thr Glu Lys Gln Gln Met Leu
 130 135 140
 Glu Gln His Leu Gln Asp Val Arg Lys Arg Val Gln Asp Leu Glu Gln
 145 150 155 160
 Lys Met Lys Val Val Glu Asn Leu Gln Asp Asp Phe Asp Phe Asn Tyr
 165 170 175
 Lys Thr Leu Lys Ser Gln Gly Asp Met Gln Asp Leu Asn Gly Asn Asn
 180 185 190
 Gln Ser Val Thr Arg Gln Lys Met Gln Gln Leu Glu Gln Met Leu Thr
 195 200 205
 Ala Leu Asp Gln Met Arg Arg Ser Ile Val Ser Glu Leu Ala Gly Leu
 210 215 220
 Leu Ser Ala Met Glu Tyr Val Gln Lys Thr Leu Thr Asp Glu Glu Leu
 225 230 235 240
 Ala Asp Trp Lys Arg Arg Pro Glu Ile Ala Cys Ile Gly Gly Pro Pro
 245 250 255
 Asn Ile Cys Leu Asp Arg Leu Glu Asn Trp Ile Thr Ser Leu Ala Glu
 260 265 270
 Ser Gln Leu Gln Thr Arg Gln Gln Ile Lys Lys Leu Glu Glu Leu Gln
 275 280 285
 Gln Lys Val Ser Tyr Lys Gly Asp Pro Ile Val Gln His Arg Pro Met
 290 295 300
 Leu Glu Glu Arg Ile Val Glu Leu Phe Arg Asn Leu Met Lys Ser Ala
 305 310 315 320
 Phe Val Val Glu Arg Gln Pro Cys Met Pro Met His Pro Asp Arg Pro
 325 330 335

Leu Val Ile Lys Thr Gly Val Gln Phe Thr Thr Lys Val Arg Leu Leu
 340 345 350
 Val Lys Phe Pro Glu Leu Asn Tyr Gln Leu Lys Ile Lys Val Cys Ile
 355 360 365
 Asp Lys Asp Ser Gly Asp Val Ala Ala Leu Arg Gly Ser Arg Lys Phe
 370 375 380
 Asn Ile Leu Gly Thr Asn Thr Lys Val Met Asn Met Glu Glu Ser Asn
 385 390 395 400
 Asn Gly Ser Leu Ser Ala Glu Phe Lys His Leu Thr Leu Arg Glu Gln
 405 410 415
 Arg Cys Gly Asn Gly Gly Arg Ala Asn Cys Asp Ala Ser Leu Ile Val
 420 425 430
 Thr Glu Glu Leu His Leu Ile Thr Phe Glu Thr Glu Val Tyr His Gln
 435 440 445
 Gly Leu Lys Ile Asp Leu Glu Thr His Ser Leu Pro Val Val Val Ile
 450 455 460
 Ser Asn Ile Cys Gln Met Pro Asn Ala Trp Ala Ser Ile Leu Trp Tyr
 465 470 475 480
 Asn Met Leu Thr Asn Asn Pro Lys Asn Val Asn Phe Phe Thr Lys Pro
 485 490 495
 Pro Ile Gly Thr Trp Asp Gln Val Ala Glu Val Leu Ser Trp Gln Phe
 500 505 510
 Ser Ser Thr Thr Lys Arg Gly Leu Ser Ile Glu Gln Leu Thr Thr Leu
 515 520 525
 Ala Glu Lys Leu Leu Gly Pro Gly Val Asn Tyr Ser Gly Cys Gln Ile
 530 535 540
 Thr Trp Ala Lys Phe Cys Lys Glu Asn Met Ala Gly Lys Gly Phe Ser
 545 550 555 560
 Phe Trp Val Trp Leu Asp Asn Ile Ile Asp Leu Val Lys Lys Tyr Ile
 565 570 575
 Leu Ala Leu Trp Asn Glu Gly Tyr Ile Met Gly Phe Ile Ser Lys Glu
 580 585 590
 Arg Glu Arg Ala Ile Leu Ser Thr Lys Pro Pro Gly Thr Phe Leu Leu
 595 600 605
 Arg Phe Ser Glu Ser Ser Lys Glu Gly Gly Val Thr Phe Thr Trp Val
 610 615 620
 Glu Lys Asp Ile Ser Gly Lys Thr Gln Ile Gln Ser Val Glu Pro Tyr
 625 630 635 640
 Thr Lys Gln Gln Leu Asn Asn Met Ser Phe Ala Glu Ile Ile Met Gly
 645 650 655
 Tyr Lys Ile Met Asp Ala Thr Asn Ile Leu Val Ser Pro Leu Val Tyr
 660 665 670
 Leu Tyr Pro Asp Ile Pro Lys Glu Glu Ala Phe Gly Lys Tyr Cys Arg
 675 680 685

Pro Glu Ser Gln Glu His Pro Glu Ala Asp Pro Gly Ser Ala Ala Pro
 690 695 700
 Tyr Leu Lys Thr Lys Phe Ile Cys Val Thr Pro Thr Thr Cys Ser Asn
 705 710 715 720
 Thr Ile Asp Leu Pro Met Ser Pro Arg Thr Leu Asp Ser Leu Met Gln
 725 730 735
 Phe Gly Asn Asn Gly Glu Gly Ala Glu Pro Ser Ala Gly Gly Gln Phe
 740 745 750
 Glu Ser Leu Thr Phe Asp Met Asp Leu Thr Ser Glu Cys Ala Thr Ser
 755 760 765
 Pro Met
 770

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:
 (B) CLONE: human Stat91

(x) PUBLICATION INFORMATION:
 (H) DOCUMENT NUMBER: PCT/US93/02569
 (I) FILING DATE: 19-MAR-1993

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Leu Asp Gly Pro Lys Gly Thr Gly Tyr Ile Lys Thr Glu Leu Ile
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

25

GATCGAGATG TATTTCCAG AAAAG

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Leu Asp Gly Pro Lys Gly Thr Gly Tyr Ile Lys Thr Glu Leu Ile
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Gly Tyr Ile Lys Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Lys Val Asn Leu Gln Glu Arg Arg Lys Tyr Leu Lys His Arg
1 5 10

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Glu Pro Gln Tyr Glu Glu Ile Pro Ile Tyr Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 105 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vii) IMMEDIATE SOURCE:
(B) CLONE: Src

(x) PUBLICATION INFORMATION:
(A) AUTHORS: Waksman, et al.
(C) JOURNAL: Nature
(D) VOLUME: 358
(F) PAGES: 646-653
(G) DATE: 1992

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Ala Glu Glu Trp Tyr Phe Gly Lys Ile Thr Arg Arg Glu Ser Glu Arg
1 5 10 15

Leu Leu Leu Asn Pro Glu Asn Pro Arg Gly Thr Phe Leu Val Arg Glu
20 25 30

Ser Glu Thr Thr Lys Gly Ala Tyr Cys Leu Ser Val Ser Asp Phe Phe
 35 40 45
 Asp Asn Ala Lys Gly Leu Asn Val Lys His Tyr Lys Ile Arg Lys Leu
 50 55 60
 Asp Ser Gly Gly Phe Tyr Ile Thr Ser Arg Thr Gln Phe Ser Ser Leu
 65 70 75 80
 Gln Gln Leu Val Ala Tyr Tyr Ser Lys His Ala Asp Gly Leu Cys His
 85 90 95
 Arg Leu Thr Asn Val Cys Pro Thr Ser
 100 105

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 99 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vii) IMMEDIATE SOURCE:
 (B) CLONE: Abl

- (x) PUBLICATION INFORMATION:
 (A) AUTHORS: Overduin, et al.
 (C) JOURNAL: Proc. Natl. Acad. Sci. U.S.A.
 (D) VOLUME: 89
 (F) PAGES: 11673-11677
 (G) DATE: 1992

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Glu Lys His Ser Trp Tyr His Gly Pro Val Ser Arg Asn Ala Ala Glu
 1 5 10 15
 Tyr Leu Leu Ser Ser Gly Ile Asn Gly Ser Phe Leu Val Arg Glu Ser
 20 25 30
 Asp Arg Arg Pro Gly Gln Arg Ser Ile Ser Leu Arg Tyr Glu Glu Gly
 35 40 45
 Arg Val Tyr His Tyr Arg Ile Asn Thr Ala Ser Asp Gly Lys Leu Tyr
 50 55 60
 Val Ser Ser Glu Ser Arg Phe Asn Thr Leu Ala Glu Leu Val His His
 65 70 75 80
 His Ser Thr Val Ala Asp Gly Leu Ile Thr Thr Leu His Tyr Pro Ala
 85 90 95
 Pro Lys Arg

(2) INFORMATION FOR SEQ ID NO:21:

WO 95/08629

117

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 102 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
 (iii) HYPOTHETICAL: NO
 (iv) ANTI-SENSE: NO
 (v) FRAGMENT TYPE: internal

- (vii) IMMEDIATE SOURCE:
 (B) CLONE: Lck

- (x) PUBLICATION INFORMATION:
 (A) AUTHORS: Eck, et al.
 (C) JOURNAL: Nature
 (D) VOLUME: 362
 (F) PAGES: 87-91
 (G) DATE: 1993

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Trp Phe Phe Lys Asn Leu Ser Arg Lys Asp Ala Glu Arg Gln Leu Leu
 1 5 10 15
 Ala Pro Gly Asn Thr His Gly Ser Phe Leu Ile Arg Glu Ser Glu Ser
 20 25 30
 Thr Ala Gly Ser Phe Ser Leu Ser Val Arg Asp Asp Phe Asp Gln Asn
 35 40 45
 Gln Gly Glu Val Val Lys His Tyr Lys Ile Arg Asn Leu Asp Asn Gly
 50 55 60
 Gly Phe Tyr Ile Ser Pro Arg Ile Thr Phe Pro Gly Leu His Asp Leu
 65 70 75 80
 Val Arg His Tyr Thr Asn Ala Ser Asp Gly Leu Cys Thr Arg Leu Ser
 85 90 95
 Arg Pro Cys Gln Thr Gln
 100

- (2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 99 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
 (iii) HYPOTHETICAL: NO
 (iv) ANTI-SENSE: NO
 (v) FRAGMENT TYPE: internal

- (vii) IMMEDIATE SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

[illegible]

WHAT IS CLAIMED IS:

1 1. A receptor recognition factor implicated in the transcriptional stimulation of
2 genes in target cells in response to the binding of a specific polypeptide ligand to
3 its cellular receptor on said target cell, said receptor recognition factor having the
4 following characteristics:

5 a) apparent direct interaction with the ligand-bound receptor and
6 activation of one or more transcription factors capable of binding with a specific
7 gene;

8 b) an activity demonstrably unaffected by the presence or concentration
9 of second messengers;

10 c) direct interaction with tyrosine kinase domains;

11 d) a perceived absence of interaction with G-proteins.

12 e) an amino acid sequence selected from the group consisting of SEQ

13 ID NO:8, SEQ ID NO:10, and SEQ ID NO:12.

1 2. The receptor recognition factor of Claim 1 labeled with a detectable label.

1 3. The receptor recognition factor of Claim 2 wherein the label is selected
2 from enzymes, chemicals which fluoresce and radioactive elements.

1 4. An antibody to a receptor recognition factor, the factor to which said
2 antibody is raised having the following characteristics:

3 a) apparent direct interaction with the ligand-bound receptor and
4 activation of one or more transcription factors capable of binding with a specific
5 gene;

6 b) an activity demonstrably unaffected by the presence or concentration
7 of second messengers;

8 c) direct interaction with tyrosine kinase domains;

9 d) a perceived absence of interaction with G-proteins; and

10 e) an amino acid sequence selected from the group consisting of SEQ
11 ID NO:8, SEQ ID NO:10, and SEQ ID NO:12.

1 5. The antibody of Claim 4 which is a polyclonal antibody.

1 6. The antibody of Claim 4 which is a monoclonal antibody.

1 7. An immortal cell line that produces a monoclonal antibody according to
2 Claim 6.

1 8. The antibody of Claim 4 labeled with a detectable label.

1 9. The antibody of Claim 8 wherein the label is selected from enzymes,
2 chemicals which fluoresce and radioactive elements.

1 10. An isolated DNA sequence or degenerate variant thereof, which encodes a
2 receptor recognition factor, or a fragment thereof, selected from the group
3 consisting of:

4 (A) the DNA sequence of SEQ ID NO:7 (FIGURE 1);

5 (B) the DNA sequence of SEQ ID NO:9 (FIGURE 2);

6 (C) the DNA sequence of SEQ ID NO:11 (FIGURE 3);

7 (D) DNA sequences that hybridize to any of the foregoing DNA
8 sequences under standard hybridization conditions; and

9 (E) DNA sequences that code on expression for an amino acid sequence
10 encoded by any of the foregoing DNA sequences.

1 11. A recombinant DNA molecule comprising a DNA sequence or degenerate
2 variant thereof, which encodes a receptor recognition factor, or a fragment
3 thereof, selected from the group consisting of:

4 (A) the DNA sequence of SEQ ID NO:7 (FIGURE 1);

5 (B) the DNA sequence of SEQ ID NO:9 (FIGURE 2);

- 6 (C) the DNA sequence of SEQ ID NO:11 (FIGURE 3);
7 (D) DNA sequences that hybridize to any of the foregoing DNA
8 sequences under standard hybridization conditions; and
9 (E) DNA sequences that code on expression for an amino acid sequence
10 encoded by any of the foregoing DNA sequences.

1 12. The recombinant DNA molecule of either of Claims 10 or 11, wherein said
2 DNA sequence is operatively linked to an expression control sequence.

1 13. A probe capable of screening for the receptor recognition factor in alternate
2 species prepared from the DNA sequence of Claim 10.

1 14. A unicellular host transformed with a recombinant DNA molecule
2 comprising a DNA sequence or degenerate variant thereof, which encodes a
3 receptor recognition factor, or a fragment thereof, selected from the group
4 consisting of:

- 5 (A) the DNA sequence of SEQ ID NO:7 (FIGURE 1);
6 (B) the DNA sequence of SEQ ID NO:9 (FIGURE 2);
7 (C) the DNA sequence of SEQ ID NO:11 (FIGURE 3);
8 (D) DNA sequences that hybridize to any of the foregoing DNA
9 sequences under standard hybridization conditions; and
10 (E) DNA sequences that code on expression for an amino acid sequence
11 encoded by any of the foregoing DNA sequences;
12 wherein said DNA sequence is operatively linked to an expression control
13 sequence.

1 15. A method for detecting the presence or activity of a receptor recognition
2 factor, said receptor recognition factor having an amino acid sequence selected
3 from the group consisting of SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:12,
4 wherein said receptor recognition factor is measured by:

5 A. contacting a biological sample from a mammal in which the
6 presence or activity of said receptor recognition factor is suspected with a binding
7 partner of said receptor recognition factor under conditions that allow binding of
8 said receptor recognition factor to said binding partner to occur; and
9 B. detecting whether binding has occurred between said receptor
10 recognition factor from said sample and the binding partner;
11 wherein the detection of binding indicates that presence or activity of said
12 receptor recognition factor in said sample.

1 16. A method for detecting the presence and activity of a polypeptide ligand
2 associated with a given invasive stimulus in mammals comprising detecting the
3 presence or activity of a receptor recognition factor according to the method of
4 Claim 15, wherein detection of the presence or activity of the receptor recognition
5 factor indicates the presence and activity of a polypeptide ligand associated with a
6 given invasive stimulus in mammals.

1 17. The method of Claim 16 wherein said invasive stimulus is selected from
2 the group consisting of viral infection, protozoan infection, tumorous mammalian
cells, and toxins.

1 18. A method for detecting the binding sites for a receptor recognition factor,
2 said receptor recognition factor having an amino acid sequence selected from the
3 group consisting of SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:12, wherein
4 the binding sites for said receptor recognition factor are measured by:

5 A. placing a labeled receptor recognition factor sample in
6 contact with a biological sample from a mammal in which binding sites for said
7 receptor recognition factor are suspected;

8 B. examining said biological sample in binding studies for the
9 presence of said labeled receptor recognition factor;

10 wherein the presence of said labeled recognition factor indicates a binding
11 site for a receptor recognition factor.

1 19. A method of testing the ability of a drug or other entity to modulate the
2 activity of a receptor recognition factor which comprises
3 A. culturing a colony of test cells which has a receptor for the
4 receptor recognition factor in a growth medium containing the receptor recognition
5 factor;
6 B. adding the drug under test; and
7 C. measuring the reactivity of said receptor recognition factor with the
8 receptor on said colony of test cells,
9 wherein said receptor recognition factor has an amino acid sequence selected from
10 the group consisting of SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:12.

1 20. An assay system for screening drugs and other agents for ability to
2 modulate the production of a receptor recognition factor, comprising:
3 A. culturing an observable cellular test colony inoculated with a drug
4 or agent;
5 B. harvesting a supernatant from said cellular test colony; and
6 C. examining said supernatant for the presence of said receptor
7 recognition factor wherein an increase or a decrease in a level of said receptor
8 recognition factor indicates the ability of a drug to modulate the activity of said
9 receptor recognition factor, said receptor recognition factor having an amino acid
10 sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:10,
11 and SEQ ID NO:12.

1 21. A test kit for the demonstration of a receptor recognition factor in a
2 eukaryotic cellular sample, comprising:
3 A. a predetermined amount of a detectably labelled specific binding
4 partner of a receptor recognition factor, said receptor recognition factor having the
5 an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ
6 ID NO:10, and SEQ ID NO:12;
7 B. other reagents; and
8 C. directions for use of said kit.

1 22. A test kit for demonstrating the presence of a receptor recognition factor in
2 a eukaryotic cellular sample, comprising:
3 A. a predetermined amount of a receptor recognition factor, said
4 receptor recognition factor having the an amino acid sequence selected from the
5 group consisting of SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:12;
6 B. a predetermined amount of a specific binding partner of said
7 receptor recognition factor;
8 C. other reagents; and
9 D. directions for use of said kit;
10 wherein either said receptor recognition factor or said specific binding
11 partner are detectably labelled.

1 23. The test kit of Claim 21 or 22 wherein said labeled immunochemically
2 reactive component is selected from the group consisting of polyclonal antibodies
3 to the receptor recognition factor, monoclonal antibodies to the receptor
4 recognition factor, fragments thereof, and mixtures thereof.

1 24. Use of a material selected from the group consisting of a receptor
2 recognition factor, an agent capable of promoting the production and/or activity of
3 said receptor recognition factor, an agent capable of mimicking the activity of said
4 receptor recognition factor, an agent capable of inhibiting the production of said
5 receptor recognition factor, and mixtures thereof, or a specific binding partner
6 thereto, said receptor recognition factor having an amino acid sequence selected
7 from the group consisting of SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:12,
8 in the manufacture of a medicament for preventing and/or treating cellular
9 debilitations, derangements and/or dysfunctions and/or other disease states in
10 mammals.

1 25. The use according to Claim 24 wherein said disease states include chronic
2 viral hepatitis, hairy cell leukemia, and tumorous conditions.

1 26. A pharmaceutical composition for the treatment of cellular debilitation,
2 derangement and/or dysfunction in mammals, comprising:

3 A. a therapeutically effective amount of a material selected from
4 the group consisting of a receptor recognition factor, an agent capable of
5 promoting the production and/or activity of said receptor recognition factor, an
6 agent capable of mimicking the activity of said receptor recognition factor, an
7 agent capable of inhibiting the production of said receptor recognition factor, and
8 mixtures thereof, or a specific binding partner thereto, said receptor recognition
9 factor having an amino acid sequence selected from the group consisting of SEQ
10 ID NO:8, SEQ ID NO:10, and SEQ ID NO:12; and

11 B. a pharmaceutically acceptable carrier.

1 27. A method of determining the interferon-related pharmacological activity of
2 a compound comprising:

3 administering the compound to non-human a mammal;

4 determining the level of phosphorylated ISGF3 proteins present, wherein
5 said phosphorylated ISGF3 proteins are proteins having an amino acid sequence
6 selected from the group consisting of SEQ ID NO:8, SEQ ID NO:10, and SEQ ID
7 NO:12; and

8 comparing the level of ISGF3 protein-phosphate to a standard.

1 28. An antisense nucleic acid against a receptor recognition factor mRNA
2 comprising a nucleic acid sequence hybridizing to said mRNA, wherein said
3 receptor recognition factor has an amino acid sequence selected from the group
4 consisting of SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:12.

1 29. The antisense nucleic acid of Claim 28 which is RNA or DNA.

1 30. A recombinant DNA molecule having a DNA sequence which, on
2 transcription, produces an antisense ribonucleic acid against a receptor recognition
3 factor mRNA, said antisense ribonucleic acid comprising an nucleic acid sequence

4 capable of hybridizing to said mRNA, wherein said receptor recognition factor has
5 an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ
6 ID NO:10, and SEQ ID NO:12.

1 31. A receptor recognition factor-producing cell line transfected with the
2 recombinant DNA molecule of Claim 30.

1 32. A method for creating a cell line which exhibits reduced expression of a
2 receptor recognition factor, comprising transfecting a recognition factor-producing
3 cell line with a recombinant DNA molecule of claim 30.

1 33. A ribozyme that cleaves receptor recognition factor mRNA, wherein said
2 receptor recognition factor has an amino acid sequence selected from the group
3 consisting of SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:12.

1 34. A recombinant DNA molecule having a DNA sequence which, upon
2 transcription, produces the ribozyme of claim 33.

1 35. A receptor recognition factor-producing cell line transfected with the
2 recombinant DNA molecule of claim 34.

1 36. A method for creating a cell line which exhibits reduced expression of a
2 receptor recognition factor, comprising transfecting a recognition factor-producing
3 cell line with the recombinant DNA molecule of claim 33.

FIG. 1A

1 MSQWFELQQL DSKFLEQVHQ LYDDSEFMEI RQYLAQWLEK QDWEHAAYDV
51 SFATIRFHD LLSQLDDQYSR FSLENNFLLQ INIRKSKRNL QDNFQEDPVQ
101 MSMIIYNCLK EERKILENAQ RFNQAQEGNI QNTVMLDKQK ELDSKVRNVK
151 DQVMCIEQEI KTLLELQDEY DFKCKTSQNR EGEANGVAKS DQKQEQLLLH
201 KMFLMLDNKR KEIIHKIREL LNSIELTQNT LINDELVEWK RRQQSACIGG
251 PPNACLDQLQ TWFTIVAETL QQIROQLKKL EELEQKFTYE PDPITKNKQV
301 LSDRTFLLFQ QLIQSSFVVE RQPCMPHPQ RPLVLKTGVQ FTVKSRLLVK
351 LQESNLLTKV KCHFDKDVNE KNTVKGERKE NILGTHTKVM NMEESTNGSL
401 AAELRHQLK EQKNAGNRTN EGPLIVTEEL HSLSFETQLC QPGLVIDLET
451 TSLPVVVISN VSQLP SGWAS ILWYNMLVTE PRNLSFFLNP PCAWWSQLSE
501 VLSWQFSSVT KRGLNADQLS MLGEKLLGPN AGPDGLIPWT RFCKENINDK
551 NFESEFWIDT ILELIKNDLL CLWNDGCIMG FISKERERAL LKDQQPGTFL
601 LRFSESSREG AITFTWVERS QNGGEPDFHA VEPYTKKELS AVTFPDIIRN
651 YKVMMAENIP ENPLKYLYPN IDKDHAFGKY YSRPKEAPEP MELDDPKRTG
701 YIKTELISVS EVHPSRLQTT DNLLPMSPEE FDEMSRIVGP EFDSMMSTV

FIG. 1B

1 caggatgtca cagtgggttcg agcttcagca gctggactcc aagttcctgg
51 agcagggtcca ccagctgtac gatgacagtt tcccatgga aatcagacag
101 tacctggccc agtggctgga aaagcaagac tgggagcaag ctgcctatga
151 tgtctcgttt gcgaccatcc gcttccatga cctcctctca cagctggacg
201 accagtacag ccgcttttct ctggagaata atttcttggt gcagcacaac
251 atacggaaaa gcaagcgtaa tctccaggat aacttccaag aagatcccgt
301 acagatgtcc atgatcatct acaactgtct gaaggaagaa aggaagattt
351 tggaaaatgc ccaaagattt aatcaggccc aggagggaac tattcagaac
401 actgtgatgt tagataaaca gaaggagctg gacagtaaag tcagaaatgt
451 gaaggatcaa gtcattgtgca tagagcagga aatcaagacc ctagaagaat
501 tacaagatga atatgacttt aaatgcaaaa cctctcagaa cagagaaggt
551 gaagccaatg gtgtggcgaa gagcgaccaaa aaacaggaac agctgctgct
601 ccacaagatg tttttaatgc ttgacaataa gagaaaggag ataattcaca

FIG. 1B I

651 aaatcagaga gttgctgaat tccatcgagc tcactcagaa cactctgatt
701 aatgacgagc tcgtggagtg gaagcgaagg cagcagagcg cctgcatcgg
751 gggaccgccc aacgcctgcc tggatcagct gcaaacgtgg ttcaccattg
801 ttgcagagac cctgcagcag atccgtcagc agcttaaaaa gctggaggag
851 ttggaacaga aattcaccta tgagcccgac cctattacaa aaaacaagca
901 ggtgttgtca gatcgaacct tctcctctt ccagcagctc attcagagct
951 ccttcgtggg agaacgacag ccgtgcatgc ccactcacc gcagaggccc
1001 ctggctcttga agactggggg acagttcact gtcaagtcga gactgttggg
1051 gaaattgcaa gagtcgaatc tattaacgaa agtgaaatgt cactttgaca
1101 aagatgtgaa cgagaaaaac acagttaaag gatttcggaa gttcaacatc
1151 ttgggtacgc acacaaaagt gatgaacatg gaagaatcca ccaacggaag
1201 tctggcagct gagctccgac acctgcaact gaaggaacag aaaaacgctg
1251 ggaacagaac taatgagggg cctctcattg tcaccgaaga acttcactct
1301 cttagctttg aaaccagtt gtgccagcca ggcttggtga ttgacctgga
1351 gaccacctct ctctctgtcg tggatgctc caacgtcagc cagctcccca

FIG. 1C

1401 gtggetgggc gtctatcctg tggtaacaaca tgctgggtgac agagcccagg
1451 aatctctcct tcttctgaa cccccctgc gcgtgggtggc cccagctctc
1501 agaggtggtg agttggcagt tttcatcagt caccaagaga ggtctgaacg
1551 cagaccagct gagcatgctg ggagagaagc tgctggggccc taatgctggc
1601 cctgatgggc ttattccatg gacaagggtt tgtaaggaaa atattaatga
1651 taaaaatttc tccttctggc cttggattga caccatccta gagctcatta
1701 agaacgacct gctgtgcctc tggaatgatg ggtgcattat gggcttcac
1751 agcaaggagc gagaacgcgc tctgctcaag gaccagcagc cagggacgtt
1801 cctgcttaga ttcagtgaga gctcccgga agggggccac acattcacat
1851 ggggtggaacg gtcccagaac ggaggtgaac ctgacttcca tgccgtggag
1901 ccctacacga aaaaagaact ttcagctgtt actttcccag atattattcg
1951 caactacaaa gtcattggctg ccgagaacat accagagaat cccctgaagt
2001 atctgtaccc caatattgac aaagaccacg cctttgggaa gtattattcc
2051 agaccaaagg aagcaccaga accgatggag cttgacgacc ctaagcgaac
2101 tggatacatc aagactgagt tgatttctgt gtctgaagtc cacccttcta
2151 gacttcagac cacagacaac ctgcttccca tgtctccaga ggagtttgat
2201 gagatgtccc ggatagtggg ccccgaaatt gacagtatga tgagcacagt
2251 ataaacacga atttctctct ggcgaca

FIG. 2A

1 MSQWNQVQQL EIKFLEQVDQ FYDDNFPMEI RHLLAQWIET ODWEVASNNE
51 TMATILLQNL LIQLDEQLGR VSKEKNLLLI HNLKRIRKVL QGKFHGNPMH
101 VAVVISNCLR EERRILAAAN MPIQGPLEKS LQSSSVSERQ RNVEHKVSAI
151 KNSVQMTQD TKYLEDLQDE FDYRYKTIQT MDQGDKNSIL VNQEVLTLLQ
201 EMLNSLDFKR KEALSKMTQI VNETDLLMNS MLEELQDWK KRIRIACIGG
251 PLINGLDQLQ NCFLLAESL FQLRQOLEKL QEQSTKMTYE GDPIPAQRAH
301 LLERATFLIY NLFKNSFVVE RHACMPHPQ RPMVLKTLIQ FTVKLRLLIK
351 LPELNYQVKV KASIDKNVST LSNRRFVLCG THVKAMSSEE SSNGSLSVEL
401 DIATQGDEVQ YWSKGNEGCH MVTEELHSIT FETOICLYGL TINLETSSLP
451 VVMISNVSQL PNAWASIIWY NVSTNDSQNL VFFNNPPSVT LGQLLEVMSW
501 QFSSYVGRGL NSEQLNMLAE KLTQVSNYND GHLTWAKFCK EHLPGKTFTF
551 WTWLEAILDL IKKHILPLWI DGYIMGFVSK EKERLLLKDK MPGTFLLRFS
601 ESHLGGITFT WVDQSENGEV RFHSVEPYNK GRLSALAFAD ILRDYKVIMA
651 ENIPENPLKY LYPDIPKDKA FGKHYSSQPC EVSRPTERGD KGYVPSVFIP
701 ISTIRSDSTE PQSPDLLPM SPSAYAVLRE NLSPTTIETA MNSPYSAE

FIG. 2B

1 tgccactacc tggacggaga gagagagagc agcatgtctc agtggaatca
51 agtccaacaa ttagaaatca agtttttggg gcaagtagat cagttctatg
101 atgacaactt tcctatggaa atccggcatc tgctagctca gtggattgag
151 actcaagact ggggaagtgc ttctaacaat gaaactatgg caacaattct
201 gcttcaaaac ttactaatac aattggatga acagttgggg cgggtttcca
251 aagaaaaaaaa tctgctattg attcacaatc taaagagaat tagaaaagtt
301 cttcagggca agtttcatgg aaatccaatg catgtagctg tggtaatttc
351 aaattgctta agggaagaga ggagaatatt ggctgcagcc aacatgccta
401 tccagggacc tctggagaaa tccttacaga gttcttcagt ttctgaaaga
451 caaaggaatg tggaacacaa agtgtctgcc attaaaaaca gtgtgcagat
501 gacagaacaa gataccaaat acttagaaga cctgcaagat gagtttgact
551 acaggtataa aacaattcag acaatggatc agggtgacaa aaacagtatc
601 ctggtgaacc aggaagtttt gacactgctg caagaaatgc ttaatagtct
651 ggacttcaag agaaaggaag cactcagtaa gatgacgcag atagtgaacg
701 agacagacct gctcatgaac agcatgcttc tagaagagct gcaggactgg
751 aaaaagcggc acaggattgc ctgcattggg ggcctgctcc acaatgggct
801 ggaccagctt cagaactgct ttacctact ggcagagagt cttttccaac
851 tcagacagca actggagaaa ctacaggagc aatctactaa aatgacctat

FIG. 2C

901 gaaggggata ccatccctgc tcaaagagca cacctcctgg aaagagctac
951 ctctctgata tacaaccttt tcaagaactc atttggtggtc gagcgacacg
1001 catgcatgcc aacgcacct cagaggccga tggacttaaa aacctcatt
1051 cagttcactg taaaactgag attactaata aaattgccgg aactaaacta
1101 tcaggtgaaa gttaaaggcgt ccattgacaa gaatgtttca actctaagca
1151 atagaagatt tgtgctttgt ggaactcacg tcaaagctat gtccagtga
1201 gaatcttcca atgggagcct ctcaagtggag ttagacattg caaccaagg
1251 agatgaagtg cagtactgga gttaaaggaaa cgagggtgc cacatggtga
1301 cagaggagtt gcattccata acctttgaga cccagatctg cctctatggc
1351 ctaccatta acctagagac cagtcatta cctgtcgtga tgatttctaa
1401 tgtcagccaa ctacctaatg catgggcata catcatttgg tacaatgtat
1451 caactaacga ctcccagaac ttggttttct ttaataaacc tccatctgtc
1501 actttgggcc aactcctgga agtgaatgagc tggcaatttt catcctatgt
1551 cggtcgtggc cttaattcag agcagctcaa catgctggca gagaagctca
1601 cagttcagtc taactacaat gatggtcacc tcacctgggc caagttctgc
1651 aaggaacatt tgccctggcaa aacatttacc ttctggactt ggcttgaagc
1701 aatattggac ctaattaaaa aacatattct tccctctgg attgatgggt
1751 acatcatggg atttgtagt aaagagaagg aacggcttct gctcaaagat
1801 aaaatgcctg ggacattttt gttaagattc agtgagagcc atcttggagg

FIG. 2D

1851 gataaccttc acctgggtgg accaatctga aaatggagaa gtgagattcc
1901 actctgtaga accctacaac aaagggagac tgcgggtctt ggccttcgct
1951 gacatcctgc gagactacaa gggtatcatg gctgaaaaca tcctgaaaa
2001 ccctctgaag tacctctacc ctgacattcc caaagacaaa gcctttggca
2051 aacactacag ctcccagccg tgcgaagtct caagaccaac cgaacgggga
2101 gacaagggtt acgtcccctc tgtttttatc cccatttcaa caatccgaag
2151 cgattccacg gagccacaat ctcttccaga ccttctcccc atgtctccaa
2201 gtgcatatgc tgtgctgaga gaaaacctga gcccaacgac aattgaaact
2251 gcaatgaatt ccccatattc tgetgaatga cggtgcaaac ggacacttta
2301 aagaaggaag cagatgaaac tggagagtgt tctttaccat agatcacaat
2351 ttatttcttc ggctttgtaa atacc

FIG. 3A

1 MAQWNQLQQL DTRYLKQLHQ LYSDFPMEL RQFLAPWIES QDWAYAASKE
51 SHATLVFHNH LGEIDQQYSR FLQESNVLYQ HNLRRIKQFL QSRYLEKPMK
101 IARIVARCLW EESRLLQTAA TAAQQGGQAN HPTAAVVTEK QQMLEQHLQD
151 VRKRVQDLEQ KMKVVENLQD DFDENYKTLK SQGDMQDLNG NNQSVTRQKM
201 QQLEQMLTAL DQMRRSIVSE LAGLLSAMEY VQKTLTDEEL ADWKRRPEIA
251 CIGGPPNICL DRLENWITSL AESQLQTRQQ IKKLEELQOK VSYKGDPIVQ
301 HRPMLEERIV ELFRNLMKSA FVVERQPCMP MHPDRPLVIK TGVQFTTKVR
351 LLVKFPELNY QLKIKVCIDK DSGDVAALRG SRKFNILGTN TKVMNMEESN
401 NGSLSAEFKH LTLREQRCGN GGRANCDASL IVTEELHLIT FETEVYHQGL
451 KIDLETHSLP VVVISNICQM PNAWASILWY NMLTNNPKNV NFFTCKPIGT
501 WDQVAEVLWS QFSSTTKRGL SIEQLTTLAE KLLGPGVNYS GCQITWAKFC
551 KENMAGKGF SFWWLDNIID LVKKYILALW NEGYIMGFIS KERERAILST
601 KPPGTPELLRF SESSKEGGVT FTWVEKDISG KTQIQSVEPY TKQQLNNMSF
651 AEIIMGYKIM DATNILVSPL VYLYPDIPKE EAFGKYCRPE SQEHPEADPG
701 SAAPYLKTKF ICVTPTTCN TIDLPMSPRT LDSLMQFGNN GEGAEPGAGG
751 QFESLTFDMD LTSECATSPM

FIG. 3B

1 gccgcgacca gccaggccgg ccagtcgggc tcagcccga gacagtcgag
51 acccctgact gcagcaggat ggctcagtgg aaccagctgc agcagctgga
101 cacacgtac ctgaagcagc tgcaccagct gtacagcgac acgttcccca
151 tggagctgcg gcagttcctg gcaccttgga ttgagagtca agactgggca
201 tatgcagcca gcaaagagtc acatgccacg ttgggtgttc ataattctt
251 gggtgaaatt gaccagcaat atagccgatt cctgcaagag tccaatgtcc
301 tctatcagca caaccttcga agaataagc agtttttgca gagcaggtat
351 cttgagaagc caatggaaat tgcccggatc gtggcccgat gcctgtggga
401 agagtctcgc ctctccaga cggcagccac ggcagcccag caagggggcc
451 aggccaacca cccaacagcc gccgtagtga cagagaagca gcagatgttg
501 gagcagcadc ttcaggatgt ccggaagcga gtgcaggatc tagaacagaa
551 aatgaaggtg gtggagaacc tccaggacga ctttgatttc aactacaaaa
601 ccctcaagag ccaaggagac atgcaggatc tgaatggaaa caaccagtct
651 gtgaccagac agaagatgca gcagctggaa cagatgctca cagccctgga
701 ccagatgcgg agaagcattg tgagttagct ggcggggctc ttgtcagcaa
751 tggagtacgt gcagaagaca ctgactgatg aagagctggc tgactggaag
801 aggcggccag agatcgctg catcgaggc cctcccaaca tctgcctgga
851 ccgtctggaa aactggataa cttcattagc agaattctaa cttcagaccc

FIG. 3C

901 gccacaaat taagaaactg gaggagctgc agcagaaagt gtcctacaag
951 ggcgacccta tcgtgcagca ccggcccatg ctggaggaga ggatcgtgga
1001 gctgttcaga aacttaatga agagtgcctt cgtggtggag cggcagccct
1051 gcatgcccat gcacccggac cggcccttag tcatcaagac tgggtgccag
1101 tttaccacga aagtcaggtt gctggtcaaa tttcctgagt tgaattatca
1151 gcttaaaatt aaagtgtgca ttgataaaga ctctggggat gttgctgccc
1201 tcagaggggc tcggaaattt aacattctgg gcacgaacac aaaagtgatg
1251 aacatggagg agtctaacaa cggcagcctg tctgcagagt tcaagcacct
1301 gacccttagg gagcagagat gtgggaatgg aggccgtgcc aattgtgatg
1351 cctccttgat cgtgactgag gagctgcacc tgatcacctt cgagactgag
1401 gtgtaccacc aaggcctcaa gattgaccta gagaccact ccttgccagt
1451 tgtggtgatc tccaacatct gtcagatgcc aaatgcttgg gcatcaatcc
1501 tgtggtataa catgctgacc aataacccca agaacgtgaa cttcttcact
1551 aagccgcca ttggaacctg ggaccaagtg gccgaggtgc tcagctggca
1601 gttctcgtcc accaccaagc gagggtgag catcgagcag ctgacaacgc
1651 tggctgagaa gctcctaggg cctggtgtga actactcagg gtgtcagatc
1701 acatgggcta aattctgcaa agaaaacatg gctggcaagg gcttctcctt
1751 ctgggtctgg ctagacaata tcatcgacct tgtgaaaaag tatactcttg
1801 ccctttggaa tgaagggtag atcatgggtt tcatcagcaa ggagcgggag

FIG. 3D

1851 cgggccatcc taagcacaaa gcccccgggc accttctac tgcgcttcag
1901 cgagagcagc aaagaaggag gggtcacttt cacttgggtg gaaaaggaca
1951 tcagtggcaa gaccagatc cagtctgtag agccatacac caagcagcag
2001 ctgaacaaca tgtcatttgc tgaaatcatc atgggctata agatcatgga
2051 tgcgaccaac atcctgggtg ctccacttgt ctacctctac cccgacattc
2101 ccaaggagga ggcatttga aagtactgta ggcccgagag ccaggagcac
2151 cccgaagccg acccaggtag tgetgccccg tacctgaaga ccaagttcat
2201 ctgtgtgaca ccaacgacct gcagcaatac cattgacctg ccgatgtccc
2251 cccgcacttt agattcattg atgcagtttg gaaataacgg tgaaggtgct
2301 gagccctcag caggagggca gtttgagtcg ctacagtttg acatggatct
2351 gacctcggag tgtgtacct ccccatgtg aggagctgaa accagaagct
2401 gcagagacgt gacttgagac acctgccccg tgctccaccc ctaagcagcc
2451 gaaccccata tcgtctgaaa ctcttaactt tgtggttcca gatttttttt
2501 tttaatttcc tacttctgct atctttgggc aatctgggca ctttttaaaa
2551 gagagaaatg agtgagtgtg ggtgataaac tgttatgtaa agaggagaga
2601 cctctgagtc tggggatggg gctgagagca gaagggaggc aaaggggaac
2651 acctcctgtc ctgcccgcct gccctccttt ttcagcagct cgggggttgg
2701 ttgttagaca agtgccctct ggtgcccctg gctacctgtt gcccactct
2751 gtgagctgat accccattct gggaactcct ggctctgcac ttccaacctt

FIG. 3E

2801 gctaatatcc acatagaagc taggactaag cccaggaggt tcctctttaa

2851 attaaaaaaaa aaaaaaaaaa

FIG. 4A




FIG. 4B

C0 C1 C2 C3 C4 C5

PTH-P-Tyr →

Ori →

X →

←Ori

FIG. 4C




FIG. 4D



FIG. 4E



FIG. 5A




FIG. 5B



FIG. 5C




FIG. 6A




FIG. 6B



FIG. 6C




FIG. 6D



FIG. 6E




FIG. 6F




FIG. 6G



FIG. 7A




FIG. 7B

1 2 3 4 5

FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 11B




FIG. 11A

C84 Cmx C91L



FIG. 12




FIG. 13




FIG. 14




FIG. 15A




FIG. 15B



FIG. 16B

stat91	(665)	KYLY	P	NID	X	KDHAFGKYYSRP	PK EA PEP M	ELD GPKGTGYIKT	(704)
src	(211)	GFYI	TSR	TQF	S	SLQQLVAYYSKH	AD GL CH	RLT NVC PTS	(248)
lck	(190)	GFYI	SPR	ITF	P	GLHDLVRHYTNA	SD GL CT	RLS RPC QTQ	(227)
abl	(201)	KLXV	SSE	SRE	N	TLAELVHHSTV	AD GL IT	TLH YPA PKR	(238)
p85αN	(389)	KYGF	SDP	LTF	N	SVVELINHYRHE	S LA QYN PKLDV KL	LYP	(427)

αB9

SCR'S	XXX	[--]	[--]	[--]	XXXXXXX	[-----]	[--]	[--]
Name	βE	EF	βF	αB	BG	BG	GΩ	

INTERNATIONAL SEARCH REPORT

Inter: al Application No
PCT/US 94/10849

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/47 C07K16/18 G01N33/68 C12N15/11
C12N9/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO, A, 93 19179 (ROCKEFELLER UNIVERSITY, US) 30 September 1993 cited in the application see the whole document ---	1-36
X	WO, A, 92 08740 (ROCKEFELLER UNIVERSITY, US) 29 May 1992 see the whole document ---	10-14
X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 89, August 1992, WASHINGTON US pages 7836 - 7839 SCHINDLER, C. ET AL.; 'Proteins of transcription factor ISGF-3 : one gene encodes the 91- and 84-kDA ISGF-3 proteins that are activated by interferon alpha' see the whole document ---	10-14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* "&" document member of the same patent family

Date of the actual completion of the international search

30 January 1995

Date of mailing of the international search report

23.01.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Nauche, S

INTERNATIONAL SEARCH REPORT

Inter nal Application No

PCT/US 94/10849

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>SCIENCE, vol.264, 1 April 1994, LANCASTER, PA pages 95 - 98 ZHONG ZHONG ET AL.; 'Stat3 : a STA family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6' see the whole document -----</p>	1-36

INTERNATIONAL SEARCH REPORT

information on patent family members

Inter: nal Application No

PCT/US 94/10849

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9319179	30-09-93	AU-B- 3926893 CA-A- 2132317	21-10-93 30-09-93
WO-A-9208740	29-05-92	AU-A- 9092091	11-06-92